June, 07

NEIL H. SHEAR, MD, FRCPC

CURRICULUM VITAE

TITLE	**HELEN & PAUL PHELAN PROFESSOR, CHIEF OF DERMATOLOGY, FACULTY OF MEDICINE, UNIVERSITY OF TORONTO**
MAILING ADDRESS	Sunnybrook & Women's College Health Sciences Centre 2075 Bayview Avenue, Room M1-700 Toronto, Ontario, CANADA, M4N 3M5
CITIZENSHIP	Canadian
MARITAL STATUS	Married; Two children

CURRENT APPOINTMENTS

HELEN & PAUL PHELAN PROFESSOR & CHIEF	Dermatology	University of Toronto
DIRECTOR	Drug Safety Research Group	University of Toronto
PROFESSOR	Medicine, Pharmacology and Pediatrics Pharmacy	Faculty of Medicine Faculty of Pharmacy
Member	School of Graduate Studies	Department of Pharmacology Faculty of Medicine, & Pharmaceutical Sciences Faculty of Pharmacy

EDUCATION and DEGREES

B.A.Sc.(Honors)	Faculty of Engineering (Division of Engineering Science) University of Toronto	1973
M.D.	McMaster University Hamilton, Ontario	1976
Diplomate	American Board of Internal Medicine	1979
FRCPC	Internal Medicine	1980
FRCPC	Dermatology	1982
Diplomate	American Board of Dermatology	1982
FACP	Fellow of American College of Physicians	1993

POST-GRADUATE TRAINING

1976 - 1977	Internship	Internal Medicine	McMaster University Hamilton
1977 - 1978	Resident	Internal Medicine	McMaster University Hamilton
1978	Fellow	Immunology	McMaster University Hamilton (Dr. J. Bienenstock)
1979	Chief Resident/ Teaching Fellow	Internal Medicine	McMaster University Hamilton (Dr. J. Laidlaw)
1979 - 1981	Resident	Dermatology	University of Toronto
1981 - 1982	Chief Resident	Dermatology	University of Toronto (Dr. C. Ramsay)
1982 - 1984	M.R.C. Research Fellow	Clinical Pharmacology	Hospital for Sick Children Toronto (Dr. S. MacLeod)

PROFESSIONAL QUALIFICATIONS

Licentiate	Medical Council of Canada	1976
Fellow (Internal Medicine)	Royal College of Physicians	1980
Fellow (Dermatology)	Royal College of Physicians	1982
Diplomate	American Board of Internal Medicine	1979
Diplomate	American Board of Dermatology	1982
Fellow	American Academy of Dermatology	1983
Fellow	Canadian Dermatology Association	1984

LICENSURE

Ontario, Canada	1977	GL 31499

CERTIFICATES OF TRAINING

GCP Training Level 1	Ventana Clinical Research	January 5, 2005
Physician's introduction & basic training	Ventana Clinical Research	January 5, 2005
GCP Training Level 2	Ventana Clinical Research	May 31, 2005

PROFESSIONAL APPOINTMENTS

CURRENT ACADEMIC APPOINTMENTS AT UNIVERSITY OF TORONTO:

2002 – present	Division Director of Dermatology	University
1998 - present	Faculty of Medicine Department of Medicine	Professor
1998 - present	Department of Pharmacology (cross-appointment)	Professor
1998 - present	Department of Pediatrics (cross-appointment)	Professor
1998 - present	Faculty of Pharmacy (status appointment)	Professor
1993 - present	School of Graduate Studies (Pharmacology)	Member

PREVIOUS ACADEMIC APPOINTMENTS AT UNIVERSITY OF TORONTO:

1991 - 1993	School of Graduate Studies (Pharmacology)	Associate member
1992 - 1998	Faculty of Medicine, Department of Medicine	Associate Professor
1992 - 1998	Department of Pharmacology (cross-appointment)	Associate Professor
1992 - 1998	Department of Pediatrics (cross-appointment)	Associate Professor
1992 - 1998	Faculty of Pharmacy (status appointment)	Associate Professor
1991 - 1992	Faculty of Pharmacy	Assistant Professor
1984 - 1992	Medicine	Assistant Professor
1988 - 1989	Department Divisional Director (acting) Clinical Pharmacology	Faculty of Medicine
1988 - 1992	Pharmacology (cross-appointment)	Assistant Professor
1988 - 1994	Supervisor Year III Pharmacology & Therapeutics	Faculty of Medicine
1989 – 2002	Department Division Director Clinical Pharmacology	Faculty of Medicine
2002 – present	Department Division Director Dermatology	Faculty of Medicine

Date of First University of Toronto Academic Appointment:

1984	Department of Medicine	Assistant Professor

HOSPITAL APPOINTMENTS:

2006 – present	Division of Dermatology	**HEAD** Sunnybrook Health Sciences Centre
2006 – present	Division of Dermatology	Women's College Hospital
2001 – 2006	Division of Dermatology	**HEAD** Sunnybrook & Women's College Health Sciences Centre
2001 – present	Division of Clinical Pharmacology & Director Drug Safety Clinic	Attending staff Sunnybrook & Women's College Health Sciences Centre
1990 - 2001	Division of Clinical Pharmacology	**HEAD** Sunnybrook Health Science Centre, Toronto
1984 - 2001	Medicine/Dermatology	Attending Staff Sunnybrook Health Science Centre, Toronto
1984 - Present	Pediatrics/Clinical Pharmacology	Active Staff Hospital for Sick Children, Toronto
1984 - 2001	Medicine/Clinical Pharmacology	Sunnybrook Health Science Centre, Toronto
1987 - 1990	Division of Clinical Pharmacology Sunnybrook Health Science Centre, Toronto	Head (acting)

RESEARCH APPOINTMENTS:

1989 - 2003	Senior Scientist	Sunnybrook Health Science Centre, University of Toronto
1984 - 1991	Senior Research Staff	Research Institute Hospital for Sick Children University of Toronto
1991 -1993	Associate member	Department of Pharmacology School of Graduate Studies
1993 -present	Member	Department of Pharmacology School of Graduate Studies
1994 - 1995	Scientific Advisory Board	PharmaPatch Inc.

MEMBERSHIP IN PROFESSIONAL SOCIETIES

Ontario Medical Association	1976 – 1987, 1992 – present
Canadian Medical Association	1976 – 1987, 1992 – present
Royal College of Physicians and Surgeons of Canada	1980 – present
Toronto Dermatologic Society	1982 – present
Canadian Dermatologic Association	1982 – present
Board of Directors	1988 – 1991
American Academy of Dermatology	1982 – present
American College of Physicians	1984 – 1998
Society for Investigative Dermatology	1982 – 1998
Canadian Society for Clinical Pharmacology	1984 - present
Secretary-Treasurer	1988 - 1991
President-elect	1991 - 1992
President	1992 - 1994
Past-president	1994 - 1995
Editor of newsletter	1992, 1995
CPT 2008 National Organizing Comm. (Secretary-Treasurer)	2002 – present
Editor-in-Chief of Society Journal (Canadian Journal of Clinical Pharmacology)	1993 - 2003
Skin Pharmacology Society	1984 – 1998
Canadian Society for Clinical Investigation	1985 - 2001
Member of Council	1986 - 1988
Communications Committee	1994 - 1997
American Federation of Clinical Research	1987 – 1995
American Society of Clinical Pharmacology & Therapeutics	1988 – present
Finance committee	1998 – 2001
New York Academy of Sciences	1988 – 1998
Canadian Association of Professors of Dermatology	1988 – present
President	1998 – present
International Society of Dermatology	1992 – 1998
Drug Information Association	1994 – 2001
American Dermatological Association	1995 – 2005
Canadian Society of Investigative Dermatology	1995 – present
President	1998 – 2000
Canadian Dermatology Foundation	
Life Member	1995
Board Member	2002 - present
Chair, Medical Advisory Committee	2002 – 2003
Executive Committee	2003 – present

President 2003 - present

HONORS AND AWARDS

Ontario Scholarships	Ontario Ministry of Education	1969
CIBA-Geigy Medical Student Award	CIBA-Geigy Ltd.	1974
Research Fellowship	Medical Research Council (Canada)	1982 - 1984
Career Scientist Award - Health Research Personnel Development	Ontario Ministry of Health	1984 – 1989
Career Scientist Award - Renewal Health Research Personnel Development	Ontario Ministry of Health	1989 – 1994
Barney Usher Award - "for excellence in dermatological research"	Canadian Dermatology Association	1986
Roche Best Publication Award	Canadian Society for Clinical Pharmacology	1986
K.M. Piafsky Young Investigator Award	Canadian Society for Clinical Pharmacology	1989
Who's Who (Canadian edition)		1992 - present
Who's Who (Ontario)		1995 - present
Dean A. L. Chute Award "The Silver Shovel Award" Best clinical teacher (yrs II - III)	Medical Society Faculty of Medicine University of Toronto	1992
Gold Award Teaching value - residents Cutaneous reactions to anticonvulsants	American Academy of Dermatology Annual Meeting San Francisco	1992
Daniel Chang & Neil Shear Research Award "Researcher of the Year"	Department of Medicine Sunnybrook Health Science Centre	1993
Dean A. L. Chute Award "The Silver Shovel Award" Best clinical teacher (years II - III)	Medical Society Faculty of Medicine University of Toronto	1994
Norman Wrong Lecture: Drug Eruptions: Past, Present & Future	The 16th Postgraduate Derm Seminar Toronto Dermatological Society	1994
Norma MacLeod Lecture Drug Interactions	16th Postgraduate Derm Seminar Toronto Dermatological Society	1998
Distinguished Achievement Award	Canadian Society for Clinical Pharmacology	1998
Pommerening Lectureship	University of Washington Division of Dermatology	1998
Outstanding Service Award	Drug Information Association (DIA)	2000
PAIRO Excellence in Clinical Teaching Award (Nominee)	Professional Association of Interns and Residents of Ontario (PAIRO)	2000
Canadian Dermatology Foundation Lectureship	Canadian Dermatology Foundation (CDF)	2001
Best Doctors in Canada		2002 – present
284th Dr. Luis E. Geurrero Memorial Lecturer	University of Santo Tomas Manila, Philippines	2003
Helen & Paul Phalen Professor of Dermatology	Sunnybrook & Women's College Health Sciences Centre	2003 – present
Procter & Gamble Visiting Professor	University of Cincinatti	2004
Dr. and Mrs. Paul Cook Traveling Professor	Duke University	2006
Louis Durhing Lectureship	University of Pennsylvania	2007
Werner K. Stiefel Lectureship	Dermatology Foundation (US)	2007

COMMITTEES AND OTHER ACTIVITIES

UNIVERSITY OF TORONTO

Drug Safety Research Group (Extra-Departmental Unit)

Director	1992 - present
Chairman - Executive Committee	1992 - present

Faculty of Medicine

Faculty Council	1991 - 2000
Academic Services Committee	1994 - 1995
Continuing Education Committee	1992 - 2001
Search Committee - Chair Pharmacology	1993
Editorial Advisory Committee – Health News	2000 - 2002

Department of Medicine

Subspecialty coordinators	1988 - 1990
Curriculum Management Working Group	1990
Departmental Division Directors Committee	1992 - present
Undergraduate Education Committee	1994 - 2001
Search Committee - Director Continuing Education	1996
Promotions Committee	1998

Dermatology

Department Division **Director**	2001 - present
Department Division Deputy Director	1986 - 2001
Post-graduate Training Committee	1986 - present
Resident Selection Sub-Committee	1989 – 1996; 2001 - present
Dermatology Executive Committee	1991 - present
Chair	2001 – preesnt

Clinical Pharmacology

Department Division Director	1992 - 2001
Post-graduate Training Committee	1987 - 1988
Post-graduate Training Committee - Chair	1988 - 1995
Department Division Director (acting)	1988 - 1990
Resident Selection Sub-Committee - Chair	1988 - 1995
Resident Selection Sub-Committee	1995 - 2001

Department of Pharmacology

Pharmacology Medical Curriculum Committee	1990 - 1999
Medical Pharmacology Subject Committee	1989 - 1993
Strategic Planning Committee	1994 - 1997
Executive Committee	1997 - 2001

Other committees

Doctor of Pharmacy Curriculum Committee	1987 - 1988
Year III - Clinical Pharmacology & Therapeutics Subject Supervisor	1988 - 1993
Undergraduate Curriculum Committee - Clinical Pharmacology Chair	1988 - 1993
Undergraduate Curriculum Committee - Geriatrics	1988 - 1990
Undergraduate Curriculum Committee - Dermatology	1986 - 1990
Department of Medicine Search Committee - Director of Dermatology	1988 - 1989
Division of Internal Medicine 5 year Review Committee	1993

SUNNYBROOK HEALTH SCIENCE CENTRE – SUNNYBROOK & WOMEN'S

Research

Research Assessment Team / Projects Committee	1986 - 1988
Research Tower Planning Committee	1987 - 1988
Research Space Committee	1988 - 1990
Research Assessment Committee (Dept of Medicine)	1988 - 1993
General Research Program - Advisory Committee	1989 - 1993
Aging Research Program - Advisory Committee	1988 - 1990
Scientific Review Committee	1990 - 1993
Research Ethics Committee	1991 - 2001
Hospital Research Committee	1993 - 1995
Research Executive Committee	1993 - 1995

Education

Coordinator - Year III Clinical Teaching - Integumentary	1986 - 1990
Year I, II, III Committee	1986 - 1990
Residency Advisory Committee - Department of Pharmacy	1992 - 2001

Clinical

Founding Director of Adverse Reaction Clinic	1985 - 1996
Director of Glaxo Wellcome - Sunnybrook Drug Safety Clinic	1996 - present
Director of CosMedic Clinic	1985 - present
Medical Day Treatment Steering Committee	1992 - 1995

Administration

Dept of Medicine Day Organizing Committee - Chair	1989 - 1993
Pharmacy and Therapeutics Committee	1990
Pharmacy and Therapeutics Committee- Chair	1990 - 2001
Department of Medicine, Executive Committee	1991 - 1992
Physician Unit Director	1992 - 1994
Committee on Academic Activities	1992 - 1993
Department of Medicine 5 year Review Committee	1993
Quality of Care Committee	1997 – 2001
Department of Medicine Research Committee – Chair	2001
Gender Issues Committee	2001 - 2003

SUNNYBROOK HOSPITAL UNIVERSITY OF TORONTO CLINICS (SHUTC)

SHUTC Board of Directors	1994 - 1998

TORONTO DERMATOLOGICAL SOCIETY

Adverse Reaction Reporting Committee	1986 – 1993

CANADIAN MEDICAL ASSOCIATION

Pharmaceutical Advertising Advisory Board (PAAB) CMA Representative	2001 - 2003

CANADIAN DERMATOLOGY ASSOCIATION

Committee on Therapeutics/Toxicology Chair	1987 - 1998
Board of Directors	1988 – 1991
2007 Annual Meeting – Scientific Chair	2006 - 2007
Scientific Advisory Committee Chair	2006 - 2007

CANADIAN DERMATOLOGY FOUNDATION

Grant reviewer	1997 - 2001
Board of Directors	2001 – present
Medical Advisory Committee - Chair	2001 – 2003
President	2003 - present

CANADIAN ASSOCIATION OF PROFESSORS OF DERMATOLOGY

Research committee Chair	1988 - 1995
President	1997 - present

AMERICAN ACADEMY OF DERMATOLOGY

Task Force on Derm/Pharm	1985 - 1988
Committee on Youth Education	1991 – 1995
Editorial Board – Journal of the American Academy of Dermatology	2001 – present
Lila Gruber Lecture Selection Committee	2002 – 2005

AMERICAN MEDICAL ASSOCIATION

Editorial Board – Archives of Dermatology	2004 - 2006

ONTARIO MEDICAL ASSOCIATION

Committee on Drugs and Pharmacotherapy	1992 - 1999

ONTARIO MINISTRY OF HEALTH

Drug Quality and Therapeutics Committee	1987 - 1991
Single Source Product Sub-committee	1987 - 1991
Priorities & Planning Sub-committee	1987 - 1988
Special authorization Sub-committee	1988 - 1991
Information Sub-committee	1989 - 1991
Professional relations Sub-committee	1989 - 1991
Consultant to Drug Quality & Therapeutics Committee	1991 - 2003
Ministry of Health Drug Utilization Review Committee	1992 - 1993
Drug Programs Reform Secretariat - Working Group on Prescribing	1992 - 1993
Drug Utilization Steering Committee	1994 – 1996
Drug Utilization Advisory Committee (DUAC) – MOHLTC & Rx&D	2001 - 2003

CANADIAN SOCIETY FOR CLINICAL INVESTIGATION

Member of Council	1986 - 1988
Local organizer - annual meeting	1986
Membership Sub-committee	1987 - 1988
By-laws Sub-committee	1987 - 1988
Finance committee - Chair	1987 - 1988
Communications committee	1994 - 1996

CANADIAN SOCIETY FOR CLINICAL PHARMACOLOGY

Membership Committee Chair	1987 - 1994
Executive council	1987 - 1995
Secretary-Treasurer	1988 - 1991
Finance committee - Chair	1988 - 1993
President-elect	1991 - 1992
President	1992 - 1994
Newsletter Founding Editor	1992
Publication Committee	1993 - 2003
Past-President	1994 - 1995
Newsletter Editor	1994 – 1995
Journal Editor-in-Chief	1993 - 2003

ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA

Royal College Specialty Committee in Clinical Pharmacology	1989 - 1997
Clinical Pharmacology Nucleus Committee	1989 - 1992

CANADIAN CANCER SOCIETY

Sunsense awareness program development task force (Ontario Division)	1988 - 1991
Education Committee (Ontario Division)	1991 - 1996

HEALTH CANADA - HEALTH PROTECTION BRANCH

Canadian Adverse Drug Reaction Advisory Committee (CADRAC) - Founding Chair	1994 - 1997
External Advisory Committee on Pharmacovigilance	1997 - 2002

PATENT MEDICINE PRICES REVIEW BOARD (PMPRB)

Human Drug Advisory Panel (HDAP)	1998- 2003

AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS

Pharmacoepidemiology Section - Deputy Chair	1995 – 1998
Finance Committee	1998 - 2000

OTHER COMMITTEES

Canadian Public Health Association - National Advisory Committee Risk/Benefit Management of Drugs	1990 - 1992
United States Pharmacopoeia (**USP**) Dermatology Advisory Panel	1990 – 1999
ILSI – Health and Environmental Institute (Washington, DC) Drug Hypersensitivity Planning Committee	1999
ILSI – Health and Environmental Institute (Washington, DC) Project Committee on the Predictivity of the Toxicity of Pharmaceuticals in Humans from Animal Data (Subcommittee Co-chair)	1999
International Expert Committee - Study on Severe Cutaneous Adverse Reactions (SCAR)	1990 - 1997
Canadian Association of Medical Education (CAME) Award Committee	1992 - 1993
American Hospital Formulary Service Drug Information (AHFS DI) Consultant	1993
Canadian Council on Dermatomycoses - Chair	1992 - 1998
Drug Information Association - Member Canadian Steering Committee	1994 - 1997

Pharmaceutical Advisory Boards

Sandoz Dermatology Advisory Board	1991 - 1994
Janssen International Advisory Board (Dermatology)	1994 - 2000
Westwood Canada - Dermatology Advisory Board	1998 – 1999
Novartis International Hepatotoxicity Panel	2000 – present
Sanwa Data Safety Monitoring Board	2001 – 2004
Novartis Elidel International Advisory Board	2003 – present
Galderma Global Alliance to Improve Outcomes in Acne	2000 – present
Leo Pharma Data Safety Monitoring Board (chair)	2006
Peplin Data Safety Monitoring Board (member)	2007

TEACHING

UNDERGRADUATE

TEACHING AWARDS

Laurie Chute Award for Best Clinical Lecturer ("**The Silver Shovel Award**") 1992
Laurie Chute Award for Best Clinical Lecturer ("**The Silver Shovel Award**") 1994

Classroom teaching

Numerous Clinics & Seminars in Dermatology plus Pharmacology: Whole class - Year 2 & Year 3

1986 - 1994

Year III lecture in dermatology for medical class. (Invited by the class to make these presentations.)
1991 - 1993

Bruce Tovee Lecturer - Dermatology (LMCC Review Series)(4 hours)
1992, 93, 94, 95, 96, 97, 98, 99, 2000, 01, 02, 03, 04, 05, 06, 07

Course **Supervisor** Year III Clinical Pharmacology and Therapeutics - CPT 311Y 1988 - 1993

Sunnybrook coordinator for year III Integumentary System teaching 1986 - 1990

Human experimental ethics PHL 381 (2 hours - Clinical Research Ethics) 1991

Clinical Pharmacology Academic Half-Days - Year III
(Development of novel unit and delivery of seminars - 24 hours contact time) 1994 - 1995

Clinical Pharmacology Core Teaching - Foundations of Medical Practice
Co-director (16 hours) & Speaker (4 hours) 1996

Drug Safety - Interdisciplinary Toxicology PCL473 (2 hours)
1997, 98, 99, 2000, 01, 02, 03, 04, 05

Drug Reactions and Drug-Drug Interactions
Clinical Pharmacology Course (Year II Medical School) (2 hours)
1997, 98, 99, 2000, 01, 02, 03, 04, 05, 06, 07

Undergraduate Pharmacology project supervisor (PCL 472Y, 474Y):

Samuel Nakano 1987 - 88
Using electron microscopy and MTT to assess cellular toxicity from sulfamethoxazole
Betty Chow, Clotilde Lagala, Susan Park 1988 - 89
Benzodiazepine use among the elderly in an institutional setting
Eena Sachdev 1988 - 89
Benzodiazepine prescribing on the extended care ward at Sunnybrook Medical Centre
Michael Levesque 1988 - 89
Development of an adverse reaction clinic database
Stephanie Smith 1989 - 90
Benefit/risk analysis of antidepressants in a geriatric psychiatry clinic
Toni Irwin 1990 - 91
Risk/benefit analysis of antidepressant drugs in a geriatric psychiatry outpatient clinic
Mamta Pranjivan 1990 - 91
Adverse reactions to sulfonamides
Anna Recchia 1990 - 91
Database for the Adverse Drug Reaction Clinic: Data collection, storage, retrieval, analysis
Esther Viira 1991 - 92

Adverse drug reaction clinic: Penicillin skin testing 1986 – 1991

Jack Dorkhom 1991 -92
Anticonvulsant hypersensitivity syndrome: Characterization and susceptibility of patients at the ADR clinic
Ozgur Huner 1992
Pharmacologic characterization of a novel ion channel in keratinocytes
Rachel Rosenberg 1994
Perception of risk before and after skin testing to penicillin and local anesthetics
Jennifer McGowan 1994
Corticosteroids and the risk of osteonecrosis
Wei Wong 1995
Economic analysis of antidepressant use in the elderly
Christina Tunzi 1997
A study on adverse drug reactions in children
Chau Tran 1997
Gender differences in adverse drug reactions
Laura Chodorowicz 1998
Efficacy of therapies for genital warts

GRADUATE TEACHING

Clinical pharmacology (Adverse drug reactions 2 h) PCL 1004Y
1995, 96, 96, 98, 99, 2000, 01, 02, 03, 04, 05, 06, 07

Pharmacoepidemiology (Postmarketing surveillance 2 h) PHM 1118Y 1992 - 99

Pharm D Seminar Series (Adverse reactions, CADRAC 1.5 h) March 18, 1996 1996

Graduate Students Supervised

Nicole Mittmann	M.Sc. 1993
Kostas Trakas	M.Sc. 1997
Nicole Mittmann	Ph.D. 1997
Angie Wong	M.Sc. 1999
Chau Tran	M.Sc. 1999
Ally Popat	M.Sc. 2001
Debra Ong	M.Sc. 2001
Alla Vilner	M.Sc. 2002
Maysoon LoLou	M.Sc. 2002
Asma Ibrahim	M.Sc. 2002
Kostas Trakas	Ph.D. 2003
John Sullivan, MD	M.Sc. incomplete
Melissa Notman	M.Sc. 2003
Natash Nanwa (co supervisor)	M.Sc. expected 2007

Graduate student committees

Rachel Tyndale external reviewer M.Sc. granted 1988
In vitro research into the genetic polymorphism of sparteine metabolism.
Krista Lanctôt co-supervisor M. Sc. granted 1989
A Bayesian approach to the assessment of the toxicity of new drugs.

Monica Bologa external reviewer M.Sc. granted 1990
Drug handling and pregnancy outcome in pregnant epileptics.

Karen Graham external reviewer M.Sc. granted 1990
Infants of cocaine users: Verification of exposure and behavioural outcome.
Huiping Zhoa co-supervisor M. Sc. granted 1991
Enhanced causality assessment of anticonvulsant hypersensitivity reactions by an integrated approach.
Rachel Tyndale external reviewer Ph.D. granted 1991
Genetically polymorphic P450IIDI (Sparteine/debrisoquine - type CYP2D6): Neuronal characterization and structural variants.
Rachel Forman internal reviewer M.Sc. granted 1992
Fetal exposure to cocaine in Toronto, 1990-1991: Analysis of prevalence in determination of perinatal complications.
Nicole Mittmann co-supervisor M.Sc. granted 1993
Risk:benfit analysis of antidepressant usage in a geriatric population
Kathleen Shilalukey co-supervisor M.Sc. granted 1993
Are current pediatric dose recommendations for intravenous theophylline appropriate?
Shannon Stobie internal reviewer M.Sc. granted 1993
Novel oral iron chelator, L1, in acute and chronic iron overload.
Donna Zemlickis internal reviewer M.Sc. granted 1993
Maternal and fetal outcome following cancer in pregnancy: Breast cancer, Hodgkin's disease, cervical cancer, cancer chemotherapy, and cisplatin protein binding.
Shannon Stobie committee member Ph.D. granted 1994
Propylthiouracil-induced autoimmune disease in the cat: The role of reactive metabolites generated by leukocyte myeloperoxidase.
Chrisoula Eliopoulos internal reviewer M.Sc. granted 1995
Hair analysis of nicotine and cotinine: A biological marker for fetal exposure to cigarette smoke.
Elena Pope internal reviewer M.Sc. granted 1995
Critical review of standard and new methods of assessing compliance with chelation therapy in thalassemic patients.
Brad Hamilton external reviewer Ph.D. granted 1996
Motion and obesity, Institute of Medical Sciences.
Laura Magee external reviewer M.Sc. granted 1996
Department of Community Health
Yoav Timsit internal reviewer M.Sc. granted 1997
Department of Pharmacology
Carmine Simone external reviewer Ph.D. granted 1997
Institute of Medical Sciences
Cindy Woodland internal reviewer Ph.D. granted 1999
Department of Pharmacology
Kiran Chandra internal reviewer M.Sc. granted 2000
Department of Pharmacology
Inbal Gafni examiner M.Sc. granted 2000
Institute of Medical Sciences
Michael Gordon internal reviewer M.Sc. granted 2000
Institute of Medical Sciences
Dorothy Kruk Romanus examiner M.Sc. granted 2000
Pharmaceutical Sciences
Diana Stempak internal appraiser M.Sc. granted 2001
Department of Pharmacology

Since 2001: *2 to 3 committees per year in Department of Pharmacology, PhD committee chair for SGS when asked, and committee member / reviewer for Deptarment of Community Health occasionally.*

POST-GRADUATE TEACHING

Program Director for Clinical Pharmacology	1988 - 1996
Clinical Pharmacology PCK 1004Y	
(Postgraduate course developed in collaboration with Dr. G. Koren)	1987
Training of Family Practice residents in Dermatology (weekly clinic)	1989 – 1998
Annual Lectures to Clinical Pharmacology Residents (4 hours/year)	1988 – present
Adverse Drug Reactions; Medical Legal Consultations; Clin Pharm Consultations	
Annual Lectures to Dermatology Residents (4 hours/year)	1995 – present
Drug Eruptions, Mechanism of Action of Drugs Used in Dermatology; Drug Interactions	

POST-DOCTURAL RESEARCH FELLOWS

Robert Solomon, MD (Canada)	1990 - 1
Islam Khan, PhD (United States)	1991 - 3
Paul Oh, MD (Canada)	1994 - 5
Manuela Neuman, PhD (Canada)	1994 - 6
Barbara Liu, MD (Canada)	1995 - 6
Michael Singer, MD (Montreal)	1995 - 6
Nicole Mittmann, PhD (Canada)	1996 – 7
Marina Landau, MD (Israel)	1997 - 8
Raymond Schlienger, PhD (Switzerland)	1996 - 8
Elizabeth Phillips, MD (Canada)	1998 – 9
Ibrahim Fayez, MD (Egypt)	1998 - 9
John R. Sullivan, MD (Australia)	1999 – 2001
Simon Nigen (Canada)	2002 – 3
Gavin Wong (United Kingdom)	2003 – 4
Perla Lansang (Phillipines)	2005 - 6

CONTINUING MEDICAL EDUCATION (COURSE DIRECTORSHIPS)

see *Presentations* for major presentations

Dermatology rounds program American Academy of Dermatol.	Director	1988 - 90 Toronto, Ontario
Therapeutics Update American College of Physicians	Course Co-Director Course A11	July 1991 London, Ontario
Therapeutics Update American College of Physicians	Course Co-Director Course A21	July 1992 - 97 Niagara-on-the-Lake, Ontario
The 15th Post-Graduate Dermatology Seminar	Program Committee	October 1993 - present Toronto, Ontario
Annual Bruce Tovee Lecture Series	Dermatology Lecture	1992 - present
Frontiers in Dermatology	Director, founder	1995
Canadian Dermatology Association Annual Meeting	Scientific chair	1998
MKSAP American College of Physicians	Dermatology Review	1998
Regional Meeting - Toronto American College of Physicians- American Society of Internal Med.	Organizing Committee	1999
The Toronto Dermatological Society: The 23rd Post-Graduate Dermatology Seminar	Course Director	2001
The Toronto Dermatological Society: The 24th Post-Graduate Dermatology Seminar	Course Director	2002
The Toronto Dermatological Society: The 25th Post-Graduate Dermatology Seminar	Course Director	2003
The Toronto Dermatological Society: The 26th Post-Graduate Dermatology Seminar	Course Director	2004
The 27th Robert Lester Post-Graduate Dermatology Seminar	Course Director	2005
Toronto Psoriasis Seminar (ToPS)	Course Director	2005
The 28th Robert Lester Post-Graduate Dermatology Seminar	Course Director	2006
Toronto Psoriasis Seminar (ToPS)	Course Director	2006

RESEARCH GRANTS

Peer-reviewed Operating Funds

Mechanisms of sulfonamide toxicity in vitro	Ontario Ministry of Health	$28,000	1984-5
Keratinocyte cultures as in vitro models of toxicity	Canadian Dermatology Foundation	$10,000	1985
Phenytoin toxicity assessed in keratinocyte cultures	Ontario Ministry of Health	$15,000	1985-6
Pharmacologic mechanisms of dermatological drug toxicity	Medical Research Council Canada	$106,536	1986-8
Mechanisms of dioxin toxicity in vitro	Canadian Dermatology Foundation	$2,000	1986
Mechanisms of sulfonamide toxicity to skin	Medical Research Council Canada	$120,000	1988-90
Hypersensitivity drug reactions: Combined biochemical and Bayesian approach.	Physician Services Incorporated	$95,000	1988-90
Mechanisms of sulfonamide toxicity to skin - Equipment grant	Sunnybrook Trust for Medical Research	$13,600	1988
Mechanisms of drug toxicity to skin	Medical Research Council of Canada	$23,563	1990 - 1991
Mechanisms of drug toxicity to skin	Sunnybrook Trust for Medical Research	$14,000	1990 - 1991
Toxic epidermal necrolysis and Stevens-Johnson syndrome: A case control study	Sunnybrook General Research Group	$8,000	1990 - 1991
Cytokines in the development of adverse drug reactions	Leo Foundation Dermatology Research Grant	$50,000	1991 - 1992
Canadian Centre for the investigation of severe skin reactions to drugs	Canadian Dermatology Foundation	$8,375	1991
Randomized trial of the use of N-acetylcysteine in the prevention of sulfonamide hypersensitivity reactions in patients with HIV infection (co-investigator)	Physician Services Incorporated (PSI)	$95,000	1992 - 3
Role of cytokines in the development of drug reactions	Canadian Dermatology Foundation	$10,000	1992 - 3
Molecular mechanisms of AHH in keratinocytes	Canadian Dermatology Foundation	$8,000	1993 - 4

Vitamin D deficiency in the elderly: Prevalence in long-term care (Resident grant to Dr. B. Liu)	Physicians' Services Incorporated Foundation	$15,000	1994 - 5
Protection induced by TUDCA and UDCA on liver steatosis in HepG2 cells (co-investigator)	Fondo per lo Studio delle malattie del Fegato (FSF) Italy	$28,000	1993 - 4
Mechanisms of ethanol-induced liver damage and protective of bile acids	Fondo per lo Studio delle malattie del Fegato (FSF) Italy	$85,000	1995- 8
Sulfonamide toxicity to skin	Canadian Dermatology Foundation	$10,000	1995-6
Hip fractures and the use of selective serotonin reuptake inhibitors in the elderly (Co-investigator)	Physicians' Services Inc. Foundation	$20,825	1966-7
Cytotoxicity of drugs on skin cells in vitro and cytoprotection by silymarin (Principal investigator)	Canadian Dermatology Foundation	$10,000	1996-7
Modeling methotrexate-induced toxicity to human hepatocytes in vitro (Co-investigator)	Canadian Dermatology Foundation	$10,000	1996-7
A phase I/II study of docetaxel and epirubicin as first line therapy for metastatic breast cancer (NCIC CTG MA.15) (Principal investigator for safety & kinetics)	Clinical Trials Group National Cancer Institute Can. Rhône-Poulenc Rorer	$25,000	1996-7
Liver toxicity in vitro - functional and electron microscopy model (co PI)	Fondo per los studio delle malattie del fegato	$2,800	1997
Carbamazepine hypersensitivity In vitro and Bayesing modelling (Principal investigator)	Canadian Dermatology Foundation	$10,000	1997 - 8
The time-dependent pharmaco-kinetics of zidovudine in HIV-positive patients (Collaborator)	Positive action program Ontario Ministry of Health	$164,459	1997 - 8
In vitro studies of methotrexate induced toxicity (Principal investigator)	Canadian Dermatology Foundation	$15,000	1998 - 9
Assessment and predication of drug-induced hypersensitivity syndrome reactions (Co-principal investigator)	Canadian Dermatology Foundation	$25,000	1998 - 9
Capital Equipment Grant Microplate ELISA reader	Sunnybrook Research Committee	$22,400	1999

In vitro investigation into abacavir and nevirapine in subjects infected with human immunodeficiency virus. (Principal investigator)	AIDS Program Committee Positive Action Fund Ontario Ministry of Health	$58,438	1999 - 2000
Mechanism of lamotrigine-induced Rash (Principal investigator)	Canadian Dermatology Foundation	$35,000	1999 - 2000
Hypersensitivity syndrome reactions: In pursuit of molecular mechanisms (Co-investigator)	Canadian Dermatology Foundation	$10,000	1999 - 2000
Drug-induced hypersensitivity Syndrome reactions: In pursuit of molecular mechanisms	Physician's Services Incorporated Foundation	$70,000	1999 – 2000
Medical Determinants of Suicide in the Elderly (Co-investigator)	Ontario Mental Health Foundation	$70,140	2000 - 2001
Cutaneous drug reactions and the drug-induced hypersensitivity syndrome: Quantitative model for managing clinical information and causality assessment using in vitro toxicity studies and fuzzy logic set theory. (Principal investigator)	Canadian Dermatology Foundation	$10,000	2000 - 2001
The immuno-pathogenesis of hypersensitivity reactions to abacavir. (Co-principal investigator)	Canadian Dermatology Foundation	$25,000	2000 - 2001
New insights into the diagnosis of Abacavir hypersensitivity syndrome. (Principal investigator)	Canadian Dermatology Foundation	$10,000	2001 - 2002
Immuno-pathogenesis of hypersensitivity syndrome reactions to sulfonamide antibiotics: a possible cross reactivity between sulfamethoxazole and amprenavir. (Co-principal investigator)	Canadian Dermatology Foundation	$10,000	2001 - 2002
The validation of cutaneous testing in the diagnosis of ciprofloxacin hypersensitivity (Principal investigator)	Canadian Dermatology Foundation	$15,000	2002-2003
Understanding the role of patch testing in anticonvulsant-induced hypersensitivity syndromes (Co-Investigator)	Canadian Dermatology Foundation	$10,000	2002-2003
Immunopathogenesis of drug -induced hypersensitivity syndrome (Co-Investigator)	Canadian Dermatology Foundation	$10,000	2002-2003

Sulfamethoxazole –induced hypersensitivity syndromes: The role of patch testing as a diagnostic aid. (Sub-investigator)	Schering Can. - Canadian Dermatology Foundation	$10,000	2003-2004
Operationalizing patient-centered dermatology: An institutional ethnographic case study of PERC (Phototherapy Education and Research Centre) (Sub-investigator)	Amgen Wyeth -Canadian Dermatology Foundation	$10,000	2004-2005
Abacavir hypersensitivity reaction: Investigations of immunopathogenesis and generalizability of diagnostic testing using cutaneous challenge, lymphocyte transformation and genetic testing (Principal investigator)	Fujisawa Can. - Canadian Dermatology Foundation (CDF)	$20,000	2004-2005
The mechanism of *Trichophyton rubrum* supbilisin genes in invasion of human keratinized tissue (Principal investigator)	Galderma Canada-Can. Dermatology Foundation	$20,000	2005 – 2006
The cloning and characterization of the antifungal resistance genes of *Trichophyton rubrum.* (Sub-investigator)	Edwin Brown-CDA Endowment CDF Reearch Grant	$10,000	2005 – 2006
Further application of cutaneous, genentic and immunologic testing for the management of abacavir Hyper-sensitivity Syndrome. (Sub-investigator)	Astellas Pharma – Canadian Dermatology Foundation	$20,000	2005 - 2006
The informed patient in the era of biologics: How sytemic treatments for chronic skin disease change the need for information and the patient-dermatologist relationship. (Sub-investigator)	PremPharm-CDF	$10,000	2005 - 2006
The informed patient in the era of bilologics. (Sub-investigator)	CDF Research Grant Award	$10,000	2005 - 2006

DATA & SAFETY MONITORING BOARDS

Sanwa Kagaku Kenkyusho (JASU in USA)
Fidarestat, Phase 3 pivitol study
Expert member, Cutaneous toxicity
2002 - 2003

Novartis Pharmaceuticals (International study)
Pimecrolimus cream (PETITE study)
Chair DSMB
2004 - present

RESEARCH GRANTS

Peer-reviewed Personal Support

Career Scientist Award -	Ministry of Health (Ont) Health Research Personnel Development	$235,000	1984 - 9
Career Scientist Award - Renewal	Ministry of Health (Ont.) Health Research Personnel Development	$250,000	1989 - 94

Peer-reviewed Studentships and Fellowships

Student scholarship for Wai-Tak Kong (Adverse reactions to anticonvulsants)	Pharmaceutical Association	$3,000	1989
Student scholarship for Nathalie Campbell (Camouflage cosmetics in a medical environ)	Sunnybrook Medical Centre	$1,500	1989
Nordic fellowship to Dr. Robert Solomon	Canadian Society for Clinical Pharmacology	$35,000	1990 - 1991
Fellowship to Dr. Kathleen Shilalukey	World Health Organization (WHO)	$78,000	1990 - 1993
Life Sciences Comm. Award Summer scholarship to Ms. Anna Recchia	Dept. of Pharmacology	$1,000	1991
Flemingdon Lab/Sunnybrook Summer scholarship to Ms. Nicole Mittmann	Sunnybrook Research	$1,500	1991
Fellowship to Islam Khan Ph.D.	Ministry of Health Dermatology Grant	$19,500	1991 - 2
Pharmacologic and immunologic mechanisms involved in the pathogenesis of cutaneous reactions to drugs (Fellowship to Dr. Islam Khan)	Sunnybrook Trust for Research	$30,510	1992 - 3
Postgraduate Fellowship Award (to Dr. Paul Oh)	Department of Medicine University of Toronto	$15,000	1994 - 5
Fellowship Award in Pharmacoeconomics (to Dr. Paul Oh)	Miles Canada Inc.	$50,000	1994 - 5
Fellowship Research Award (for Dr. Barbara Liu)	Canadian Society for Clinical Pharmacology	$40,000	1995-6

Fellowship Research Award (for Dr. Michael Singer)	Canadian Society for Clinical Pharmacology	$40,000	1995-6
Fellowship Research Award (for Dr. Nicole Mittmann)	Canadian Society for Clinical Pharmacology	$40,000	1996-7
Summer Undergraduate Research Scholarship (S. Sadikian)	Faculty of Pharmacy University of Toronto	$3,680	1997
Integrative biomedical sciences summer student competition (Bindu Kumar)	Sunnybrook Health Science Centre	$1,500	1997
University Open Master's Fellowship (to Angelina Wong)*	School of Graduate Studies University of Toronto	$3,600	1997-8
Alumni Graduate Studies Award (to Angelina Wong)	Faculty of Pharmacy University of Toronto	$5,000	1997 - 8
MRC-PMAC Summer Studentship (to Winnie Su)	Medical Research Council - Canada	$4,908	1998
Fellowship Research Award (for Dr. Elizabeth Phillips)	Canadian Society for Clinical Pharmacology	$50,000	1998-9
Summer studentship (for Elaine Yeung)	Integrative Biomedical Sciences Sunnybrook Health Science Centre	$1,500	1998
Graduate Student Fellowship (to Kostas Trakas)	University of Toronto Open Fellowship	$3,600	1998 - 9
Graduate Student Fellowship (to Chau Tran)	University of Toronto Open Fellowship	$3,600	1998 - 9
Graduate Student Fellowship (to Debra Ong)	University of Toronto Open Fellowship	$3,600	1998 - 9
CDMA/CEM/MRC Studentship (to Kostas Trakas)	Medical Research Council Ph.D. Fellowship	$16,825/yr	1998 – 2001
USP/DID Fellowship (to Kostas Trakas)	United States Pharmacopoeia	$22,500	1999 - 2000
Research Summer Studentship (to Julia Haber)	Sunnybrook and Women's	$1,600	1999
Faculty of Medicine/PMAC Summer scholarship (to Elaine Yeung)	Faculty of Medicine University of Toronto	$4,000	1999
Skin & Cancer Foundation Research Fellowship (to John Sullivan, MD)	Skin & Cancer Foundation Australia	$70,000	1999 - 2001
B.J. Amos Travelling Fellowship (to John Sullivan, MD)	The Westmead Association Australia	$10,000	1999
Mentorship Grant (to Roxanne Stambuk, MD, PhD)	Women's Dermatologic Society	$4,500	1999

Graduate Student Fellowship (to Chau Tran)	University of Toronto Master's Fellowship	$3,000	1999 - 2000
Graduate Student Fellowship (to Chau Tran)	University of Toronto PhD Fellowship	$1,000	2000 - 2001
Graduate Student Fellowship (to Kostas Trakas)	University of Toronto PhD Fellowship	$3,000	2000 - 2001
Graduate Student Fellowship (to Alissa Scalera)	University of Toronto PhD Fellowship	$2,000	2000 - 2001
Graduate Student Fellowship (to Debra Ong)	University of Toronto Master's Fellowship	$1,000	2000 - 2001
Summer Student Grant (to Olivia Wu)	Burrough's Wellcome Fund Faculty of Pharmacy, U of T	$4,048	2000
University of Toronto Drug Safety Fellowship Award (to Debra Ong)	University of Toronto Drug Safety Research Group	$14,500/yr	1998 - 2000
University of Toronto Drug Safety Fellowship Award (to Ally Popat)	University of Toronto Drug Safety Research Group	$14,500/yr	1999 - 2001
Ontario Graduate Scholarship (to Ally Popat)	Ontario Ministry of Training, Colleges and Universities	$11,859/yr	2000 - 1
University of Toronto Drug Safety Fellowship Award (to Asma Ibrahim)	University of Toronto Drug Safety Research Group	$14,500/yr	2000 - 1
Graduate Student Fellowship (to Asma Ibrahim)	University of Toronto Open Fellowship	$3,600	2000 - 1
NSERC Postgraduate Scholarship (to Heather Neilson)	NSERC	$34,000	2000 – 2
NSERC Postgraduate Scholarship (to Asma Ibrahim)	NSERC	$34,600	2001 – 3
University of Toronto Drug Safety Fellowship Award (to Melissa Notman)	University of Toronto Drug Safety Research Group	$14,500/yr	2001 - 3
Research Summer Studentship (to Julia Houldin)	Sunnybrook and Women's	$1,600	2002
CIHR Health Professional Student Research Award (to Sari Herman)	McMaster University	$4,048	2002
Ben Fisher – Galderma Fellowship (to Simon Nigen)	University of Toronto Dermatology	$50,000	2002 – 3
Research Fellowship (to Gavin Wong)	Can Soc for Clin Pharmacology	$35,000	2003 - 4

Peer-reviewed Support for Scientific Activities

Bertha Rosenstadt Professorship in Health Sciences to support Dr. Claudio Tiribelli visit to Toronto	University of Toronto	$11,300	1995
The First International Symposium on Molecular Pathology and Clinical Aspects of the Inflamed Liver: Alcohol and Cytokines (M. Neuman, N. Shear, L. Blendis, R. Cameron)*	Medical Research Council of Canada - Workshop	$5,000	1997-8

RESEARCH GRANTS

Non-peer-reviewed Operating Grants

Effects of misoprostol on cytochrome P-450	G.D. Searle & Co. Ltd.	$49,627	1987
Sorbinil hypersensitivity (Co-investigator)	Pfizer, U.S.	$100,000	1986 - 8
Pharmacokinetics of etretinate (co-investigator)	Hoffman-La Roche	$95,000	1990 - 1993
Racial predisposition to anti-convulsant hypersensitivity drug reactions	Parke-Davis/Warner-Lambert Canada Inc.	$6,000	1990
Evaluation of antidepressants in the elderly: Pharmaco-epidemiologic model for the measurement of comparative benefit and risk	CIBA-Geigy Canada Ltd.	$177,443	1991 - 6
Pharmacoeconomic analysis of oral antibiotics	Eli Lilly Canada Inc.	$69,000	1993
Development of an HPCL assay for itraconazole and hydroxy-itraconazole	Janssen Pharmaceutica	$13,500	1994
Continuing education techniques to improve prescription drug utilization (co-investigator).	Ontario Ministry of Health	$159,000	1994 - 6
Pharmacoeconomic evaluation of regional vs. general anesthesia in orthopedic, vascular, thoracic and urologic surgery (co-investigator).	Astra Pharmaceutica	$30,875	1994 - 5
Pharmacoeconomic evaluation of calcium channel blockers in the treatment of mild to moderate hypertension (co-investigator).	Astra Pharmaceutica	$31,100	1994 - 5
Economic impact of severe	CIBA-Geigy Canada Inc.	$9,100	1995

systemic hypersensitivity reactions to drugs			
Comparative cost-effectiveness model of trovafloxacin in moderate for severe community acquired pneumonia in the hospital (Principal investigator)	Pfizer Canada Inc.	$164,190	1997
Absorption of oral ciprofloxacin in patients with chemotherapy-induced mucositis (Co investigator)	Bayer Inc.	$46,196	1997 - 8
Adverse Reaction Clinic Development Grant	Glaxo Wellcome	$375,000	1996
University of Toronto - Glaxo Wellcome - Sunnybrook Drug Safety Clinic Fellowship Endowment	Glaxo Wellcome, University of Toronto, Ontario Ministry of Universities	$600,000	1997
Support to Glaxo Wellcome - Sunnybrook Drug Safety Clinic for enhancement of research and patient care	Glaxo Wellcome	$137,550	1998-2000
Development of a pharmaceutical management strategy for WSIB. (Co-principal investigator)	Workplace Safety & Insurance Board	$240,360	1998 - 2000
Economic evaluation of Intravenous Immune Globulin Treatment in Patients with Toxic Epidermal Necrolysis. (Co-principal investigator)	Bayer	$30,000	2001 - 2

CONTRACT CLINICAL RESEARCH PROJECTS

Histological assessment of photo-damaged skin treated with topical Ro 15-1570 (Co-investigator)	Hoffman-LaRoche	1988 - 9
Ketoconazole 2% shampoo in the treatment of seborrheic dermatitis of the scalp (Principal investigator)	Janssen	1988
Fucidin 1% lotion in the treatment of acne vulgaris (Principal investigator)	Leo Laboratories	1988 - 9
Ketanserin ointment for decubitus ulcers (Principal investigator)	Janssen	1988 - 9
EMLA trial for debridement of venous and arterial leg ulcers. (Co-investigator)	Astra Pharma	1990 - 1
Double-blind randomized placebo-controlled trial of EMLA cream for analgesia prior to treatment of wart by cryotherapy (Principal investigator)	Astra Pharma Inc.	1990 - 3
A randomized double-blind, placebo controlled trial of the efficacy, safety and tolerability of oral terbinafine in the treatment of tinea pedis of the moccasin type. (Co-investigator)	Sandoz Canada Inc.	1990 - 2
Comparative effects of calcipotriol (MC903) ointment with Dithranol cream (short contact) in psoriasis vulgaris. (Principal investigator)	Leo Laboratories	1990 - 2
Double-blind comparative study of prednicarbate (Dermatop) emollient cream 0.1% vs betamethasone valerate cream 0.1% in subjects with atopic dermatitis. (Co-investigator)	Hoechst Canada Inc.	1991 - 2
Safety and efficacy of Occlucort lotion 0.05% and Diprisone (betamethasone diproprionate) lotion in the treatment of hand dermatitis. (Co-investigator)	GenDerm	1991 - 2
Evaluation of the clinical efficacy and safety of ketoconazole 2% emulsion in the treatment of tinea cruris (Principal investigator).	Janssen Pharmaceutica	1991 - 3
A phase IV long-term safety study of metronidazole (Metrogel) gel 0.75% in acne rosacea. (Co-investigator).	Lederle Laboratories	1992 - 4
Double blind clinical safety and efficacy evaluation of CD271 0.1% cream vs. placebo. (Co-investigator).	Owen/Galderma	1991 - 2

A multi-centre, double-blind, placebo-controlled comparative evaluation of 12 weeks and 24 weeks treatment with terbinafine (250 mg daily) vs. placebo in the treatment of onychomycosis of the toenails. (Principal investigator)	Sandoz Canada	1992 - 3
Efficacy and safety of calcipotriol cream II in treatment of scalp psoriasis (dose ranging) (Principal investigator)	Leo Laboratories	1993 - 4
DuoDerm E vs. Saline dressings in the treatment of leg ulcers: A study on cost effectiveness (Co-investigator)	Convatec-Squibb	1993 - 4
The regeneration of stratum corneum after tape-stripping (Co-investigator)	MediPro	1993
Single-blind, multicentre study comparing SCH 471 ointment daily to Diprosalic ointment b.i.d. in the treatment of psoriasis (Co-investigator)	Schering Canada	1993 - 4
Efficacy and safety of calcipotriol cream II in treating psoriasis vulgaris of the face (Co-investigator)	Leo Laboratories	1993
Evaluation of the clinical efficacy and safety of oral itraconazole in the treatment of tinea pedis (Principal investigator)	Janssen Pharmaceutica	1993 - 4
Surveillance of Safety and Effect of Sandimmune in the Treatment of Severe Psoriasis (Co-investigator)	Sandoz	1993 - 8
Vehicle controlled safety: efficacy trial evaluation 5% imiquimod cream for the treatment of genital/ perianal warts in men (Co-investigator)	3M Pharmaceuticals	1993 - 4
Low energy laser therapy in the treatment of leg ulcers (Co-investigator)	International Medical Instruments Inc.	1994 - 5
Comparative effects of fusidic acid (2%) and erythromycin (2%) solution in the treatment of acne vulgaris (Canadian Principal investigator)	Leo Laboratories	1994 - 5
Evaluation of the clinical efficacy and safety of oral itraconazole pulse therapy in the treatment of onychomycosis of the toenail (Principal investigator)	Janssen Pharmaceutica	1994 - 5
A study to compare quality of life in patients treated with suppressive acyclovir therapy vs those treated with acute oral acyclovir therapy in the management of recurrent genital herpes (Co-investigator).	Burroughs Wellcome	1994 - 5
A double-blind, parallel group comparison of the efficacy and safety of BMS 191158/1881159 solution (2% 4-hydroxyanisole/0.01% tretinoin) vs. individual active agents and vehicle in the treatment of solar lentigines and related hyperpigmented lesions. (Principal investigator)	Bristol-Myers Squibb	1994 - 5

A comparative study of the atrophogenic potential, efficacy and safety of 1) calcipotriol ointment bid, 2) betamethasone 17-valerate ointment bid, 3) clobetasol 17-propionate ointment, 4) vehicle of ointment bid in the treatment of psoriasis vulgaris (Co-investigator)	Leo Laboratories	1994 - 5
A double-blind randomized, vehicle-controlled, parallel-group, multicentre study assessing the safety, efficacy and subject acceptance of sodium sulfacetamide 10% and sulfur 5% in the treatment of rosacea. (Co-investigator)	GenDerm	1995
A protocol to assess the safety and efficacy of clindamycin phosphate cream (= to 1% clindamycin) with sunscreen compared phosphate topical solution (Co-investigator)	Stieffel	1995
A double-blind, placebo controlled study to investigate herbal extract in androgenic alopecia (Co-investigator)	Steff	1995 - 6
A study to compare the quality of life in patients treated with suppressive acyclovir therapy vs. those treated with acute oral acyclovir therapy in the management of recurrent genital herpes (Co-investigator)	Glaxo-Wellcome	1995
Evaluation of the clinical efficacy and safety of oral itraconazole in the treatment of tinea pedis (Principal investigator)	Janssen	1995
A randomized, double-blind, parallel group study of the efficacy and the safety of an emollient formulation of ammonium lactate 12% and 30% creams vs. their vehicle in the treatment of signs associated with photodamage. (Co-investigator)	Bristol Myers Squibb	1995
A double-blind, multinational trial comparing sorivudine vs acyclovir for the treatment of acute localized zoster and the effect on zoster associated pain in immunocompetent subjects (Principal investigator)	Bristol Myers Squibb	1995
A study of the efficacy and safety of topical madecassol in the treatment of keloids (Principal investigator)	Draxis	1995 - 6
A multicentre, double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of topical 3% diclofenac in 2.5% hyaluronan gel in the treatment of outpatients with actinic keratosis (Principal investigator)	Hyal Pharmaceuticals	1995
A one year open study investigating the safety and efficacy of short courses of Sandimmune Neoral to manage patients with chronic plaque psoriasis inadequately controlled with topical therapies (Co-investigator)	Sandoz	1995 - 6
A multicentred, double blind placebo controlled evaluation of topical diclofenac in 2.5% hyaluronic acid gel in the treatment of superficial basal cell carcinoma (Principal investigator)	Hyal Pharmaceuticals	1995

A Phase III blinded, randomized study to evaluate the safety, efficacy and pharmacokinetics of 2 dose levels of DAB389IL-2 (9 and 18 µg/kg/day) in cutaneous T-cell lymphoma (CTCL) patients with stage Ib-III disease who, following ≥ 4 previous therapies or stage IVa disease patients following ≤ 1 previous therapy, have recurrent or persistent disease (Co-Principal investigator)	Corning, Eli Lilly Seragen	1995 - 6
A randomized, double-blind, placebo-controlled, multicentre study of the efficacy and safety of terbinafine 250 mg tablet daily compared to placebo for one week in subjects with multiple skin infections (Principal investigator)	Sandoz	1996-7
An open-label, multicenter safety and efficacy study of topical imiquimod 5% cream in the treatment of visible, external genital/perianal warts in male and female patients. infections (Principal investigator)	3M Pharma.	1997
Efficacy and safety of BMS 1881158/181159 solution vs individual active agents and vehicle in the treatment of solar lentigines and related hyperpigmented lesions. infections (Principal investigator)	Bristol-Myers Squibb	1996-7
A study to compare quality of life in patients treated with suppressive acyclovir therapy vs acute oral acyclovir in the management of recurrent genital herpes. (Co-investigator)	Glaxo Wellcome	1996-7
A comparison of oral valacyclovir 500 mg twice daily for 3 or 5 days for treatment of recurrent genital herpes. (Principal investigator)	Glaxo Wellcome	1997
A 48 hour patch test with Solarase (3% diclofenac topical gel-CT1101) and diclofenac in petrolatum base and ethanol base in patients previously exposed to CT1101 to determine the incidence of local or systemic sensitization/irritation reactions. (Principal investigator)	Hyal Pharmaceuticals	1997
Clinical efficacy and safety of oral itraconazole pulse therapy in the treatment of onychomycosis of the toenail. (Principal investigator)	Janssen-Ortho Inc.	1997
Open long-term safety trial, with oral liarozole for subjects with severe plaque psoriasis. (Principal investigator)	Janssen-Ortho Inc.	1996-7
Skin atrophy with MCO 9407 by ultrasound (Co-investigator)	Leo Laboratories	1997
A randomized double blind placebo controlled multicentre study of the efficacy and safety of terbinafine 250 mg tablet daily compared to placebo for one week in subjects with multiple skin infections.	Novartis	1997

(Principal investigator)		
Profore extra four layer bandage system in patients with venous leg ulceration (Co investigator)	Smith & Nephew	1997
A parallel arm, double blind, placebo controlled, efficacy study of ammonium lactate lotion (12% - PLI) and Lachydrin in patients with moderate or greater ichthyosis vulgaris. (Co-investigator)	Paddock Lab. Inc	1997-8
A multicentre, parallel group, double blind, active control study to evaluate the long-term safety and efficacy of SDZ ASM 981 cream applied twice daily for up to 12 months in patients with atopic dermatitis. (Principal investigator)	Novartis	1998-2000
A pan-European/Canadian double blind randomized study to evaluate the efficacy and safety of 0.03% tacrolimus (FK506) ointment, 0.01% tacrolimus (FK506) ointment, and 1% hydrocortisone acetate ointment in children with moderate to severe atopic dermatitis. (Co-investigator)	Fujisawa	1997-9
A phase II to III evaluation of Targretin capsules in patients with refractory advanced stage cutaneous T cell lymphoma. (Co-investigator)	Ligand	1997-8
Phase III evaluation of Targretin topical gel in patients with refractory or persistent early stage cutaneous T cell lymphoma. (Co-investigator)	Ligand	1997-8
A randomized parallel arm dose comparison study evaluating the safety, tolerability and efficacy of AE941, administered orally for 12 weeks, in patients with moderate to severe plaque psoriasis. (Co-investigator)	Aeterna	1997-8
A randomized, placebo controlled, double-blind study to evaluate the safety and efficacy of activated glycirrhinzinic acid (Epigen) spray vs placebo t.i.d. for 5 days in the treatment of recurrent genital herpes. (Co-investigator)	Cheminova SA	1997 - 8
A one year open study investigating the safety and efficacy of short courses of Sandimmune Neoral to manage patients with chronic plaque psoriasis inadequately controlled with topical therapies. (NEO-CDN-13) (Co-investigator)	Novartis	1997 - 8
Surveillance of safety and effects of Sandimmune in the treatment of severe psoriasis: A Canadian post-approval study (Co-investigator)	Novartis	1997 - 8
A double blind, placebo controlled study to investigate herbal extract in androgenetic alopecia.	Stef International	1997 - 9

(Co-investigator)		
High frequency ultrasound assessment of skin elasticity. (Co-investigator)	Unilever Res. U. S.	1997 - 8
A double-blind, placebo-controlled, multicentre, phase II study to assess the safety, biological activity, and efficacy of hu1124 in patients with moderate to severe plaque psoriasis (Principal investigator)	Xoma Corporation	1998
VAS 972 in Moderate to Severe Psoriasis (Co-investigator)	Vasogen	1999 – 2000
GM-CSF in Chronic Venous Ulcers (Co-investigator)	Schering	1999
Tazoarac & Elocom in Mild to Moderate Psoriasis (Co-investigator)	Allergan	1999
Apligraf (APL-02) in Venous Leg Ulcers (Principal Investigator)	Novartis	1999
Phase I/II study of the safety and efficacy of tea polyphenols in the treatment of external genital warts in men (Co-investigator)	Epitome Pharma	1999 – 2000
An open-label, pilot study of VAS972 therapy to determine the safety and effectiveness in patients with moderate to severe psoriasis (Co-investigator)	Vasogen	2000 - 1
A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Multidose Study to Evaluate the Efficacy and Safety of Subcutaneously Administered Anti-CD11a in Adults with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy (Protocol ACD2059g) (Principal Investigator)	Genentech	2000 - 2001
An Open-Label Study to Evaluate the Safety of Topically Applied Tacrolimus Ointment for the Treatment of Atopic Dermatitis (Protocol PRO-004) (Co-Principal Investigator)	Fujisawa Canada, Inc.	2000-2001
An Open-Label, Multi-Arm, Multi-Centre Study of the Efficacy of Various Treatment Schedules of VAS 972 in Patients with Moderate to Severe Psoriasis (Protocol 004) (Co-Principal Investigator)	Vasogen Inc.	2001 - 2
A phase III study comparing a new ointment containing calcipotriol 50ug/g plus betamethasone (as dipropionate) 0.5mg/g with calcipotriol 50ug/g in new ointment vehicle, betamethasone (as dipropionate) 0.5mg/g in new ointment vehicle and the new ointment vehicle, all used once daily, in psoriasis vulgaris (Protocol No. MCB 0003 INT) (Principal Investigator)	Leo Pharma Inc.	2001
A Phase II Randomized, Double-Blind, Placebo-Controlled	MedImmune, Inc.	2001 - 2

Study of MEDI-507, a Humanized Monoclonal Antibody that Binds to the CD2 Receptor, Administered by Intravenous Infusion to Adults with Plaque Psoriasis (Protocol MI-CP074) (Sub-investigator)		
A double-blind, placebo controlled study to assess the incidence of rash and risk of sensitization on re-exposure with 10 day repeat doses of 320mg gemifloxacin and the potential for development of cross-sensitization to ciprofloxacin in healthy female volunteers – pathology & immunopathology study component (referral site for international study). (Principal investigator)	GlaxoSmithKline	2001 - 2
Pharmacokinetics of 4-Oxo-Isotretinoin 30 mg and 60 mg in Healthy Male Volunteers – Phase I study (Sub-investigator)	Hoffmann LaRoche	2001 - 2
A Randomized, Double-Blind Placebo Controlled Exploratory Study to Investigate the Effects of Multiple Oral Doses of 4-oxo-isotretinoin and Isotretinoin (Accutane™) on Sebum Excretion in Male Acne Patients – Phase II study (Principal investigator)	Hoffmann LaRoche	2001 - 2
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group, Dose-Finding Study to Determine the Dose Response, Safety and Tolerability of Three Doses (10,20, 30 mg b.i.d.) of SDZ ASM 981 Tablets in Subjects with Atopic Dermatitis. Protocol Number: CASM981 C202 Phase II study (Principal investigator)	Novartis	2001 - 2
A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study of MEDI-507, a Humanized Monoclonal Antibody that Binds to the CD2 Receptor, Administered by Intravenous Infusion to Adults with Plaque Psoriasis (MI-CP074) (Sub-investigator)	Medimmune	2001 - 2
Randomized Double Blind Rosacure Cream vs. Rosacure Improved Cream vs. a Placebo Moisturizer in the Treatment of Erythema Associated with Rosacea (C2000-1) (Principal investigator)	Canderm	2002
A Phase II study comparing Cipamfylline ointment 2.5 mg/g with Tacrolimus ointment 0.1%, applied twice daily for 4 weeks in the treatment of atopic dermatitis (Principal Investigator)	Leo	2002
KH 1650 in Psoriasis Vulgaris proof of concept and dose finding study (Principal investigator)	Leo	2003 - 4
An open-label safety and efficacy study of Solage (2% 4- hydroxyanisole/0.01% Tretinoin) to assess pigmentary changes in ethnic groups of Asian, Latin/Hispanic and African American descent with skin types II – IV (Principal investigator)	Galderma	
A study to assess the clinical safety and efficacy of a ciclopirox	Stiefel Canada Inc.	2003 - 4

olamine shampoo (Stieprox) compared to a placebo shampoo
in the treatment of seborrhoeic dermatitis
(Principal investigator)

A multicentre, randomized, double blind, placebo-controlled phase Ib study of subcutaneously administered recombinant human interleukin- 18 binding protein for the treatment of patients with moderate to severe plaque psoriasis with or without active psoriatic arthritis. (Principal investigator)	Serono International SA	2003 - 4
An exploratory, randomized, double blind, vehicle controlled, multicentre, parallel dose study investigating the use of Elidel cream 1% in mild to moderate atopic dermatitis patients who demonstrate a clinical insensitivity to topical glucocorticoids (Principal investigator)	Novartis	2003 - 4
A multicentre, randomized, double-blinded, placebo controlled phase III study of subcutaneously administered Raptiva in the treatment of patients with moderate to severe psoriasis (Principal investigator)	Serono International SA	2004
Efficacy and safety of Alitretinoin in the treatment of severe chronic hand dermatitis refractory to topical therapy (Principal investigator)	Basilea Pharmaceutica	2004
A double blind, randomized, placebo-controlled, follow-up efficacy and safety study of (Alitretinoin) BAL 4079 in the treatment of chronic hand dermatitis refractory to topical therapy (Principal investigator)	Basilea Pharmaceutica	2004
A phase III, multicentre, randomized, double blind, placebo-controlled trial evaluating the efficacy and safety of Infliximab induction therapy followed by multiple regimens of maintenance Infliximab therapy in subjects with plaque type psoriasis (Principal investigator)	Centocor	2003 - 4
A randomized, multicentre, double-blinded controlled study to compare the effectiveness of single dose (1500 mg) of Famciclovir, one day (750 mg Q12) of Famciclovir and placebo in patient initiated episodic treatment of recurrent herpes labialis (Principal investigator)	Novartis	2003 - 4
An international, randomized, double blind, placebo-controlled, multicentre, 6 month study of the efficacy and safety of Valaciclovir 1g QD versus placebo for the suppression of HSV-2 genital herpes in newly infected immunocompetent subjects. (Principal investigator)	GlaxoSmithKline	2004
A multicentre, randomized, double blind, placebo-controlled, parallel group phase III study to evaluate corticosteroid-reduction and sparing effects of Mepolizumab 750 mg in subjects with Hypereosinophilic Syndrome (HES), and to evaluate the efficacy and safety of Mepolizumab in controlling the clinical signs and symptoms of HES over nine months (Principal investigator)	GlaxoSmithKline	2004
A phase III, randomized, double blind study comparing twice daily FK506 cream 0.03% versus Cream Vehicle in the treatment of atopic dermatitis in pediatric subjects (Principal investigator)	Fujisawa	2003

A 26-week, randomized, multicentre, parallel group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when ASM981 (pimecrolimus) cream 1% is used at the first signs and/or symptoms of atopic dermatitis and it's safety and tolerability in adults 18 years of age or older. (Principal investigator)	Novartis	2003 - 4
A safety extension of patients treated in a 12-week, randomized, double-blind, placebo-controlled, multicentre, parallel group, dose-finding core study to determine the dose-response, safety and tolerability of three doses (10, 20, 30 mg b.i.d.) of pimecrolimus tablets in subjects with atopic dermatitis	Novartis	2004
An open-label extension study to study MHE100185, to evaluate long-term safety, efficacy and optimal dosing frequency of 750 mg intravenous Mepolizumab in subjects with Hypereosinophilic Syndrome	GlaxoSmithKline	2004
A study to evaluate the effect of single and repeat doses of Rosiglitazone on the pharmacokinetics of Methotrexate in patients receiving Methotrexate for psoriasis	GlaxoSmithKline	2003 - 4
A multicentre, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of GW406381 35 mg and 70 mg, administered once daily for 21 days to subjects with Postherpetic Neuralgia	GlaxoSmithKline	2004
A randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of three dose levels of Rosiglitazone Maleate in the treatment of chronic plaque psoriasis	GlaxoSmithKline	2003 - 4

PUBLICATIONS
(peer-reviewed)

1. **Shear NH**, Spielberg SP. Pharmacogenetics and cutaneous adverse drug reactions. Pediatr Dermatol 1983; 1(2): 165-73.
2. Koren G, **Shear NH**, MacLeod SM. The role of the skin in the distribution of digoxin and the digoxin-quinidine interaction. IRCS J Med Sci 1985; 13: 72-3.
3. Butt WW, Koren G, England S, **Shear NH**, Whyte H, Bryan CA, Swyer PR. Hypoxia associated with helium-oxygen therapy in neonates. J Pediatr 1985; 106: 474-7.
4. Dupuis LL, **Shear NH**, Zuker RM. Hyperpigmentation due to topical application of silver sulfadiazine cream. J Am Acad Dermatol 1985; 12: 1112-4.
5. Uetrecht JP, Zahid N, **Shear NH**, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Therap 1988; 245: 274-9.
6. **Shear NH**, Spielberg SP. An in vitro lymphocytotoxicity assay for studying adverse reactions to sulfonamides. Br J Dermatol 1985; 113 (Suppl. 28): 112-3.
7. **Shear NH**, Spielberg SP. In vitro evaluation of a toxic metabolite of sulfadiazine. Can J Phys Pharmacol 1985; 63: 1370-2.
8. **Shear NH**, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-84.
9. Roberts EA, **Shear NH**, Okey AB, Manchester DL. The Ah receptor and dioxin toxicity: From rodent to human tissues. Chemosphere 1985; 14: 661-74.
10. Koren G, Feldman Y, **Shear NH**. Motherisk - A new approach to antenatal counseling of drug/chemical exposure. Vet Hum Toxicol 1986; 28(6): 563 - 5.
11. **Shear NH**. Ketoconazole in superficial fungal infections. Seminars Dermatol 1987; 6: 58 - 61.
12. Page EH, **Shear NH**. Temperature-dependent skin disorders. J Am Acad Dermatol 1988; 18: 1003 - 19.
13. **Shear NH**, Graff L. Camouflage cosmetics in dermatologic therapy. Can Fam Physician 1987; 33: 2343 - 6.
14. Rieder MJ, Uetrecht JP, **Shear NH**, Spielberg SP. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Therap 1988; 244: 724 - 8.
15. **Shear NH**, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in-vitro assessment of risk. J Clin Invest 1988; 82: 1826 - 32.
16. Koren G, Demitrakoudis D, Weksberg R, Rieder M, **Shear NH**, Sonley M, Shandling B, Spielberg SP. Neuroblastoma after prenatal exposure to phenytoin: cause and effect? Teratology 1989; 40: 157-162.
17. Koren G, Bologa-Campeneau M, Long D, Feldman Y, **Shear NH**. The perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obst Gyn 1989; 160: 1190 - 4.
18. Rieder MJ, Uetrecht JP, **Shear NH**, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286 - 289.
19. Bentur L, **Shear NH**, Roifman C. Cutaneous lymphohistiocytic infiltrates in patients with hypogammaglobulinemia. J Pediatr 1990; 116: 68 - 72.
20. **Shear NH**. Diagnosing cutaneous adverse reactions to drugs. Arch Dermatol 1990; 126: 94 - 97.
21. Ghajar BM, Lanctôt K, **Shear NH**, Naranjo CA. Bayesian differential diagnosis of a cutaneous reaction associated with the administration of sulfonamides. Seminars Dermatol 1989; 8: 213-218.
22. **Shear NH**, Bhimji S. Pharmacogenetic differences and cutaneous drug reactions. Seminars Dermatol 1989; 8: 219-226.

23. Rieder MJ, **Shear NH**, Kanee A, Tang BK, Kalow W, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13 - 7.

24. **Shear NH**, Solomon RS. Getting to the bottom of a cutaneous drug reaction. Can J Diag 1990; 7: 101 - 116.

25. McLeod PJ, **Shear NH**, MacLeod SM. Faculty attitudes toward various teaching formats at two Canadian medical schools. Acad Med 1991; 66: 121.

26. **Shear NH**. Diagnóstico de reacciones cutáneas adversas a fármacos. Arch Dermatol Edición Española 1990; 1: 164 - 8.

27. Spielberg SP, **Shear NH**, Cannon M, Hutson NJ, Gunderson K. In vitro assessment of hypersensitivity reactions to sorbinil. Ann Intern Med 1991;114: 720-4.

28. Levy M, **Shear NH**. Mycoplasma pneumonia infections and Stevens-Johnson syndrome: Report of 8 cases and analysis of the literature with implications to clinical characteristics, pathogenic and diagnostic criteria. Clin Pediatr (Phila) 1991; 30:42-9

29. Pastuszak A, Klein J, **Shear NH**, Koren G. Therapeutic drug monitoring of retinoid concentrations in female patients. Can Dermatol Assoc J 1991; 5(2): 21-3.

30. Guenther L, Wexler DM, Baxter ML, Lester RS, Sauder DN, **Shear NH**, et al. Inducing remission of severe psoriasis with low-dose Cyclosporin A. Can J Dermatol 1991; 3 (5): 163 - 7.

31. **Shear NH**. Penicillin allergy - 1991. Can J Dermatol 1991; 3 (6): 183 - 4.

32. Naranjo CA, **Shear NH**, Lanctôt K. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol 1992; 32: 897 - 904.

33. Gupta A, Eggo M, Uetrecht J, Cribb A, Daneman D, Rieder MJ, **Shear NH**, Spielberg SP. Drug-induced hypothyroidism: The thyroid as a target in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992; 51: 56 - 7.

34. Recchia A, **Shear NH.** Organization and functioning of an adverse drug reaction clinic. J Clin Pharmacol 1994; 34: 68 - 79.

35. **Shear NH**, Maddin SW. Benzoyl peroxide-miconazole cream vs. erythromycin lotion in patients with moderate to severe acne vulgaris. Can J Dermatol 1992; 4: 213 - 6.

36. **Shear NH**, Pastuszak A, Klein J, Koren G. Management program for retinoid therapy in women. Can J Dermatol 1992; 4: 249 - 52.

37. Jaunkalns R, **Shear NH**, Sokoluk B, Gardner D, Claas F, Uetrecht JP. Antimyeloperoxidase antibodies and adverse reactions to clozapine. Lancet 1992; 339: 1611 - 2.

38. Bastuji-Garin S, Rzany B, Stern RS, **Shear NH**, Naldi L, Roujeau JC. A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92 - 6.

39. Turner CC, Assaad D, **Shear NH**. Bullae on the legs of an elderly man: Mycosis fungoides bullosa. Arch Dermatol 1994; 130: 1552.

40. Uetrecht JP, **Shear NH**, Zahid N. N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system. Drug Metab Dispos Biol Fate Chem 1993; 21:830-4

41. Einarson TR, Arikian SR, **Shear NH**. Oral treatments for severe psoriasis: Government payor analysis for Canada. J Dermatol Treat 1993; 4: S23 - 7.

42. Spier C, **Shear NH,** Lester R. Klinefelter's syndrome presenting as leg ulcerations. Arch Dermatol 1995; 131: 230.

43. Gupta AK, Knowles SR, Gupta MA, Jaunkalns R, **Shear NH.** Lithium therapy associated with hidradenitis suppurativa: Case report and a review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995; 32: 382-6.

44. Solish NJ, **Shear NH**, Lester RS. Fatal etretinate-induced toxic epidermal necrolysis. Can Dermatol Assoc J 1993; 7: 19 - 20.

45. Kwok M, Lanctôt KL, **Shear NH**, Naranjo CA. Enhanced computerized Bayesian assessment of suspected drug rashes with "BARDI - Q & A." Can J Clin Pharmacol 1994; 1: 19 - 26.

46. Shilalukey K, Robieux I, Spino M, Greenwald M, **Shear NH**, Koren G. Are current pediatric dose recommendations for intravenous theophylline appropriate? J Asthma 1993; 30: 109 - 21.

47. Knowles S, Choudhury T, **Shear NH**. Metronidazole hypersensitivity. Ann Pharmacother 1994; 28: 325 - 6.

48. Knowles S, **Shear NH**. Levamisole causing a fixed drug eruption. Can J Hosp Pharm 1994; 47: 65 - 6.

49. Gupta AK, Sauder DN, **Shear NH**. Antifungals - an overview I. J Am Acad Dermatol 1994 ; 30: 677 - 98.

50. Gupta AK, Sauder DN, **Shear NH**. Antifungals - an overview II. J Am Acad Dermatol1994; 30: 711 - 33.

51. Naranjo CA, Kwok M, Lanctôt KL, Zhao H, Spielberg SP, **Shear NH**. Enhanced differential diagnosis of anticonvulsant hypersensitivity reactions by an integrated Bayesian and biochemical approach. Clin Pharm Ther 1994; 56: 564 - 75.

52. Koren G, Kriska M, Pons G, **Shear NH**, Sanz E, MacLeod SM. The network of pediatric pharmacology training programs. Clin Pharmacol Ther 1993; 54: 1 - 6.

53. Einarson TR, Arikian SR, **Shear NH**. Cost effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130 (Supp 43): 32 - 4.

54. Gupta AK, **Shear NH**, Lester RS, Baxter ML, Sauder DN. Betamethasone dipropionate polyacrylic film-forming lotion in the treatment of hand dermatitis. Int J Dermatol 32: 828 - 9.

55. Parker K, Mittmann N, **Shear NH**, Hermann N, Shulman K, Silver I, Gardner D, Busto U. Lithium augmentation in geriatric depressed outpatients: a clinical report. Int J Geriatr Psychiatry 1994; 9: 995 - 1002.

56. Gupta AK, **Shear NH**. Terbinafine in the treatment of superficial dermatomycoses. Can J Dermatol 1994; 6: 561 - 5.

57. Knowles SR, Gupta AK, **Shear NH**, Sauder DN. Azathioprine hypersensitivity-like reactions: case report and a review of the literature. Clin Exp Dermatol 1995; 20: 353-6.

58. Lanctôt KL, Ghajar BM, **Shear NH**, Naranjo CA. Improving the diagnosis of hypersensitivity reactions associated with sulfonamides. 1994 J Clin Pharmacol 34: 1228 - 33.

59. **Shear NH,** Einarson TE, Arikian S. Clinical and economic factors in the use of topical antifungal agents. Pharmacoeconomics 1995; 7: 251-67.

60. Chang DK, **Shear NH.** Cutaneous reactions to anticonvulsants. Semin Neurol 1992; 12:329-37

61. Gupta AK, **Shear NH**, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 1995; 32: 140 - 2.

62. Oh PI, **Shear NH**. Pharmacoeconomics: Measurement of cost and benefit. Annals Roy Coll Phys Surg 1995; in press.

63. Prussick R, Knowles SR, **Shear NH**. Cutaneous aspects of drug reactions. Curr Probl Dermatol 1994; 6(3): 83 - 122.

64. Knowles SR, Gupta AK, **Shear NH**. Spot diagnosis or pharmacological folly? Can J Clin Pharmacol 1994; 1: 145 - 7.

65. Laredo ES, Knowles S, **Shear NH**. Cutaneous reactions to amiodarone. Can J Clin Pharmacol 1994; 1: 133 - 40.

66. Oh PI, Lanctôt KL, Naranjo CA, **Shear NH.** Fatal aplastic anemia associated with ticlopidine therapy - Approaches to an adverse drug reaction. Can J Clin Pharmacol 1995; 2:19-22.

67. Knowles SR, **Shear NH.** Hypersensitivity to trimethoprim-sulfamethoxazole in HIV-infected patients. Opportunistic Complications of HIV 1995; 4: 40-53.

68. Einarson TR, Arikian SR, **Shear NH.** Pharmacoeconomic analysis of oral treatments for onychomycosis: A Canadian study. J Res Pharm Econ 1995; 6(1): 3-22.

69. Einarson TR, Arikian SR, **Shear NH.** Pharmacoeconomic analysis of oral drugs in treatment of tinea infections. J Res Pharm Econ 1995; 6(3): 15-36.

70. Neuman MG, Cameron RG, **Shear NH,** Bellentani S, Tiribelli C. Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced injuries in the human Hep G2 cell line. Gastroenterology 1995; 109: 555-63.

71. Einarson TR, Gupta AK, **Shear** NH Arikian S. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics 1996; 9: 307 - 20.

72. **Shear NH**, Gupta AK. Terbinafine for the treatment of pedal onychomycosis: A foot closer to the promised land of cured nails? Arch Dermatol 1995; 131: 937-42.

73. Herrmann N, Mittmann N, Silver IL, Shulman KI, Busto UA, **Shear NH,** Naranjo C. A validation study of the geriatric depression scale short form. Int J Ger Psychiatr 1996: 11: 457-60.

74. Liu BA, Mittmann N, Knowles SR, **Shear NH.** Hyponatremia and selective serotonin reuptake inhibitors: a review of spontaneous reports. Can Med Assoc J 1996; 155: 519-27.

75. **Shear NH,** Einarson TR, Arikian SR, Doyle JJ, van Assche D. Therapie von tinea-infektionen: Eine pharmakoökonomische Analyse der topischen Therapie in Österreich, Deutschland und der Schwiez. Z Allg Med 1995; 71: 1055-60.

76. **Shear NH,** Malkiewicz IM, Klein D, Koren G, Randor S, Neuman MG. Acetaminophen-induced toxicity to human epidermoid cell line A431 and hepatoblastoma cell line Hep G2, in vitro, is diminished by silymarin. Skin Pharmacol 1995; 8: 279 - 91.

77. Knowles SR, **Shear NH.** Anaphylaxis from bacitracin and polymyxin B (Polysporin) ointment. Int J Dermatol 1995; 34: 572-3.

78. Tailor SAN, Gupta AK, Walker S, **Shear NH.** Peripheral edema due to nifedipine-itraconazole interaction. Arch Dermatol 1996;132: 350 - 2.

79. **Shear NH,** Gratton D . Issues in the management of onychomycosis - Developing more effective treatment strategies [Proceedings]. Can J Dermatol 1995; 7: S25-29.

80. Liu B, Knowles S, Cohen L, Werb M, **Shear NH.** Pancreatic insufficiency due to anti-tuberculous therapy. Ann Pharmacother 1997; 31: 724 - 726.

81. Knowles SR, Shapiro L, **Shear NH.** Serious adverse reactions induced by minocycline: Report of 13 patients and review of the literature. Arch Dermatol 1996; 132: 934-9.

82. Oh PI, Maerov P, Pritchard D, Knowles SR, Einarson TR, **Shear NH.** A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther 1996; 18: 160 - 182.

83. Einarson TR, Gupta AK, **Shear NH**, Arikian S. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics. 1996; 9: 307 - 20.

84. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern R, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti C, Shapiro S, **Shear NH,** Schöpf E, Kaufman DW. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600 - 7.

85. Prussick R, **Shear NH**. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996: 35: 346-9

86. Shapiro LE, Knowles SR, **Shear NH.** Sulfonamide allergies - Management in the nineties. ACI International 1996; 8: 5 - 12.

87. **Shear NH**, Knowles SR, Shapiro LE, Poldre P. Dapsone in the prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1996; 35: 819-22.

88. Singer MI, **Shear NH.** Informed patient decision making and the use of prescription medications: A Canadian dermatologic perspective. J Cutan Med Surg 1996; 1: 10 - 6.

89. Gupta AK, Gonder JR, **Shear NH,** Dilworth GR. The development of green vision in association with terbinafine therapy. Arch Dermatol 1996; 132: 845-6.

90. Gupta AK, Kopstein JB, **Shear NH.** Hypersensitivity reaction to terbinafine. J Am Acad Dermatol 1997; 36: 1018 - 9.

91. **Shear NH**, Black F, Lexchin J. Examining the physician-detailer interaction. Can J Clin Pharmacol 1996; 3: 175 - 9.

92. Singer MI, **Shear NH.** The SAFER MD informed patient decision-making check-list for the use of prescription medications: A foundation for responsible risk management. Can J Clin Pharmacol 1996; 3: 172 - 4.

93. Gupta AK, Scher RK, De Doncker P, Sauder DN, **Shear NH.** Onychomycosis: New therapies for an old disease. West J Med 1996; 165: 349-351.

94. Gupta AK, Oh PI, **Shear NH.** Pharmacoeconomics for dermatologists: An introduction. J Cut Med Surg 1996; 1: 185 - 9

95. Singer M, Shapiro LE, **Shear NH.** Cytochrome P450 3A: Interactions with dermatologic therapies. J Am Acad Dermatol 1997; 37: 765 - 771.

96. Virani A, Mailis A, Shapiro LE, **Shear NH.** Drug interactions in human neuropathic pain pharmacotherapy. Pain 1997; 73: 3 -13.

97. Gupta AK, **Shear NH.** Onychomycosis: Going for cure. Can Fam Physician 1997; 43: 299-305.

98. **Shear NH.** Terfenadine: Where do we stand? Can J Clin Pharmacol 1997; 4: 39 - 41.

99. Shapiro LE, **Shear NH.** Mechanisms of drug reactions: The metabolic track. Sem Cutan Med Surg 1996; 15: 217 - 27.

100. Gupta AK, Sibbald RG, Lynde CW, Hull PR, Prussick R, **Shear NH,** DeDoncker P, Elewski BE. Onychomycosis in children: Prevalence and treatment strategies. J Am Acad Dermatol 1997; 36: 395 - 402.

101. Einarson TR, **Shear NH**, Oh PI. Models for pharmacoeconomic analysis. Can J Clin Pharmacol 1997; 4: 25 - 29.

102. Singer MI, Sauder DN, **Shear NH.** Informed patient decision making: Cyclosporine and skin disease. J Cut Med Surg 1997; 1: 203 - 208.

103. Gupta AK, Sibbald RG, Knowles SR, Lynde CW, **Shear NH.** Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: Four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol 1997; 36: 858 - 62.

104. Liu BA, Gordon M, Labrache JM, Murray TM, Vieth R, **Shear NH.** Seasonal prevalence of vitamin D deficiency in institutionalized older adults. J Am Geriatr Soc 1997; 45: 598-603

105. Mittmann N, Herrmann N, Einarson TR, Busto UE, Lanctôt KL, Liu BA, Shulman KI, Silver IL, Naranjo CA, **Shear NH.** The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disorders 1997; 46: 191 - 217.

106. Mittmann N, Liu BA, Iskedjian M, Bradley C, Pless R, **Shear NH**, Einarson TR. Drug-related mortality in Canada (1984 - 1994). Pharmacoepid Drug Saf 1997; 6: 157 - 168.

107. Oh PI, Gupta AK, Einarson TR, Maerov P, **Shear NH.** Calcipotriol in the treatment of psoriasis of limited severity: Pharmacoeconomic evaluation. J Cut Med Surg 1997; 2: 7 - 15.

108. Gupta AK, Koren G, **Shear NH.** A double-blind, randomized, placebo-controlled trial of eutectic lidocaine/prilocaine cream 5% (EMLA) for analgesia prior to cryotherapy of warts in children and adults. Ped Dermatol 1998; 15: 146 - 50.

109. Pon K, **Shear NH**. Bazex syndrome (acrokeratosis paraneoplasitca). J Cut Med Surg 1997; 2: 86 - 89.

110. Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, **Shear NH**. Montgomery Asberg severity predictors. Am J Psychiatr 1997; 154: 1320 - 21.

111. Shapiro LE, Knowles SR, **Shear NH.** Fluoxetine-induced serum sickness-like reaction. Ann Pharmacother 1997; 31: 927.

112. Cameron RG, Neuman MG, **Shear NH,** Blendis L. Multivesicular stellate cells in primary biliary cirrhosis. Hepatology 1997, 26: 819 - 822.

113. Gupta AK, **Shear NH.** A questionnaire study on the management of onychomycosis: A Canadian perspective. Int J Dermatol 1998; 37: 457 - 460.

114. Einarson TR, Oh PI, Shear NH. Multinational pharmacoeconomic analysis of topical and oral therapies for onychomycosis. J Dermatological Treat 1997; 8: 229-235.

115. Shapiro LE, Knowles SR, **Shear NH.** Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133: 1224 - 1230.

116. Gupta AK, **Shear NH.** Terbinafine: An update. J Am Acad Dermatol; 1997; 37: 978 - 988.

117. Schlienger R, **Shear NH.** Serotoninsyndrom: Eine potentiell schwerwiegende Nebenwirkung unter selektive Serotonin-Wiederaufnahme-Hemmern. Dtsch med Wschr 1997; 122: 1495 - 9.

118. Gupta AK, **Shear NH.** Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol 1998; 138: 529 - 532.

119. Gupta AK, Summerbell R, Einarson TE, **Shear NH.** An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 1998; 55: 645 - 74.

120. Gupta AK, Soori GS, Del Rosso JQ, Bartos PB, **Shear NH.** Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol 1998; 765 - 7.

121. Drake LA, **Shear NH,** Arlette JP, Cloutier R, Danby FW, Elewski BE, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740 - 745.

122. Shilalukey K, Kaufman M, Bradley S, Francombe WH, Amankwah K, Goldberg E, **Shear NH**, Olivieri NF, Koren G. Counseling sexually active teenagers treated with potential human teratogens. J Adolesc Health 1997; 21: 143 – 6.

123. Knowles S, Gupta AK, **Shear NH.** The spectrum of cutaneous reactions associated with diltiazem: Three cases and a review of the literature. J Am Acad Dermatol 1998; 38: 201 - 6.

124. **Shear NH**, Einarson TR, Arikian SR, Doyle JJ, van Assche D. Pharmacoeconomic analysis of topical treatments for tinea infections. Inter J Dermatol 1998; 37: 64 - 71.

125. Liu B, Anderson G, Mittmann N, To T, Axcell T, **Shear NH.** Use of selective serotonin reuptake inhibitors or tricyclic antidepressants and risk of hip fracture in elderly people. Lancet 1998; 351: 1303 - 1307.

126. Neuman MG, **Shear NH,** Bellentani S, Tiribelli C. The role of cytokines in ethanol-induced cytotoxicity in vitro in HepG2 cells. Gastroenterology 1998; 115: 157 - 166.

127. Schlienger RG, Knowles SR, **Shear NH.** Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998; 51: 1172 – 5.

128. Schlienger RG, **Shear NH.** Anti-epileptic drug hypersensitivity syndrome. Epilepsia 1998; 39 (S7): S3 - S7

129. Schlienger RG, Oh PI, Knowles SR, **Shear NH.** Quantifying the costs of serious adverse reactions to anticonvulsants. Epilepsia 1998; 39 (S7): S27 - S32.

130. Schlienger RG, Shapiro LE, **Shear NH.** Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 39 (S7): S22 - S26.

131. Trakas K, Lawrence K, **Shear NH.** Increased resource utilization by the Canadian obese population. Can Med Assoc J 1999; 160: 1457 - 62.

132. Cameron RG, Neuman MG, **Shear NH,** Katz G, Bellentani S, Tiribelli C. Modulation of liver-specific cellular response to ethanol in vitro in HepG2 cells. Toxicol In Vitro 1998; 12: 111 - 122.

133. **Shear NH.** Antihistamines: Safer than you might think. J Cut Med Surg 1998; 3: 23 - 24.

134. Mittmann N, Herrmann N, Shulman K, Silver IL, **Shear NH**, Naranjo CA. Comparison of the global assessment of functioning scale and the Montgomery Asberg depression rating scale in elderly depressed patients. Int J Geriatr Psychiatr, 1998; 13: 568 - 74.

135. Phillips E, Knowles S, Weber E, **Shear NH.** Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management. J Aller Clin Immunol 1998; 102: 697 - 8.

136. Tran C, Knowles SR, Liu BA, **Shear NH.** Gender differences in adverse drug reactions. J Clin Pharmacol 1998; 38: 1003 - 9.

137. Walmsley SL, Khorasheh S, Singer J, Djurdjev O, and the Canadian HIV Trials Network 057 Study Group. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). J Acquired Imm Def Syndr Hum Retrovirol 1999; 19: 498 - 505.

138. Arikian S, Casciano J, Frech F, **Shear NH**, Smith B, Leyden J, Einarson T, Schein J, Doyle J. Economic analysis of oral therapies for onychomycosis of the toenails and fingernails. Submitted for publication 1998.

139. **Shear NH**, Levine C. Needs survey of Canadian rosacea patients. J Cutan Med Surg 1999; 3: 178 - 81.

140. Nulman I, Berkovitch M, Klein J, Pastuszak A, Lester RS, **Shear NH**, Koren G. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol 1998; 38: 926 – 30.

141. Gupta AK, del Rosso JQ, Lynde CW, Brown GH, **Shear NH.** Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol 1998; 23: 64 – 7.

142. Mittmann N, Herrmann N, Shulman KI, Silver IL, Busto UE, Borden EK, Naranjo CA, **Shear NH**. The effectiveness of antidepressants in elderly depressed outpatients; a prospective case series study. J Clin Psychiatr 1999; 60: 690 – 97.

143. Knowles SR, Shapiro LE, **Shear NH.** Anticonvulsant hypersensitivity syndrome: incidence, prevention, and management. Drug Safety 1999; 489 -501.

144. **Shear NH**, Landau M, Malkiewicz I, Katz GG, Neuman MG. Ethanol-modulated cytokine production and expression in skin cells exposed to methotrexate. Skin Pharmacol Appl Skin Physiol 1999; 12: 64 – 78.

145. Gupta AK, **Shear NH.** The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venerol 1999; 12: 1 – 13.

146. Rzany B, et al. [**Shear NH as** Member of Severe Cutaneous Adverse Reaction Study Group] Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy. Lancet 1999; 353: 2190 – 4.

147. Gupta AK, **Shear NH.** Safety review of the oral antifungal agents used to treat superficial mycoses. Int J Dermatol 1999; 38: Suppl 2: 40 - 52.

148. Gupta AK, Katz HI, **Shear NH.** Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol 1999; 41: 237 – 49.

149. Rochon PA, Anderson GM, Tu JV, Gurwitz JH, Clark JP, **Shear NH,** Lau P. Age- and gender-related use of low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc 1999; 47: 954 – 9

150. Shapiro LE, **Shear NH.** Drug-drug interactions: How scared should we be? Can Med Assoc J 1999; 161: 1266 – 7.

151. Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, **Shear NH.** Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytotoxicity. Clin Biochem 1999; 32: 519 – 536.

152. Neuman MG, Benhamou JP, Martinot M, Boyer N, **Shear NH**, Malkiewicz IM, Katz GG, Suneja A, Singh S, Marcellin P. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin Biochem 1999; 32: 537 – 546.

153. Neuman MG, **Shear NH**, Cameron RG, Katz G, Tiribelli C. Ethanol-induced apoptosis in vitro. Clin Biochem 1999; 32: 547 – 556.

154. Gupta AK, **Shear NH**. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Safety 2000; 22: 33 – 52.

155. Gupta AK, DeKoven J, Lester RS, **Shear NH,** Sauder DN. Open-label study to evaluate the healing rate and safety of the Profore extra four-layer bandage system in patients with venous leg ulceration. J Cut Med Surg 2000; 4: 13 – 15.

156. Eisen ER, Fish J, **Shear NH.** Management of drug-induced toxic epidermal necrolysis. J Cut Med Surg 2000; 4: 96 - 102.

157. Liu BA, Knowles SR, Mittmann N, Einarson TR, **Shear NH**. Reporting fatal adverse drug reactions. Canadian Journal of Clinical Pharmacology 2001; 8: 84 - 8.

158. Tavadia SMB, Mydlarski PR, M.D. Reis MD, Mittmann N, Pinkerton PH, **Shear NH**, Sauder DN. Screening for azathioprine toxicity-a pharmacoeconomic study based on a target case. J Am Acad Dermatol 2000; 42: 628 - 32.

159. Neuman MG, Malkiewicz I, **Shear NH.** A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clinical Biochem 2000; 517 – 24.

160. Knowles SR, Uetrecht J, **Shear NH.** Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356: 1587 - 91.

161. Sullivan JR, **Shear NH.** What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions? Br J Dermatol 2000; 142: 205 - 207.

162. Gupta AK, Lambert J, Revuz J, **Shear NH.** Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur J Dermatol 2001; 10: in press.

163. **Shear NH,** Drake L, Gupta AK, Lambert J, Yaniv R. The implications and management of drug interactions with itraconazole, fluconazole, and terbinafine. Dermatol 2000; 196 – 203.

164. Trakas K, Oh P, Singh S, Risebrough N, **Shear NH.** The health status of obese individuals in Canada. Int J Obesity 2001; 25: 662 - 668.

165. Knowles SR, Uetrecht JP, **Shear NH.** Confirming false positive adverse reactions to drugs by performing individualized, randomized trials. Can J Clin Pharmacol 2002; 9: 149 - 53.

166. Ozdemir V, **Shear NH**, Kalow W. Pharmacogenetics: What will be its role in evaluating drug safety and minimizing adverse effects? Drug Safety 2001; 24: 75 – 85.

167. Knowles S, Shapiro L, **Shear NH**. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of “sulfa” allergy. Drug Safety 2001; 24: 239 - 47.

168. Fleischer Jr AB, Schwartzel EH, Colby SI, Altman DJ and the Depigmenting Solution Study Group (incl. **Shear NH**). The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol 2000;42:459-67.

169. Popat A, **Shear NH,** Malkiewicz I, Stewart MJ, Steenkamp V, Thomson S, Neuman MG. The toxicity of Callilepis laureola, a South African traditional herbal medicine. Clin Biochem 2001; 34: 229 - 36.

170. Sullivan JR, **Shear NH.** The drug hypersensitivity syndrome: What is the pathogenesis? Arch Dermatol 2001; 137: 357 – 64.

171. Valois M, **Shear NH**. Clinical pharmacology consult: Consult requests may be misleading – An organized approach to drug-induced hepatitis. Can J Clin Pharmacol 2001; in press.

172. Katz GG, **Shear NH**, Malkiewicz IM, Valentino K, Neuman M. Signaling for ethanol-induced apoptosis and repair in vitro. Clinical Biochem 2001; 34: 219 – 7.

173. Neuman MG, Blendis LM, **Shear NH**, Malkiewicz IM, Ibrahim A, Katz GG, Sapir D, Halpern Z, Brill S, Peretz H, Magazinik S, Konikoff FM. Cytokine network in non-responding chronic hepatitis C

patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate. Clin Biochem 2001; 34: 183 – 8.

174. Neuman MG, Benhamou JP, Malkiewicz I, Akremi R, **Shear NH**, Asselah T, Ibrahim A, Boyer N, Marinot-Peignoux M, Jacobson-Brown P, Katz GG, Le Breton V, Le Guludec G, Suneja A, Marcellin P. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 2001; 34: 173 – 82.

175. Neuman MG, **Shear NH**, Jacobson-Brown P, Katz GG, Neilson HK, Malkiewicz IM, Cameron RG, Abbott F. CYP2E1-mediated modulation of valproic acid-induced hepatotoxicity. Clin Biochem 2001; 34: 211 – 8.

176. **Shear NH.** The science of health technology assessment: The safety perspective. Can J Clin Pharmacol 2001; 8 (Suppl A): 24A – 28A.

177. Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Pater P, Shapiro J, **Shear NH**, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy M. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 667 – 74.

178. Shapiro LE, Uetrecht JP, **Shear NH.** Minocycline, perinuclear antibody, and pigment. The biochemical basis. J Am Acad Dermatol 2001; 45: 787 – 9.

179. Lowitt M, **Shear NH.** Pharmacogenomics and dermatological therapeutics. Arch Dermatol 2001; 137: 1512 – 4.

180. Liu BA, Knowles SR, Mittmann N, Einarson T, **Shear NH**. Reporting of fatal adverse drug reactions. Can J Clin Pharmacol 2001; 8: 84-88 .

181. Popat A, **Shear NH**, Malkiewicz I, Thomson S, Neuman MG. Mechanism of Impila (Callilepis laureola)-induced cytotoxicity in Hep G2 cells. Clin Biochem 2002; 35: 57-64.

182. Neuman MG, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T, Martinot-Peignoux M, **Shear NH**, Katz GG, Akremi R, Marcellin P. Kinetics of serum TNF-□ and TGF-β levels in chronic hepatitis reflect the severity of the disease. J Viral Hepatitis 2002; 9: 1 – 7.

183. Neuman MG, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T, Martinot-Peignoux M, **Shear NH**, Katz GG, Akremi R, Benali S, Boyer N, LecomteL, Le Breton V, Le Guludec G, Marcellin P. Serum TNF-□ and TGF-β levels in chronic hepatitis C patients are modulated by therapy. Cytokine 2002; 17: 108-17.

184. Neuman M, Angulo P, Malkiewicz I, Jorgensen R, **Shear NH**, Dickson ER, Haber J, Katz G, Lindor K. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002; 17: 196-202

185. Neuman MG, Malkiewicz I M, Cameron RG, Haber JA, Katz GG, **Shear NH**. Ethanol-induced apoptosis in skin cells. Alcohol 2002: 26, 1-12.

186. Scalera A, Bayoumi AM, Oh P, Risebrough N, **Shear N**, Lin-in Tseng A. Clinical and economic implications of non-adherence to HAART in HIV infection. Disease Management & Health Outcomes 2002; 2: 85-91.

187. Neuman MG, Brenner DA, Rehermann B, Taieb J, Chollet-Martin S, Cohard M, Garaud JJ, Poynard T, Katz GG, Cameron RG, **Shear NH**, Gao B, Takamatsu M, Yamauchi M, Ohata M, Saito S, Maeyama S, Uchikoshi T, Toda G, Kumagi T, Akbar SM, Abe M, Michitaka K, Horiike N, Onji M: Mechanisms of alcoholic liver disease: Cytokines. Alcohol Clin Exp Res 2001; 25(5 Suppl ISBRA): 251S-253S.

188. Rivers JK, Arlette J, **Shear NH,** Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.

189. Neuman MG, Benhamou JP, Malkiewicz IM, Ibrahim A, Valla DC, Martinot-Peignoux M, Asselah T, Bourliere M, Katz GG, **Shear NH**, Marcellin P. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 2002; 9: 134-140.

190. Iskedjian M, Einarson TR, MacKeigan LD, **Shear NH**, Addis A, Mittmann N, Ilersich AL. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis. Clinical Therapeutics 2002; 24(2):302-316.

191. Mandelcorn Monson R, **Shear NH.** Lupus-associated toxic epidermal necrolysis (LATEN): A novel entity? J Am Acad Dermatol 2003; 48(4):525-9.

192. The Health and Environmental Sciences Institute Task Force: Atkinson NF Jr, Essayan D, Gruchalla R, Haggerty H, Kawabata T, Sandler D, Updyke L, **Shear NH,** Wierda D. Task Force Report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J Allergy Clin Immunol 2002; 109: S461 – 78.

193. Neuman MG, Haber JA, Malkiewicz IM, Cameron RG, Katz GG, **Shear NH.** Ethanol signals for apoptosis in cultured skin cells. Alcohol 2002; 26: 179 – 190.

194. Shapiro LE, **Shear NH**. Drug interactions and the dermatologist: proteins, pumps and P450s. J Am Acad Dermatol 2002; 47: 467 - 84.

195. Phillips EJ, Sullivan JR, Knowles SR, **Shear NH**. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. *AIDS* 2002; 16: 2223 – 5.

196. Forman R, Koren G, **Shear NH.** Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Safety 2002; 25: 965 – 72.

197. Shapiro LE, Knowles SR, Weber E, Neuman MG, **Shear NH**. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf. 2003; 26(3):187-95.

198. Neuman MG, Malkiewicz IM, Phillips EJ, Rachlis AR, Ong D, Yeung E, **Shear NH**. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit. 2002; 24(6):728-36.

199. Knowles SR, Uetrecht JP, **Shear NH**. Confirming false adverse reactions to drugs by performing individualized, randomized trials. Can J Clin Pharmacol. 2002; 9(3):149-53.

200. Neuman MG, Benhamou JP, Ibrahim A, Malkiewicz I, Spircu T, Martinot-Peignoux M, **Shear NH**, Katz GG, Akremi R, Bourliere M, Marcellin P. Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy. Rom J Gastroenterol. 2002;11(2):97-103.

201. Perri D, Ito S, Rowsell V, **Shear NH.** The kidney – the body's playground for drugs: An overview of renal drug handling with selected clinical correlates. Can J Clin Pharmacol 2003; 10: 17 – 23.

202. Mandelcorn-Monson RL, **Shear NH**, Yau Y, Barber B, Spaner D, DeBenedette MA . Cytotoxic T lymphocyte reactivity to Gp100, MelanA/MART-1,and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003; 121: 550 - 6.

203. Kuehl BL, Fyfe KS, **Shear NH.** Cutaneous cleansers. Skin Therapy Lett 2003; 8 (3): 1 - 4.

204. Casciano J, Amaya K, Doyle J, Arikian S, **Shear NH**, Haspel M, Kahler K. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Managed Care 2003; 12 (3): 47 – 54 (ref. at http://www.managedcaremag.com/antifungal.pdf).

205. Valois M, Phillips EJ, **Shear NH**, Knowles SR. Clindamycin-associated acute generalized exanthematous pustulosis. Contact Dermatitis. 2003; 48(3):169.

206. Phillips EJ, Knowles SR, **Shear NH.** Cutaneous manifestations of antiviral therapy. J Am Acad Dermatol. 2003; 48(6): 985-6.

207. Knowles S, Shapiro L, **Shear NH**. Reactive metabolites and adverse drug reactions: clinical considerations. Clin Rev Allergy Immunol. 2003; 24(3):229-38.

208. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS, and the SCAR Study Group (**Shear NH** as member of SCAR study group). The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: A multinational perspective. J Rheumatol 2003; 30: 2234 – 40.

209. Nigen S, Knowles S, **Shear NH.** Drug Eruptions: Approaching the diagnosis of drug-induced skin diseases. J Drugs in Dermatol – New Methods and Techniques 2003; 2: 278 – 98.

210. Shapiro LE, Knowles SR, **Shear NH.** Drug interactions of clinical significance for the dermatologist. Recognition and avoidance. Am J Clin Dermatol 2003; 4: 623 – 39.

211. Wong GAE, **Shear NH.** Is a drug alone sufficient to cause the drug hypersensitivity syndrome? Arch Dermatol 2004;140 226-230.

212. Koren G, Avner M, **Shear NH.** Generic isotretinoin: a new risk for unborn children. CMAJ 2004; 170: 1567 – 8.

213. Mittmann N, Knowles SR, Gomez M, Fish JS, Cartotto R, **Shear NH**. Evaluation of the extent of under-reporting of serious adverse drug reactions : the case of toxic epidermal necrolysis. Drug Saf. 2004;27: 477-87.

214. Mydlarski PR, Mittmann N, **Shear NH**. Intravenous immunoglobulin: use in dermatology. Skin Therapy Lett. 2004; 9:1-6.

215. Wong GA, **Shear NH**. Melkersson-Rosenthal syndrome associated with allergic contact dermatitis from octyl and dodecyl gallates. Contact Dermatitis 2003; 49: 266-7.

216. Walsh SRA, **Shear NH.** Psoriasis and the new biologic agents: interupting a T-AP dance. CMAJ 2004; 170: 1933 – 41.

217. Iskedjian M, Piwko C, **Shear NH**, Langley RG, Einarson TR. Topical calcineurin inhibitors in the treatment of atopic dermatitis : a meta-analysis of current evidence. Am J Clin Dermatol. 2004;5(4):267-79.

218. Romanus D, Iscoe N, DeAngelis C, **Shear N**, Einarson TR. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Support Care Cancer. 2004 Jul 3 [Epub ahead of print] PMID: 15235902

219. Ong D, Popat A, Knowles SR, Arrowood JS, **Shear NH**, Binkley KE. Objective psychological measurement and clinical assessment of anxiety in adverse drug reactions. Can J Clin Pharmacol. 2004 Spring;11(1):e8-16. Epub 2004 Apr 01. PMID: 15226522

220. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, Martin AM, Mallal S, **Shear NH.** Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19: 979 – 87.

221. Guenther L, Langley RG, **Shear NH**, Bissonnette R, Ho V, Lynde C, Murray E, Papp K, Poulin Y, Zip C. Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg. 2005 May 5; [Epub ahead of print]

222. **Shear NH**. Fulfilling an unmet need in psoriasis: Do biologicals hold the key to improved tolerability? Drug Safety 2006; 29: 49 - 66.

223. Notman MJ, Phillips EJ, Knowles SR, Weber EA, **Shear NH**. Clindamycin skin testing has limited diagnostic potential. Accepted for publication. Contact Dermatitis 2005.

224. Freiman A, Barzalai DA, Barankin B, Natsheh A, **Shear NH.** National appraisal of dermatology residency training: A Canadian study. Arch Dermatol 2005; 141: 1100 – 4.

225. Lynde C, Barber K, Claveau J, Gratton D, Ho V, Krafchik B, Langley R, Marcoux D, Murray E, **Shear NH.** Canadian practical guidelines for the treatment and management of atopic dermatitis. J Cutan Med Surg 2005; 8 [Supp 5]: 1 – 9.

226. Ortonne JP, **Shear NH,** Shumack S, Henninger E. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139] BMC Dermatology 2005, 5:13 (16 Dec 2005)

227. Freiman A, Natsheh A, Barankin B, **Shear NH.** Dermatology postgraduate training in Canada: CanMEDS competencies. Dermatol Online J. 2006 Jan 27;12(1):6.

228. **Shear NH**, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2005; 9: Suppl 1, 4 – 9.

229. Dubetret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, **Shear NH,** Papp KA. Br J Dermatol 2006; DOI 10.1111/J.1365-2133.07344x

230. Mittmann N, Chan B, Knowles S, Mydlarski PR, Cosentino L, **Shear NH**. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. J Cutan Med Surg 2006; 10: 222-7.

231. Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, **Shear NH**, Maksymowich W. A phase III, randomized, multicenter, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients. Lancet 2007 (in press).

232. Mydlarski PR, Ho V, **Shear NH.** Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J Cutan Med Surg 2006; 10: 205 – 221.

233. Neuman MG, **Shear NH**, Malkiewicz IM, Taeri M, Shapiro LE, Krivoy N, Haber j, Gomez M, Fish J, Cartotto R, Cohen L. Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides. Translational Res 2007 (In press).

234. Mittmann N, Chan B, Knowles S, Cosentino L, **Shear NH**. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol. 2006; 7: 359 – 368.

235. Haider A, Mamdani M, **Shear NH**. Socioeconomic status and the prevalence of melanoma in Ontario, Canada. J Cutan Med Surg. 2007 Jan-Feb;11(1):1-3.

236. Mittmann N, Chan BC, Knowles S, **Shear NH**. IVIG for the treatment of toxic epidermal necrolysis. Skin Ther Lett 2007; 12: 7-9.

237. Papp KA, Keystone EC, **Shear NH.** Mechanism of action, pharmacokinetics, and drug interactions of etanercept in dermatology. J Cutan Med Surg 2007; 11 (Suppl 1), S3 –S13.

238. Neuman MG, **Shear NH,** Malkiewicz IM, Taeri M, Shapiro LE, Krivoy N, Haber J, Gomez M, Fish J, Cartotto R, Cohen L. Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides. Translational Research 2007; 149: 243 – 253.

INVITED PUBLICATIONS

1. **Shear NH**. Ketoconazole in the treatment of severe and recalcitrant dermatophytoses. Today's Therapeutic Trends 1985; 3(4): 23-30.
2. Solomon RS, **Shear NH**. Drug-induced hypersensitivity syndromes. Contemporary Allergies 1990; 1 (2): 4 - 10.
3. Knowles S, **Shear NH**. Antihistamines. Clinics in Dermatology 1989; 7: 48-59.
4. Willoughby J, **Shear NH**. Antimalarials. Clinics in Dermatology 1989; 7: 60-68.
5. **Shear NH**. Year-round safe sun. Pharmacy Practice 1990; 6 (6): 11-14.
6. Bologa M, Pastuszak A, **Shear NH,** Koren G. Dermatological drugs in pregnancy. Clin Dermatol 1991; 9: 435 - 451.
7. Papp K, **Shear NH**. Systemic gold therapy. Clinics in Dermatology 1991; 9: 535 - 51
8. **Shear NH**, Villars V, Marsolais C. Oral and topical terbinafine in the treatment of fungal infections. Clinics in Dermatology 1992; 9: 487 - 495.
9. Khan I, **Shear NH**. Cytokines as anti-cancer therapy. Clinics in Dermatology 1991; 9: 523 - 533.
10. Katz A, **Shear NH**. Choosing the best antifungal agents. Med (North America) 1992: 3540 - 6.
11. Singer M, **Shear NH**, Sauder DN. Approaching the patient with alopecia. Can J Diag 1992; 9(2): 101 - 25.
12. **Shear NH**, Katz AM. Antifungal therapies. Contemporary Dermatol 1992; 1 (2): 5 - 10.
13. Oh P, **Shear NH**. Case report: Ticlopidine and aplastic anemia. The Drug Report 1992; (November) no. 39: 1 - 2.
14. Oh P, Knowles S, **Shear NH**. An approach to the patient in an adverse reaction clinic. Contemporary Allergies 1992; 3 (3): 10 - 14.
15. **Shear NH**. Empowering the physician [Editorial]. Contemporary Dermatol 1993; 4: 3.
16. Gupta AK, **Shear NH**, Sauder DN. New antifungal agents. Current Opinion in Dermatol 1993; 2: 200-206.
17. **Shear NH**. Innovations in dermatologic therapy. Can Therapeutics 1993; 1: 31 - 6.
18. Knowles SR, Gupta AK, **Shear NH**. Oral contraceptives and acne. Contemp Ob/Gyn 1995; supplement 1 - 8.
19. **Shear NH**. Current status of risk information. in proceedings of Communicating Risk to Patients, September 20 -1, 1994. United States Pharmacopoeia Convention Inc. 1995, Rockville Maryland, USA.
20. Knowles SR, Prussick R, **Shear NH.** Unexpected skin reactions to systemic drugs. Medicine North America 1995; 273-7.
21. Gupta AK, Sauder DN, **Shear NH.** Efficacy of the antifungal agent terbinafine in the treatment of superficial dermatophyte infections - An overview. Today's Therapeutic Trends 1995; 13: 9-20.
22. **Shear NH**, Gratton D. Issues in the management of onychomycosis. Proceedings - Editors. Can J Dermatol Int 1995; 7: 1-30.
23. **Shear NH**. Developing more effective strategies. Can J Dermatol Int 1995; 25-9.
24. Shapiro LE, Knowles SR, **Shear NH.** Sulfonamide allergies - Management in the nineties. ACI International 1996; 8: 5 - 12.
25. Knowles S, Shapiro L, **Shear NH.** Serious dermatologic reactions in children. Current Opinions in Pediatrics 1997; 9: 388 - 395.
26. **Shear NH.** Holding up your end in meeting drug reps. Patient Care Can 1997; 8: 51-4.

27. Shapiro LE, Singer MI, **Shear NH.** Pharmacokinetic mechanisms of drug-drug and drug-food interactions in dermatology. Curr Opin Dermatol 1997; 4: 25 - 31.

28. **Shear NH.** What we do and don't know about rosacea. Skin and Aging 1998; 6 (2): 30 - 32.

29. **Shear NH.** What we know so far about the new alopecia drugs. Skin and Aging 1998 (4); 6: 27 - 29.

30. Knowles SR, **Shear NH.** Managing the risks of corticosteroid therapy. J Watch Dermatol 1998; 6: 41 - 43.

31. Lester RS, Knowles SR, **Shear NH**. The risks of systemic corticosteroid use. Dermatol Clin 1998; 16: 277 - 288.

32. **Shear NH**. Reading the skin: Dermatology and research into drug safety. Odyssey 1998; 4(1): 36 - 37.

33. **Shear NH**. Choosing an optimal strategy for rosacea treatment. Skin & Aging 1998; 6 (8): 21 - 4.

34. **Shear NH**. Rosacea: A condition that needs special care. J Cut Med Surg 1998; 2: S4-1.

35. Knowles SR, **Shear NH.** Skin testing and adverse drug reactions. The Drug Report 1999; 65: 1 – 3 [in Ont Med Rev 1999; 66 (6)].

36. Knowles SR, Shapiro LE, **Shear NH.** Drug eruptions. Curr Probl Dermatol 2000; 12: 58 – 62.

37. Shapiro LE, **Shear NH.** Drug interactions / P450. Curr Probl Dermatol 2001; 13: 141 - 152.

38. Sullivan JR, **Shear NH.** Drug eruptions and other adverse drug effects in aged skin. Clinics in Geriatric Medicine 2002; 18: 21 – 42.

39. Wong GAE, **Shear NH.** Cutaneous adverse drug reactions in older adults. Part I: Assessment and diagnosis. Geriatrics & Aging 2004; 7 (4): 50 – 53.

40. Wong GAE, **Shear NH.** Cutaneous adverse drug reactions in older adults. Part II: Management. Geriatrics & Aging 2004; 7 (5): 22 – 25.

41. Wong GAE, **Shear NH.** Adverse drug interactions and reactions in dermatology: Current issues of clinical relevance. Dermatol Clin 2005; 23(2): 335 – 43.

CHAPTERS

1. **Shear NH**, MacLeod SM, Milochik JA. Cutaneous drug toxicity in children. In: Drill V, Lazar P. eds. Cutaneous Toxicity. New York: Raven Press, 1984: 213 - 27.
2. **Shear NH**. Approach to adverse reactions to antimicrobial therapy in children. Antimicrobial Therapy in Children. eds G Koren, C Prober, R Gold, Marcel-Dekker, New York: 1987: 793 - 803.
3. **Shear NH**. The skin as a target organ for drug reactions. In: Idiosyncratic Adverse Drug Reactions: Impact on drug development and clinical use after marketing. Naranjo CA, Jones J (eds) Elsevier, Amsterdam: 1990: 99 - 115.
4. Ghadially R, **Shear NH**. Topical therapy and percutaneous absorption. In: Pediatric pharmacology: Therapeutic principles in practice [2nd edition]. Yaffe SJ, Aranda JV. eds. W.B. Saunders, Philadelphia 1992: 72 - 77.
5. Page EH, **Shear NH**. Temperature-dependent skin disorders. In: Dermatology in General Medicine. 4th edition. Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IW, Austen KF, eds. McGraw-Hill , New York. 1993; 1581 - 92.
6. Kovacs JAJ, **Shear NH**. Therapeutic efficacy of retinoids. In: Koren G, ed. Retinoids in clinical practice — the risk benefit ratio. Marcel Dekker, New York 1993, 1 - 36.
7. Kovacs JAJ, **Shear NH**. Adverse nonreproductive effects of retinoids in humans. In: Koren G, ed. Retinoids — the risk benefit ratio. Marcel Dekker, New York 1993, 241 - 260.
8. **Shear NH**, Radde IC. Percutaneous drug absorption. Pediatric Pharmacology and Therapeutics (second edition). Radde IC, MacLeod SM eds. Mosby, St. Louis 1993, 377 - 383.
9. Oh PI, **Shear NH**. Drug Eruptions. In Bone RC, ed. Current Practice of Medicine - Dermatology Volume 1, Philadelphia. Current Medicine 1995, 131-8.
10. Stern R, **Shear NH**. Cutaneous reactions to drugs and biological response modifiers. In: Cutaneous Medicine and Surgery. Arndt K, LeBoit P, Robinson J, Wintroub BU eds. W.B. Saunders Company, Philadelphia 1995; 412 - 25.
11. **Shear NH**, Prussick R. Drug eruptions and skin manifestations of immune suppression. in Cutaneous Medicine and Surgery: Self assessment and review. Dover J, Arndt K, LeBoit P, Robinson J, Wintroub BU eds W.B. Saunders Company, Philadelphia 1995, 129-141.
12. **Shear NH**, Kronovic SR. Scabies and pediculosis. in Therapeutic Choices. Gray J ed. Canadian Pharmaceutical Association 1995, 422-7.
13. Tailor S, Rachlis A, **Shear NH**. Cellulitis. in Therapeutic Choices. Gray J ed. Canadian Pharmaceutical Association 1995, 651-7.
14. **Shear NH**, Kronovic SR. Scabies and pediculosis. in Therapeutic Choices 2nd ed. Gray J ed. Canadian Pharmaceutical Association 1998, 482 - 486.
15. Tailor S, Rachlis A, **Shear NH**. Cellulitis. in Therapeutic Choices 2nd ed. Gray J ed. Canadian Pharmaceutical Association 1998, 676 - 682.
16. Naranjo CA, **Shear NH**, Busto U. Adverse drug reactions. In Principles of Medical Pharmacology 6th ed, Kalant H, Roschlau WH, eds. Oxford University Press, New York 1998; 791 780.
17. Gupta AK, Oh PI, **,**Einarson TR, **Shear NH**. Onychomycosis: An economic evaluation of therapies, in Care Management of Skin Diseases: Life Quality and Economic Impact, eds. Rajagopalan R, Sherertz EF, Anderson RT. Marcel Dekker, New York, 1998, 341 - 53.
18. Knowles S, Shapiro L, **Shear NH.** Drug eruptions in children. In Advances in Dermatology. Volume 14. Chapter 13. Mosby Inc. St. Louis. 1998; 399 - 415.
19. **Shear NH**, Knowles, SR, Shapiro LE. Cutaneous adverse drug reactions. In Scientific American Medicine. Dale DC, Federman DD, eds. Scientific American Inc. 1999; 2, VI: 1 – 8.
20. Knowles SR, **Shear NH.** Allergic reactions to drugs. Conn's Current Therapy 2000, 748 - 53.

21. Shapiro LE, **Shear NH.** Drug eruptions. In: Current Practice of Medicine. Editor: FT Fitzgerald. 1999; 2: 421 – 30.
22. Neuman MG, Cameron RG, **Shear NH,** Blendis LM. Electron microscopic study on antifibrotic effects of ursodeoxycholate treatment in primary biliary cirrhosis. Proceedings of Falk Symposium 108: Bile Acids and Cholestasis (XV International Bile Acid Meeting). Eds: G Paumgartner, et al. Kluwer Academic Publishers. Dordrecht / Boston / London. 1999; 31: 254 – 269.
23. **Shear NH,** Landau M, Shapiro LE. Hypersensitivity reactions to drugs. In: Harper J, Oranje J, Prose N, eds. Textbook of Pediatric Dermatology. Oxford, Blackwell Scientific. 2000; 1743 – 52.
24. Shapiro LE, **Shear NH.** Drug eruptions. In: Current Practice of Medicine. [serial online: http://praxis.md]. 2001.
25. Neuman M, Cameron R, **Shear NH**, Feuer G. Drug induced apoptosis of skin cells and liver. In: Apoptosis and its modulation by drugs. Eds. Cameron RG, Feuer G. Springer, Berlin. Handbook of Experimental Pharmacology, 2000; 142: 343 – 356.
26. Knowles SR, **Shear NH**. Scabies and pediculosis. in Therapeutic Choices, 3rd ed. Gray J ed. Canadian Pharmaceutical Association 2000, 552-7.
27. **Shear NH**, Knowles, SR, Shapiro LE. Cutaneous adverse drug reactions. In Scientific American Medicine. Dale DC, Federman DD, eds. Scientific American Inc. 2001; 2, VI: 1 – 9.
28. Sullivan JR, **Shear NH.** Drug eruptions. PocketMedicine/Internal Medicine, www.pocketmedicine.com, 2002
29. Knowles SR, **Shear NH.** Drug hypersensitivity syndromes. In: SE Wolverton, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia: W. B. Saunders Co., 2001, pp 872 – 84
30. Shapiro LE, **Shear NH.** Drug interactions. In: SE Wolverton, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia: W. B. Saunders Co., 2001, pp 848 – 71.
31. Knowles SR, Shapiro LE, **Shear NH.** Approach to the patient with a drug eruption. Best Practices in Medicine 2002; praxis press, in press.
32. Shapiro LE, Knowles SR, **Shear NH.** Drug interactions. In: Bolognia JL, Jorizzo JL, Rapini RP. eds. Dermatology; Mosby. 2003, 2085 - 2100.
33. **Shear NH,** Knowles SR, Sullivan JR, Shapiro LE. Cutaneous reactions to drugs. In; Austen KF, eds. Fitzpatrick's Dermatology in General Medicine - Sixth Edition. McGraw-Hill. 2003, 1330 - 7.
34. Knowles SR, Shaprio LE, **Shear NH.** In: Shachner LA, Hansen RC. Eds. Pediatric Dermatology Third edition. Mosby. Drug eruptions. 2003; 1267 – 76
35. Knowles S, Shaprio L, **Shear NH.** Cutaneous drug reactions, in Gotto A (ed): DISEASEDEX ™ - General Medicine, July 31, 2003. Thomson MICROMEDEX, Greenwood Village, Colorado http:///www.mdx.com/products/diseasedexgeneral/
36. Imrie K, **Shear NH**, Jones G. Primary skin lymphomas. In: Treatment policies of the hematology site group. Toronto-Sunnybrook Regional Cancer Centre. 3rd edition 2003.
37. Knowles SR, **Shear NH**. Scabies and pediculosis. in Therapeutic Choices. Gray J ed. Canadian Pharmaceutical Association, Fourth Edition, 2003, 724 - 31.
38. **Shear NH**, Knowles, SR, Shapiro LE. Cutaneous adverse drug reactions. In ACP Medicine. Dale DC, Federman DD, eds. WebMD Professional Publishing, New York. 2004; 2, VI: 1 – 9.
39. **Shear NH**. Adverse drug reactions. In: Principles of Medical Pharmacology. Kalant H, Grant DM, Mitchell J eds. Elselvier Canada. Toronto. Seventh Edition 2007. pp 803 - 11
40. Wong GAE, **Shear NH**. Drugs used in Dermatology. In: Principles of Medical Pharmacology. Kalant H, Grant DM, Mitchell J eds. Elselvier Canada. Toronto. Seventh Edition 2007. pp 890 - 99
41. Knowles SR, Shapiro LE, **Shear NH**. Hypersensitivity reactions to drugs. In: Harper J, Oranje J, Prose N, eds. Textbook of Pediatric Dermatology. Second edition, 2006. Oxford, Blackwell Publishing; 2131 – 41.

42. **Shear NH.** Drug Eruptions. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I, eds. Treatment of Skin Disease: Comprehensive therapeutic strategies. Second edition, 2006. Mosby Elselvier; 178 – 9.

43. Knowles SR, Wong G, **Shear NH.** Dermatological drugs, topical agents, and cosmetics. In: Aronson JK, ed. Side Effects of Drugs Annual 28, 2005. Elsevier, 168 – 176.

44. Knowles SR, **Shear NH.** Recognition and management of severe cutaneous drug reactions. In: DelRosso JQ, ed. Dermatologic Clinics. 2007; 25(2): 245 – 254.

BOOKS AND JOURNALS EDITED

1. Dermatologic Pharmacology I. **Shear NH** Editor. Clinics in Dermatology 1989; 7: (3), J.B. Lippincott, Philadelphia.
2. Dermatologic Pharmacology II. **Shear NH** Editor. Clinics in Dermatology, 1991; (4), Elselvier, New York.
3. Facts about healthy hair. **Shear NH** Editor. Grosvenor House Press, Toronto, 1989.
4. What's new in research. **Shear NH** Contributing editor. Can J Dermatol 1989.
5. Cutaneous adverse drug reactions. **Shear NH** Editor. Seminars in Dermatology 1989: 8 (3).
6. Le guide-santé du cheveu, pour toutsavoir sur les techniques modernes de prévention de la chute des cheveux et ses thérapies. Giroux JM and **Shear NH** (editors). Éditions Grosvenor Inc., Montréal 1989.
7. The consensus workshop to explore a framework for determining risk of unexpected events following medical intervention. Final report. Symposium proceedings. Ottawa, Canada, October 31 - November 2, 1989.
8. Risk estimation for pharmaceuticals - Proceedings of an international symposium. November 20 - 21, 1990. Canadian Public Health Association, Health and Welfare Canada, World Health Organization. Steering committee.
9. Pharmacotherapy Bulletin (Sunnybrook Health Science Centre) - Founder and medical editor. 1991 - present.
10. Boken om hår. **Shear NH** (editor), Juhlin L (translator into Swedish). Warne Förlag AB, Partille (Sweden) 1992.
11. Benefit, Risk and Cost Management of Drugs. Report of the CPHA National Advisory Panel on Risk/Benefit management of Drugs. Canadian Public Health Association, Ottawa 1993.
12. Dermatomycoses: Current issues in therapy. Canadian Council on Dermatomycoses. **Shear NH**, Editor-in-chief and Chair. Pegasus Healthcare International 1994.
13. Issues in the management of onychomycosis - Proceedings. Can J Dermatol 1995; 7: S1-30. Editors: **Shear NH,** Gratton D.
14. **Shear NH.** Dermatology section editor in Drugs of Choice: A formulary for general practice. 1997, 2nd ed, Can Med Assoc, eds Levine M, Lexchin J, Pellizzari R. pp 22 - 6.
15. **Shear NH.** Dermatology section editor in Drugs of Choice: A formulary for general practice. 1997, 3rd ed, Can Med Assoc, eds Levine M, Lexchin J, Pellizzari R. pp 28 - 75.
16. **Shear NH.** Editor for Drug-induced Disease series (6 articles) in Lancet, November 2000.

EDITORIAL BOARDS

1.	Canadian Journal of Dermatology	1989 - 1995
2.	Perspectives in Pain Management	1990 - 1994
3.	Contemporary Dermatology	1992 - 1994
4.	Canadian Therapeutics	1993 - 1994
5.	Canadian Journal of Clinical Pharmacology **Editor-in-chief**	1993 - 2003
6.	Grand Rounds in Infectious Diseases	1993 - 1995
7.	Journal Watch for Dermatology **Contributing Editor** **Deputy Editor-in-Chief**	1995 - present 1998 - present
8.	Canadian Journal for Diabetes Care **National Editorial Board**	1997 - 2001
9.	Journal of Cutaneous Medicine and Surgery **Associate Editor**	1995 - present
10.	Skin & Aging **Medical Editor**	1998 – present
11.	Drug Safety **International Editorial Board**	1999 – present
12.	American Journal of Clinical Dermatology **International Editorial Board**	1999 – present
13.	Health News **Editorial Advisory Board**	2000 – present
14.	Journal of Clinical Research **Editorial Board**	2001 – present
15.	*Journal of the American Academy of Dermatology* **Editorial Board**	2001 – present
16.	American Journal of Contact Dermatitis **Associate Editor for Drug Dermatitis**	2003 – present
17.	*Archives of Dermatology* **Editorial Board**	2004 - present

ABSTRACTS AND OTHER COMMUNICATIONS

1. **Shear NH**, Krafchik BR, MacLeod SM. Diffuse cutaneous mastocytosis: Treatment with ketotifen and cimetidine [Abstract]. Clin Invest Med 1983; 6: (Supp 2) :36.
2. **Shear NH**, Spielberg SP. Sulfonamide hypersensitivity: In vitro verification [Abstract]. Clin Invest Med 1983; 6 (Supp 2) :36.
3. **Shear NH**, Spielberg SP, Okey AB. Binding of 2, 3, 7, 8-tetrachloro-dibenzo-p-dioxin (TCDD) to Ah receptor in skin [Abstract]. In: Proceedings of the ninth meeting of the International Congress of Pharmacology, London (UK): International Congress of Pharmacology, 1984:87.
4. **Shear NH**, Koren G, MacLeod SM. The role of skin in the distribution of digoxin and in the digoxin-quinidine interaction [Abstract]. J Invest Dermatol 1984; 82:423.
5. **Shear NH**, MacLeod SM, Koren G. Cutaneous digoxin binding: An in vitro model for study of drug interactions [Abstract]. In: Proceedings of the ninth meeting of the International Congress of Pharmacology, London (UK): International congress of Pharmacology, 1984:87.
6. **Shear NH**, Spielberg SP, Sauder DN. Acetaminophen toxicity in human keratinocytes in vitro [Abstract]. Pediatr Res 1984; 18:161A.
7. **Shear NH**, St-Pierre MV, Koren G, Spielberg SP. Theophylline metabolism by keratinocytes in vitro [Abstract]. In: Proceedings of the sixth International Symposium on Microsomes and Drug Oxidation Brighton (UK); 1984:P4/2.
8. **Shear NH**, Spielberg SP. The in vitro investigation of adverse reactions to anticonvulsants [Abstract]. Annals Royal College Physicians and Surgeons, Canada 1984; 17:301.
9. Roberts EA, Golas CL, **Shear NH**, Okey AB. Detection of Ah receptor in human tissues by binding of [3H] 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) [Abstract]. Clin Invest Med 1984; 7(Suppl 2) :37
10. **Shear NH**, Okey AB. Location of Ah receptor for dioxin [Letter]. J Am Acad Dermatol 1984; 10: 663-4.
11. **Shear NH**, Dupuis LL, Zimmerman B. [Letter]. Can Med Assoc J 1985; 133: 93.
12. Koren G, Butt WW, **Shear NH**. [C]. Hypoxia with helium-oxygen therapy. J Pediatr 1985; 106: 648.
13. **Shear NH**, Spielberg SP. [Abstract] Pharmacogenetics of cutaneous adverse drug reactions [Abstract]. Acta Pharmacologica et Toxicologica, Supp V, 1986.
14. **Shear NH**, Spielberg SP. Anticonvulsant hypersensitivity syndrome: In vitro demonstration of a pharmacologic predisposition [Abstract]. J Invest Dermatol 1986.
15. Uetrecht JP, **Shear NH**, Biggar W. Dapsone is metabolized by human neutrophils to a hydroxylamine [Abstract]. Pharmacologist 1986; 28: 239.
16. **Shear NH**. Chronic viral diseases. [Letter]. Can Med Assoc J 1987; 136: 326.
17. Bush LE, Harper PA, Sauder DN, **Shear NH**. Acetaminophen toxicity to keratinocytes in vitro assessed by a novel assay [Abstract]. J Invest Dermatol 1987; 88: 480.
18. **Shear NH**, Rieder MJ, Spielberg SP, Uetrecht J. Hypersensitivity reactions to sulfonamide antibiotics are mediated by a hydroxylamine metabolite [Abstract]. J Invest Dermatol 1987; 88: 517.
19. Harper PA, Golas CG, **Shear NH**, Okey AB. Characterization of the Ah receptor and aryl hydrocarbon hydroxylase induction by 2,3,7,8 TCDD and benz(a)anthracene in the human epidermal cell line A431 Abstract]. J Invest Dermatol 1987; 88: 494.
20. Quaggin S, Rieder MJ, **Shear NH**, Spielberg SP. Sulfonamide hypersensitivity reactions: Clinical characteristics of patients positive on in vitro assay [Abstract]. Clin Invest Med 1987; 10: B56.
21. MacLeod SM, Rieder MJ, **Shear NH**, Somer G, Sellers EM. A survey of attitudes of medical faculty towards medical student teaching [Abstract]. Clin Invest Med 1987; 10: B100.

22. Rieder MJ, **Shear NH**, Spielberg SP, D Daneman. Drug-induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides [Abstract]. Clin Invest Med 1987; 10: B56.
23. **Shear NH**, Spielberg SP. Pharmacogenetics of cutaneous adverse drug reactions [Abstract]. Clin Exp Dermatol 1987; 12: 138.
24. **Shear NH**, Bush LE, Harper PA. Assessment of xenobiotic toxicity to keratinocytes in vitro [Abstract]. Clin Res 1987; 35: 812A.
25. Gupta A, Waldhauser L, Rieder MJ, Harper PA, Daneman D, Eggo M, **Shear NH**, Uetrecht J, Spielberg SP. Drug-induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions [Abstract]. Pediatr Res 1988; 23: 277A.
26. Rieder MJ, Kanee A, **Shear NH**, Tang BK, Spielberg SP. Acetylator phenotype in sulfonamide hypersensitivity reactions [Abstract]. Clin Invest Med 1988; 11: C17.
27. Duffy C, Rieder MJ, Laxer R, **Shear NH**, Spielberg SP. Sulfasalazine hypersensitivity [Abstract]. Clin Invest Med 1988; 11: C17.
28. **Shear NH**. Snoring and calf pain [Letter]. N Engl J Med 1987; 317: 840.
29. Koren G, Bologa M, Pellegrini E, Long D, Feldman Y, Henderson K, **Shear NH**. The perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester [Abstract]. Clin Invest Med 1988; 11: C20.
30. Spielberg SP, Stephens M, Wiholm BE, Naranjo CA, **Shear NH**, Levy M. Adverse drug reactions [Abstract]. International Conference on Pharmaceutical Sciences and Clinical Pharmacology 1988: 6.
31. Spielberg SP, Uetrecht JP, Daneman D, Eggo M, Gupta A, Kalow W, Naranjo C, Rieder MJ, **Shear NH**, Tang BK. The sulfonamides: A model for ADR investigation. [Abstract] Proceedings of the PMA Annual Meeting, Washington, DC 1988.
32. Shaw-Stiffel T, Tang BK, Spielberg SP, **Shear NH**. Caffeine: A novel probe to assess drug effects on hepatic cytochrome P450 activity [Abstract]. Hepatology l988; 8: l385.
33. **Shear NH**, Bentur L, Roifman C. Unusual skin lesions in hypogammaglobulinemia respond to intravenous gammaglobulin replacement [Abstract]. Clin Res 1988; 36: 814A.
34. Shaw-Stiffel T, Tang BK, Kalow W, Uetrecht JP, Spielberg SP, **Shear NH**. Urinary caffeine metabolite ratios - a novel technique to assess drug inhibition of hepatic cytochrome P450 activity [Abstract]. Eur J Clin Invest 1989; 19(2): A95.
35. **Shear NH**, Spielberg SP. Hypersensitivity reactions to sorbinil are associated with diminished oxidative metabolite detoxification [Abstract]. J Invest Dermatol 1989; 92: 517A.
36. Page EH, **Shear NH**. Temperature-dependent skin disorders. Dermatol Dig 1988 [Abstract]; 1 - 2.
37. **Shear NH**. Alumni as stakeholders [Letter]. McMaster alumni newsletter 1988; 10 (2): 8.
38. Rieder MJ, Uetrecht JP, Cannon M, **Shear NH**, Spielberg SP. Sulfonamide hypersensitivity reactions: Reversal of hydroxylamine toxicity by N-acetylcysteine in lymphocytes of patients and normal volunteers [Abstract]. Pediatr Res 1988; 23: 263A.
39. Richman-Eisenstat J, **Shear NH**, Kutcher S, Hill J, Miller M, Spielberg SP. Rhabdomyolysis associated with carbamazepine-induced anticonvulsant hypersensitivity syndrome [Abstract]. Clin Invest Med 1989; 12: B16.
40. Shaw-Stiffel TA, Tang BK, Kalow W, Uetrecht JP, Martin SM, Spielberg SP, **Shear NH**. Drug inhibition of hepatic cytochrome P-450 activity assessed by changes in a specific ratio of caffeine metabolites in urine [Abstract]. Clin Invest Med 1989; 12: B39.
41. Richman-Eisenstat J, Roy L, Legault L, Derry J, Uetrecht, **Shear NH**. Confirming false adverse reactions to drugs by individualized, randomized trials. Clin Invest Med 1989 [Abstract]; 12: B16.
42. Rieder M, Kanee A, **Shear NH**, Tang B, Spielberg SP. Acetylator phenotype in sulfonamide hypersensitivity reactions [Abstract]. Pediatr Res 1989; 25: 72A.

43. Rieder MJ, Uetrecht J, **Shear NH**, Spielberg SP. Pathogenesis of sulfonamide hypersensitivity reactions [Abstract]. Clin Invest Med 1989; 12: B13.

44. **Shear NH**, Spielberg SP. Sorbinil hypersensitivity reactions associated with diminished oxidative metabolite detoxification [Abstract]. Eur J Clin Pharmacol 1989; 36: A54.

45. Knight A, **Shear NH,** Weber E, Uetrecht J, Wilson N, Derry J. Penicillin skin testing followed by oral challenge in patients with suspect penicillin allergy [Poster]. Annual meeting of American Academy of Allergy and Immunology, 1989.

46. Busto U, Chow B, Silver I, **Shear NH**, McKenzie S, Knowles S. Benzodiazepine prescription and use patterns in the hospitalized elderly [Abstract]. Clin Pharmacol Ther 1990; 47: 162.

47. Ghajar BM, Naranjo CA, **Shear NH**, Lanctôt KL. Improving the accuracy of differential diagnosis of idiosyncratic adverse drug reactions: Skin eruptions and sulfonamides [Abstract]. Clin Pharmacol Ther 1990; 47: 127.

48. Shaw-Stiffel T, **Shear NH**, Tang B, Kalow W, Uetrecht J, Spielberg SP. Urinary caffeine metabolite ratios as a measure of liver enzyme inhibition. [Abstract]. Clin Pharmacol Ther 1990; 47: 159.

49. Shaw-Stiffel T, **Shear NH**, Tang B, Kalow W, Uetrecht J, Spielberg SP. Inhibition of hepatic enzyme activity measured by specific ratios of caffeine metabolites in urine [Abstract]. J Gastroenterol Hepatol 1990.

50. **Shear NH**. Rational therapeutics: A clinical pharmacologic guide for the health professional. [Book review] Ann Intern Med 1990; 113: 258 - 259.

51. Zhao H, Naranjo CA, Lanctôt K, **Shear NH**. Enhanced differential diagnosis of anticonvulsant hypersensitivity syndrome by an integrated approach. Clin Pharm Ther [Abstract] 1991; 49: 150.

52. **Shear NH**. Foreword in Physician's 1991 Drug Handbook. Springhouse Corporation. Springhouse, Pennsylvania 1991.

53. **Shear NH**, Solish N. Drug-induced toxic epidermal necrolysis in childhood: In vivo-in vitro correlation. J Invest Dermatol [Abstract] 1991; 96: 538.

54. Sauder DN, Rosenthal D, Guenther L, Wexler DM, Gratton D, Landry M, **Shear NH**, Lester R, Baxter ML, Wilkinson RD, Vanjaka A, St-Pierre J-P, Bouchard S. A placebo-controlled study of remission with cyclosporine A in patients with severe plaque-form psoriasis. Second congress on immunointervention in autoimmune diseases: the role of cyclosporin. May 13-16 1991. Paris, France.

55. **Shear NH**. Principles and practice of dermatology [Book review]. Ann Intern Med 1991; 114: 998.

56. Zhoa H, Naranjo CA, Lanctôt K, **Shear NH**. Enhanced differential diagnosis of anticonvulsant hypersensitivity syndrome. Clin Pharmacol Ther [Abstract] 1991; 49: 150.

57. **Shear NH**, McLean W. New product update - EMLA cream. Medifacts - Dermatology 1991 (1).

58. **Shear NH**. New insights into hypersensitivity drug reactions in the skin. Congress review (18th World Congress of Dermatology) 1991 (2); 6 - 7.

59. **Shear NH**. Systemic drugs for skin diseases [Book review]. Annals RCPSC 1991; 24: 437.

60. **Shear NH**. 1-Year outcome in the eosinophilia-myalgia syndrome. Annals Intern Med [Commentary] 1992; 116 [S1 - ACP J Club]: 25.

61. Khan IU, **Shear NH**. Possible role of cytokines in the development of adverse drug reactions in human skin [Abstract]. FASEBJ 1992; 6: A1019.

62. **Shear NH**, Khan IU, Malkiewicz IM. Drug toxicity to keratinocytes in vitro is diminished by silymarin [Abstract]. J Invest Dermatol 1992; 98: 651.

63. Khan IU, Malkiewicz IM, **Shear NH**. Increased epidermal cytokine released in vitro after exposure to sulfonamides. [Abstract] J Invest Dermatol 1992; 98: 652.

64. **Shear NH.** Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: The clinical and laboratory management of severe drug reactions. [Abstract] Pediatr Dermatol 1992; 9: 168.

65. Horgan-Bell C, **Shear NH.** Menkes syndrome - not just kinky hair. [Abstract] Pediatr Dermatol 1992; 9: 171.
66. Solish N, **Shear NH.** Recurrent toxic epidermal necrolysis associated with thyroxine and treated with pulse methylprednisilone. [Abstract] Pediatr Dermatol 1992; 9: 191.
67. Shaw-Stiffel T, Gu L, **Shear NH,** Tang BK, Kalow W. Urinary caffeine metabolite ratios to assess cytochrome P450IA2 (CYP1A2) activity. [Abstract] Proceedings of the Second Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology 1992.
68. Mittmann N, **Shear NH**, Busto U, Herrmann N, Shulman K, Silver I, Gardner D, Borden K, Naranjo C. Antidepressants in the elderly: Developing a model for the measurement of benefit and risk [Abstract]. Clin Invest Med 1992; 15: A55
69. Shaw-Stiffel TA, Gu L, **Shear NH**, Tang BK, Kalow BK. Caffeine as a metabolic probe of cytochrome P450 IA2 [Abstract]. Hepatology 1992, 16: 592.
70. Oh PI, **Shear NH**. Fatal aplastic anemia related to ticlopidine therapy [Abstract]. Clin Pharmacol Ther 1993; 53: 157.
71. Kwok M, Lanctôt KL, **Shear NH**, Naranjo CA. Cross-validated computerized Bayesian assessment of putative adverse drug reactions with BARDI-Q&A [Abstract]. Clin Pharmacol Ther 1993; 53: 213.
72. Mittmann N, **Shear NH**, Busto UE, Herrmann N, Shulman KI, Silver IL, Gardner DM, Borden EK, Naranjo CA. Measurement of antidepressant benefit and risk in the elderly using observational methods [Abstract]. Clin Pharmacol Ther 1993; 53: 191.
73. **Shear NH**, Chang DKM. Cutaneous reactions to anticonvulsants [Poster]. American Academy of Dermatology Annual Meeting, San Francisco, December 1992 **[Gold Award - Teaching Value]**.
74. **Shear NH**, Malkiewicz I. Cytoprotective effect of silymarin and purpurogallin on human skin and liver cells in vitro. J Invest Dermatol [Abstract/poster] 1993; 100: 594.
75. Mittmann N, **Shear NH**, Busto UE, Herrmann N, Shulman KI, Silver IL, Gardner D, Borden EK, Naranjo CA. A practice-based, observational method for the assessment of antidepressant benefit and risk in the elderly. [Abstract / presentation] 1993; The Canadian Pharmcacoepidemiology Forum, Toronto, Canada.
76. Einarson TR, Dranitsaris G, Arikian SR, **Shear NH**. Clinical and pharmacoeconomic analysis of cyclosporin in severe psoriasis [Abstract] 1993; Canadian Society of Hospital Pharmacists, Annual professional practice conference, 42.
77. **Shear NH**, Einarson TR, Dranitsaris G, Arikian SR. Pharmacoeconomic analysis of oral treatments for fungal infections of skin and nails - North American perspective. [Abstract/poster/presentation]. Dermatology 2000 proceedings, Vienna , Austria, 1993.
78. Oh P, **Shear NH**. Fatal aplastic anemia related to ticlopidine therapy [Abstract/poster]. American College of Physicians, 74th Annual Session, Washington, D.C., 1993, Clinical Vignette Competition for Associates Abstracts, 59.
79. Voorneveld CR, **Shear NH**, Rubin LA. Anaphylactic reaction after gold injection [letter] J Rheumatol 1992; 19: 1650-1.
80. Einarson TR, Arikian SR, **Shear NH**. Pharmacoeconomic analysis of oral treatments for onychomycosis: a Canadian study [Poster]. American Academy of Dermatology Annual Meeting, Washington, December 4 - 9, 1993.
81. Garnis-Jones S, Maddin S, **Shear NH**, Marsolais C. A randomized, double-blind, placebo-controlled clinical trial with oral terbinafine 250 mg once daily in the treatment of toenail onychomycosis [Poster]. American Academy of Dermatology Annual Meeting, Washington, December 4 - 9, 1993.
82. Einarson TR, Arikian SR, **Shear NH**. Pharmacoeconomic analysis of systemic treatments for severe psoriasis: a Canadian study [Poster]. American Academy of Dermatology Annual Meeting, Washington, December 4 - 9, 1993.
83. Berkovitch M, Matsui D, Oh P, **Shear NH**, Koren G. Ganciclovir in newborns [Letter]. Clin Pharmacol Ther 1993; 54: 683.

84. **Shear NH,** Malkiewicz I, Neuman M. Xenobiotic-induced cytokine production in keratinocytes and hepatocytes in vitro is decreased by silymarin and purpurogallin [Abstract/poster]. J Invest Dermatol 1994; 102: 646.

85. **Shear NH,** Malkiewicz I, Neuman M. Skin and liver cytoprotection by silymarin against acetaminophen-induced toxicity in vitro [Abstract/poster]. J Invest Dermatol 1994; 102: 647.

86. Mittmann N, **Shear NH,** Busto UE, Herrmann N, Shulman KI, Silver IL, Gardner DM, Borden EK, Einarson TR, Naranjo CA. Comparative efficacy and safety of tricyclic antidepressants and serotonin reuptake inhibitors in the elderly. Can Pharmacoepi Forum 1994 [Poster].

87. Maddin S, Arlette J, **Shear NH,** Danby W, Giroux JM, Murray A, Ross B. Evaluation of the clinical efficacy and safety of ketoconazole 2% emulsion in the treatment of tinea cruris. [Poster] Amer Acad Dermatol 1994.

88. Liu BA, Topper AK, Maki BE, Gryfe C, Reeves RA, **Shear NH.** Falls in the elderly: Relationship to medication use and orthostatic hypotension [Abstract/poster]. Clin Pharmacol Ther 1994; 55: 173.

89. Mittmann N, Busto UE, Shulman KI, Herrmann N, Silver IL, Gardner DM, Borden EK, **Shear NH.** Variations in quality of life and depression levels in elderly depressed outpatients receiving pharmacotherapy [Abstract/poster]. Clin Pharmacol Ther 1994; 55: 174.

90. Naranjo CA, Lanctôt KL, **Shear NH.** Algorithms for evaluating suspected adverse drug reactions (ADRs): Validity revisited. [Abstract/presentation]. Clin Pharmacol Ther 1994; 55: 182.

91. Rieder MJ, **Shear NH,** Spielberg SP. Metabolic basis for cross-sensitivity between sulfonamides and nitrofurantoin. [Abstract/poster]. Clin Pharmacol Ther 1994; 55: 154.

92. Oh PI, Kwok M, **Shear NH,** Lanctôt KL, Knowles SR, Naranjo CA. A comparison of methods for the assessment of suspected adverse drug reactions in the clinic setting. [Abstract/presentation]. Clin Pharmacol Ther 1994; 55: 156.

93. **Shear NH** et al. Clinical efficacy and safety of ketoconazole 2% emulsion in tinea cruris. [Poster] American Academy of Dermatology July 30, 1994, San Francisco.

94. Neuman MG, Ishay JS, Eshchar J, Cameron RG, **Shear NH**. Hepatotoxicity effect of Vespa orientalis venom sac extract on human hepatoblastoma HepG2 cell lines in vitro. [Abstract/poster] International Meeting on Toxicology 1994

95. Bellentani S, Neuman MG, Cameron RG, **Shear NH**, Tiribelli C. Taurodeoxycholic acid and ursodeoxycholic acid reduce ethanol cytotoxicity in vitro in HepG2 cells. [Abstract/poster] J Hepatol 1994; 21: S80.

96. Tiribelli C, Neuman MG, **Shear NH**, Cameron RG. An in vitro model for human ethanol-induced liver damage using HepG2 cell line. [Abstract/poster] J Hepatol 1994; 21: S80.

97. Neuman MG., Ishay JS Malkiewicz I, **Shear NH.** Toxicity of Vespa orientalis venom sac extract to human skin cells in vitro. [Abstract/poster]. 1994

98. Neuman MG, **Shear NH**, Bellentani S, Tiribelli C. Tauroursodeoxycholic and ursodeoxycholic acids reduce ethanol-induced cytotoxicity to HepG2 cells in vitro. [Abstract/poster] Alcoholism - Clinical and Experimental Research 1994; 18: 514.

99. Neuman MG, **Shear NH**, Tiribelli C. Modeling ethanol cytotoxicity in vitro in Hep G2 cells. [Abstract/poster] Clin Biochem 1994; 27: 211.

100. Mittmann N, **Shear NH,** Busto UE, Herrmann N, Shulman KI, Silver IL, Gardner DM, Borden EK, Einarson T, Naranjo CA. Comparative efficacy and safety of tricyclic antidepressants and serotonin uptake inhibitors in the elderly. [Abstract/presentation] Clin Invest Med 1994; 17: B53.

101. Neuman MG, **Shear NH,** Oh P, Zimmerman HJ. Increased hepatocytotoxicity from acetaminophen in human hepatocytes pretreated with ethanol in cell culture. [Abstract/poster] Clin Invest Med 1994; 17: B14.

102. Rieder MJ, **Shear NH,** Spielberg SP. Metabolic basis for cross-sensitivity between sulfonamides and nitrofurantoin. [Abstract/poster] Clin Invest Med 1994; 17: B14.

103. Berkovitch M, Ito S, **Shear NH**, Koren G. Morphine in kidney failure [Letter] Clin Pharmacol Ther 1994; 56: 114.

104. Weber EA, Uetrecht JP, Knowles SR, **Shear NH**. Detection of sulfamethoxazole hypersensitivity: skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol 1994;93(2):266.

105. Neuman MG, Cameron RG, **Shear NH**, Bellentani S, Tiribelli C. Protective effect of tauroursodeoxycholic acid on in vitro ethanol-induced cytotoxicity. [Abstract/poster] Hepatol 1994; 20: A867.

106. Knowles SR, RosenbergR, Knight A, **Shear NH**. The impact of skin testing on patients who may be allergic to local anesthetics. J Allergy Clin Immunol 1995; 95(2): 291.

107. Knight A, Knowles SR, McGowan J, **Shear NH**. Osteonecrosis and short-term, moderate dose corticosteroid therapy. J Allergy Clin Imunol 1995; 95(2): 312.

108. Gupta AK, Oh PI, **Shear NH**. A brief guide to pharmacoeconomics for dermatologists. [Poster, Abstract] J Allergy Clin Immunol 1995; 95: 291.

109. Drake LA, **Shear NH**, Tolpin M, et al. Oral terbinafine in the treatment of toenail onychomycosis: A North American clinical trial. [Poster] Annual Meeting of American Academy of Dermatology, February 1995.

110. Gupta AK, Sauder DN, **Shear NH.** Antifungal drugs - Reply. [Letter] J Am Acad Dermatol 1995; 32: 530 - 31.

111. Liu BA, Mittmann N, Lanctôt KL, Oh PI, Einarson TR, **Shear NH**. Benzodiazepines and falls in the elderly. [Abstract, poster] Clin Pharmacol Ther 1995; 57: 200.

112. Mittmann N, Mitter S, Borden EK, **Shear NH**, Naranjo CA. Comparison of the Hamilton depression rating scale and the Montgomery Asberg depression rating scale scores: Impact on depression research. [Abstract, poster] Clin Pharmacol Ther 1995; 57: 139.

113. Neuman M, **Shear NH**, Cameron RG, Bellentani S, Tiribelli C. Alcohol dehydrogenase activity in vitro in HepG2 cells and normal hepatocytes in primary culture [Abstract, /poster**]**. Alcoholism Clin Exp Res 1995; 10: 97A.

114. Liu BA, Bradley CA, Iskedjian M, Mittmann, Pless R, **Shear NH**, Einarson TA. Drug-related mortality in Canada: Trends from 1984 - 1994. ISPE 1995 [Poster].

115. Gupta AK, Sauder DN, **Shear NH.** Antifungal agents - reply [letter]. J Am Acad Dermatol 1995; 32: 1060-1.

116. **Shear NH,** Findlay H, Summerbell R. Onychomycosis retrospective epidemiology study. [Poster] Can Dermatol Assoc Annual Meeting 1995.

117. Cameron RG, Neuman MG, Heathcote EJ, **Shear NH,** Blendis LM. Increase of lipocyte number and lipid-storage in early stages of primary biliary cirrhosis and study of the effect of ursodeoxycholic acid on lipocytes in PBC[Abstract/poster]. Am Assoc for the Study of Liver Diseases. 1995

118. Mittmann N, Liu B, Knowles SR, **Shear NH.** Selective serotonin reuptake inhibitors and the syndrome of inappropriate antidiuretic hormone. ISPE 1995, [Poster].

119. Bellentani S, Neuman MG, Cameron RG, **Shear NH,** Tiribelli C. Protective effect of UDCA and TUDCA on ethanol intoxication of human hepatocytes culture Hep G2: A first step for the use of bile acids in liver steatosis [Abstract/poster]. Br Med J 1995; 125: 252-3.

120. **Shear NH,** Appel C. Prevention of ischemic stroke. [Letter]. N Engl J Med 1995; 333: 460.

121. **Shear NH.** History of the birth control pill. [Book review]. Can J Clin Pharmacol 1995; 2: 87.

122. Liu BA, Gordon M, Labranche J, **Shear NH.** Vitamin D deficiency in elderly residents of long-term care facilities: Interim results. [Abstract, presentation] Clin Invest Med 1995; 18: B60.

123. **Shear NH,** Marsolais C, Hamelin-Bourassa D. Review of the international experience with oral terbinafine in pediatric tinea capitis. [Poster] Dermatology Update Oct. 1996, Montreal.

124. Oh PI, Lanctôt KL, Naranjo CA, **Shear NH.** Ticlopidine and fatal aplastic anemia. [Letter] Can J Clin Pharmacol 1995; 2: 97.

125. Knowles SR, **Shear NH.** Cutaneous eruptions as part of the "Anticonvulsant hypersensitivity syndrome." [Letter] J Clin Psychopharmacol 1996; 16: 263 - 4..

126. **Shear NH**. The modern approach to drug eruptions [Abstract]. J Eur Acad Dermatol Vernerol 1995; 5: S36.

127. Neuman MG, **Shear NH**, Bellentani S, Tiribelli C. Bile acids are reducing cytokine production, enhanced by ethanol in vitro, in HepG2 cells [Abstract, Poster]. Alcoholism - Clin Exp Res 1996; 2: 119A.

128. **Shear NH.** Fluconazole and hair loss [Letter]. Ann Int Med 1996; 125: 153.

129. Birnbaum JE, Drake LA, **Shear NH,** Scher RK. Oral terbinafine in the treatment of toenail onychomycosis: Long-term outcomes of a North American Multicenter Study [Poster]. Amer Acad Dermatol Annual Meeting, Washington, D.C., Feb 10 - 5, 1996.

130. Gupta AK, **Shear NH.** A survey of onychomycosis therapy in Canada in 1995 [Poster]. Amer Acad Dermatol Annual Meeting, Washington, D.C., Feb 10 - 5, 1996.

131. Neuman MG, **Shear NH,** Malkiewicz I, Cameron RG, Tiribelli C. Cellular response to ethanol in vitro in skin and liver cells [Abstract /poster]. J Invest Dermatol 1996; in press.

132. Liu BA, Knowles SR, Mittmann N, Einarson T, **Shear NH.** Reporting of fatal adverse drug reactions: The OMA experience, 1990 - 1994 [Abstract, presentation]Clin Invest Med 1996; 19: S12.

133. Landau M, **Shear NH,** Malkiewicz I, Neuman M. Methotrexate-induced toxicity in vitro is enhanced by cytochrome P4502E1 inducers in HepG2 cells. [abstract/presentation] J Cut Med Surg 1996; 1 (Suppl 1) 12.

134. Neuman MG, Cameron RG, **Shear NH**, Tiribelli C. Morphological and molecular alterations in ethanol-induced apoptosis, in vitro. [Abstract/poster] Hepatol 1996; 24: 554A.

135. Shapiro L, Knowles SR, **Shear NH.** Serious adverse reactions induced by minocycline [Abstract, poster] Clin Pharmacol Ther 1996; 59: 159.

136. Neuman MG, Cameron RG, **Shear NH**, Tiribelli C. Apoptosis induced by ethanol in vitro. [Abstract, presentation] The 6th national congress of hepatology. Timisoara, Romania, October 2-4, 1996.

137. Oh PI, Maerov P, Pritchard SR, Knowles SR, Einarson TR, **Shear NH.** Cost-utility analysis of second line antibiotics in the treatment of acute otitis media [Abstract, Poster] Clin Pharmacol Ther 1996; 59: 180.

138. Nulman I, Klein J, Berkovitich M, Lester RS, **Shear NH**, Koren G. Pharmacokinetics of isotretinoin and its 4-oxo metabolite at steady state [Abstract, Poster] Clin Pharmacol Ther 1996; 59: 200.

139. Neuman MG, Malkiewicz I, **Shear NH.** Silymarin reduces ethanol toxicity to A431 epidermoid cells in vitro [Abstract, Poster]. The Toxicologist 1996; 30: 129.

140. Cohen LB, Liu BA, Knowles SR, Werb M, **Shear NH.** Pancreatic exocrine and endocrine insufficiency precipitated by antitubercular medications. [Abstract] Gastroenterology 1996; in press.

141. Neuman MG, **Shear NH,** Malkiewicz I, Cameron RG, Tiribelli C. Cellular response to ethanol in vitro in skin and liver cells [Abstract, poster]. J Invest Dermatol 1996; 106: 865.

142. Shapiro L, Knowles SR, **Shear NH.** Serious adverse reactions induced by minocycline: A report of 13 cases and a review of the literature. J Cut Med Surg 1996; 1 (Suppl 1) 15-6.

143. Neuman MG, **Shear NH,** Bellentani S, Tiribelli C Effect of ethanol on cytokine expression in HepG2 cells and modulation by bile salts. [abstract/poster] J Hepatol 1996; 25 (Suppl 1): 61.

144. Knowles SR, Weber EA, **Shear NH.** Allergic reactions during general anesthesia [Abstract, poster]. J Am College Immunol 1996; 97: S 344.

145. Mittmann N, Einarson TR, Naranjo CA, **Shear NH.** Efficacy and tolerability of antidepressants in the elderly: A meta-analysis [Abstract, plenary presentation]. Clin Pharmacol Ther 1997; 61: 193.

146. Liu B, Mittmann N, Anderson G, To T, **Shear NH.** Hip fractures and selective serotonin reuptake inhibitors in the elderly: Preliminary results [Abstract, plenary presentation]. Clin Pharmacol Ther 1997; 61: 193.

147. Neuman MG, Landau M, Malkiewicz I, **Shear NH.** Silymarin is protective to methotrexate-induced toxicity in vitro. World Congress of Pharm 96 [Poster], Jerusalem p53. 1996

148. Neuman MG, Landau M, Malkiewicz I, **Shear NH.** Methotrexate-induced toxicity in vitro, enhanced by cytochrome P4502E1 inducers in HepG2 cells can be reversed by silymarin. [Abstract, poster] J Hepatol 1996; 25 (S1): 206.

149. Schlienger RG, Oh PI, Knowles SR, **Shear NH.** The economic impact of serious adverse drug reactions to anticonvulsants[Abstract, poster]. Clin Pharmacol Ther 1997; 61: 138.

150. Neuman MG, Cameron RG, **Shear NH**, Casini A, Tiribelli C. Ethanol-induced apoptosis in a co-culture of HepG2 and normal human stellate cells. [Abstract/poster] Cell Biol Toxicol 1996; p 48.

151. Neuman MG, Cameron RG, Shear NH, Casini A, Tiribelli C. Ethanol-induced apoptosis in a co-culture of normal human Ito cells and Hep G2 cells. [Abstract/poster] Fund Appl Toxicol 1997; 36: 247.

152. Cohen L, Liu BA, Knowles SR, Werb M. **Shear NH.** Hypersensitivity syndrome from antituberculosus medications causing pancreatic exocrine and endocrine failure [Abstract]. Can J Gastroenterol 1997; 11: 57A.

153. Knowles SR, Tran C, Liu BA, **Shear NH.** Gender differences in adverse drug reactions [Abstract, poster]. J Allergy Clin Immunol 1997; 99: S435.

154. Weber EA, Uetrecht, Knowles SR, **Shear NH.** Validation of sulfamethoxazole skin testing [Abstract/poster]. J Allergy Clin Immunol 1997; 99: S430.

155. Mittmann N, Naranjo CA, Herrmann N, Shulman KI, Silver IL, **Shear NH.** Effectiveness of antidepressants in elderly depressed outpatients [Abstract, plenary presentation]. Can J Clin Pharmacol 1997; 4: 50.

156. Shapiro LE, Knowles SR, **Shear NH.** Serious adverse reactions to minocycline, tetracycline and doxycycline: Comparative study [Abstract, poster]. Can J Clin Pharmacol 1997; 4: 52.

157. Trakas K, **Shear NH,** Oh P. Characterization of the Canadian asthmatic population utilizing the National Population Health Survey (NPHS) [Abstract, poster]. Can J Clin Pharmacol 1997; 4: 54.

158. Neuman MG, Cameron RG, **Shear NH,** Tiribelli C. Ethanol-induced apoptosis in human liver cells. [Abstract, poster]. J Hepatol 1997; 26, S1: 127.

159. Neuman MG, Malkiewicz I, **Shear NH.** Methotrexate-induced toxicity ;is enhanced by P450 2E1 and 1A1 & 2 inducers in vitro, in Hep G2 cells. [Abstract, poster]. J Hepatol 1997; 26, S1: 159.

160. **Shear NH.** The treatment decision. [Abstract, presentation] Australasian J Dermatol 1997; 38 (S2): 11.

161. Einarson TE, **Shear NH,** Oh P. Multinational pharmacoeconomic analysis of treatments for onychomycosis. [Abstract, presentation] Australasian J Dermatol 1997; 38 (S2): 12.

162. **Shear NH.** Government sponsored drug plans: Comprehensive versus limited coverage. [Editorial] J Cut Med Surg 1997; 2: 26 - 27.

163. Knowles SR, **Shear NH.** Azathioprine hypersensitivity reactions: Caution upon rechallenge. [Letter] Muscle Nerve 1997; 20: 1467.

164. Neuman MG, Malkiewicz I, **Shear NH.** In vitro, in HepG2 cells methotrexate-induced toxicity is enhanced by cytochrome P450 2E1 inducers and protected by inhibitor of 2E1. [Abstract, poster] Ther Drug Monit 1997; 19: 547.

165. Trudeau ME, Crupm M, Latrielle J, Pritchard K, Palmer M, Tu D, Shepherd L, Delorme F, Shapiro L, **Shear NH**. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer. A phase I study of the National Cancer Institute of Canada Clinical Trials Group. Am Soc Clin Onc 1998.

166. Phillips EJ, Kumar B, Oh PI, **Shear NH**, Sawka C, Imrie K, Simor AE. Feasibility of outpatient treatment of febrile neutropenia at a Canadian tertiary care centre [Oral presentation]. Third International Febrile Neutropenia meeting. Brussels, Belgium, December 1997.

167. Mittmann N, Einarson TR, Naranjo CA, **Shear NH.** Efficacy and tolerability of antidepressants in the elderly: A meta-analysis [Abstract, **plenary** presentation]. Clin Pharmacol Ther 1997; 61: 193.

168. Liu B, Mittmann N, Anderson G, To T, **Shear NH.** Hip fractures and selective serotonin reuptake inhibitors in the elderly: Preliminary results [Abstract, **plenary** presentation]. Clin Pharmacol Ther 1997; 61: 193.

169. Neuman MG, Landau M, Malkiewicz I, **Shear NH.** Silymarin is protective to methotrexate-induced toxicity in vitro. World Congress of Pharm 96 [Poster], Jerusalem p53.

170. Neuman MG, Landau M, Malkiewicz I, **Shear NH.** Methotrexate-induced toxicity in vitro, enhanced by cytochrome P4502E1 inducers in HepG2 cells can be reversed by silymarin. [Abstract, poster] J Hepatol 1996; 25 (S1): 206.

171. Schlienger RG, Oh PI, Knowles SR, **Shear NH.** The economic impact of serious adverse drug reactions to anticonvulsants[Abstract, poster]. Clin Pharmacol Ther 1997; 61: 138.

172. Neuman MG, Cameron RG, **Shear NH**, Casini A, Tiribelli C. Ethanol-induced apoptosis in a co-culture of HepG2 and normal human stellate cells. [Abstract/poster] Cell Biol Toxicol 1996; p 48.

173. Neuman MG, Cameron RG, Shear NH, Casini A, Tiribelli C. Ethanol-induced apoptosis in a co-culture of normal human Ito cells and Hep G2 cells. [Abstract/poster] Fund Appl Toxicol 1997; 36: 247.

174. Cohen L, Liu BA, Knowles SR, Werb M. **Shear NH.** Hypersensitivity syndrome from anti-tuberculosis medications causing pancreatic exocrine and endocrine failure [Abstract]. Can J Gastroenterol 1997; 11: 57A.

175. Knowles SR, Tran C, Liu BA, **Shear NH.** Gender differences in adverse drug reactions [Abstract, poster]. J Allergy Clin Immunol 1997; 99: S435.

176. Weber EA, Uetrecht, Knowles SR, **Shear NH.** Validation of sulfamethoxazole skin testing [Abstract/poster]. J Allergy Clin Immunol 1997; 99: S430.

177. Mittmann N, Naranjo CA, Herrmann N, Shulman KI, Silver IL, **Shear NH.** Effectiveness of antidepressants in elderly depressed outpatients [Abstract, **plenary** presentation]. Can J Clin Pharmacol 1997; 4: 50.

178. Shapiro LE, Knowles SR, **Shear NH.** Serious adverse reactions to minocycline, tetracycline and doxycycline: Comparative study [Abstract, poster]. Can J Clin Pharmacol 1997; 4: 52.

179. Trakas K, **Shear NH,** Oh P. Characterization of the Canadian asthmatic population utilizing the National Population Health Survey (NPHS) [Abstract, poster]. Can J Clin Pharmacol 1997; 4: 54.

180. Neuman MG, Cameron RG, **Shear NH,** Tiribelli C. Ethanol-induced apoptosis in human liver cells. [Abstract, poster]. J Hepatol 1997; 26, S1: 127.

181. Neuman MG, Malkiewicz I, **Shear NH.** Methotrexate-induced toxicity ;is enhanced by P450 2E1 and 1A1 & 2 inducers in vitro, in Hep G2 cells. [Abstract, poster]. J Hepatol 1997; 26, S1: 159.

182. **Shear NH.** The treatment decision. [Abstract, presentation] Australasian J Dermatol 1997; 38 (S2): 11.

183. Einarson TE, **Shear NH,** Oh P. Multinational pharmacoeconomic analysis of treatments for onychomycosis. [Abstract, presentation] Australasian J Dermatol 1997; 38 (S2): 12.

184. **Shear NH.** Government sponsored drug plans: Comprehensive versus limited coverage. [Editorial] J Cut Med Surg 1997; 2: 26 - 27.

185. Neuman MG, **Shear NH,** Blendis LM, Cameron RG. Alteration in lipid transport and storage in stellate cells in primary biliary cirrhosis [Abstract/poster]. Amer Assoc for the Study of Liver Diseases, Research Single Topic Conference June 19-22, 1997; Vesicle-based transport through hepatic epithelium: Mechanisms & pathology.

186. Trakas K, Oh PI, Einarson TR, **Shear NH.** A meta-analysis of the efficacy and safety of inhaled steroids for the treatment of asthma. [Abstract, presentation] Clin Invest Med 1997; 20: S10.

187. Cameron RG, Blendis LM, **Shear NH**, Neuman MG. Perisinusoidal fibrosis and stellate cells in non-cirrhotic primary biliary cirrhosis. [Abstract, poster] Hepatol 1997; 26: 441A.

188. Neuman MG, Blendis LM, **Shear NH**, Cameron RG. Multiple Kupffer cells in primary sclerosing cholangitis. [Abstract, poster] Hepatol 1997; 26: 402A

189. Neuman MG, Malkiewicz I, **Shear NH.** In vitro, in HepG2 cells methotrexate-induced toxicity is enhanced by cytochrome P450 2E1 inducers and protected by inhibitor of 2E1. [Abstract, poster] Ther Drug Monit 1997; 19: 547.

190. Trudeau ME, Crupm M, Latrielle J, Pritchard K, Palmer M, Tu D, Shepherd L, Delorme F, Shapiro L, **Shear NH**. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer. A phase I study of the National Cancer Institute of Canada Clinical Trials Group. Am Soc Clin Onc 1998.

191. Phillips EJ, Kumar B, Oh PI, **Shear NH**, Sawka C, Imrie K, Simor AE. Feasibility of outpatient treatment of febrile neutropenia at a Canadian tertiary care centre. Third International Symposium on Febrile Neutropenia [poster, presentation] 1997

192. Neuman MG, Cameron RG, **Shear NH,** Tiribelli C. Ethanol-induced apoptosis, in vitro [Abstract, poster]. Biochem Cell Biol 1997; 75: International Symposium on Febrile Neutropenia [poster, presentation] 1997

193. Shapiro LE, Knowles SR, **Shear NH.** Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis and dermatitis. [Letter] J Am Acad Dermatol 1998; 38: 132 - 3.

194. Neuman MG, Cameron RG, **Shear NH,** Tiribelli C. Ethanol-induced apoptosis, in vitro [Abstract, poster]. Biochem Cell Biol 1997; 75: .

195. Neuman MG, **Shear NH**, Malkiewicz I, Abbott F. CYP2E1 inducers modulate valproic acid toxicity and induces 4-ene-valproic acid apoptosis in Hep G2 cells [Abstract, poster]. Hepatology 1998; 28: 90.

196. Neuman MG, **Shear NH**, Bellentani S, Tiribelli C. Taurodeoxycholic acid reduces ethanol-induced cytotoxicity by preventing mitochondrial glutathione depletion in Hep G2 cells [Abstract, poster]. Hepatology 1998; 28: 130.

197. Knowles SR, Kohn ML, **Shear NH**. Adverse drug reactions in children: a review of Health Canada's data. J Allergy Clin Immunol 1998;101(2):S50.

198. Schlienger R, **Shear NH.** DIDMOHS: A proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. [Letter]. Arch Dermatol 1998; 134: 876.

199. Forman RG, Koren G, **Shear NH.** Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in a pediatric population: 10 years experience and examination of a new classification system [Abstract, oral presentation]. Clin Invest Med 1998; 21: S28.

200. Phillips EJ, Knowles S, Weber E, **Shear NH.** Allergic reactions to bisphosphonates: A report of 3 cases and an approach to management [Abstract, poster]. Clin Invest Med 1998; 21: S10.

201. Shapiro LE, **Shear NH**. Black race may predict increased severe cutaneous adverse reactions in phenytoin hypersensitivity syndrome reactions [Abstract, poster]. Clin Invest Med 1998; 21: S15.

202. Shapiro LE, Neuman MG, Malkiewicz I, **Shear NH**. Assessment of sulfonamide-induced hypersensitivity syndrome reactions with the use of a novel lymphocyte toxicity assay: Preliminary results [Abstract, poster]. Clin Invest Med 1998; 21: S15.

203. Neuman MG, **Shear NH**, Malkiewicz I, Cameron RG, Abbott F. CYP2E1 inducers trigger valproic acid-induced apoptosis in vitro [Abstract, oral presentation]. Clin Invest Med 1998; 21: S17.

204. Mittmann N, Oh PI, McIvor A, Vaughan D, **Shear NH.** The choice of oral antibiotics in the treatment of acute sinusitis: In search of evidence [Abstract, poster]. Clin Invest Med 1998; 21: S18.

205. Liu B, Anderson G, Mittmann N, Axcell T, **Shear NH.** Elderly patients, use of antidepressants, and hip fracture [Letter]. Lancet 1998; 352: 401 - 2.

206. Schlienger RG, Knowles SR, **Shear NH.** Lamotrigine-associated anticonvulsant hypersensitivity syndrome [Abstract]. Pharmacoepi Drug Safety 1998; 7: S97.

207. **Shear NH**. The modern approach to drug eruptions. [Abstract, presentation] JEADV 1998; 11: Suppl 2: S64

208. Neuman MG, **Shear NH,** Katz G, Malkiewicz I, Cameron R, Abbott F. CYP2E1 inducers trigger valproic acid-induced apoptosis in vitro [Abstract]. Hepatology 1998; 28, 676A.

209. Park H, Knowles SR, **Shear NH.** Serum sickness-like reaction to itraconazole [letter]. Ann Pharmacother 1998; 32: 1249.

210. Trakas K, Oh PI, Einarson TR, **Shear NH**. Relative cost-effectiveness of inhaled corticosteroids for asthma is related to the choice of clinical lung function measure. 1999

211. Trudeau ME, Crump M, Latreille J, Pritchard K, Palmer M, Tu D, Shepherd L, **Shear NH**, Shapiro L, Burnell M, Vandenberg T, Gelmon K, Blackstein M, Delorme F. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer. A ;phase I/II study of the National Cancer Institute of Canada – Clinical Trials Group. OSCO 1999

212. Tiribelli C, **Shear NH**, Bellentani S, Neuman MG. The role of bile acid therapy in alcohol-induced liver damage [Abstract]. Clin Biochem 1998; 31: 706.

213. Neuman MG, **Shear NH**, Cameron RG, Tiribelli C. Alcohol-induced cell death by apoptosis versus cell death by necrosis [Abstract]. Clin Biochem 1998; 31: 700.

214. Neuman MG, **Shear NH**, Malkiewicz I, Cameron R, Abbott F. CYP2E1 induces modulate valproic acid toxicity and induces 4-ene valproic acid apoptosis in HepG2 cells [Abstract]. Clin Biochem 1998; 31: 708 - 9.

215. Mittmann N, Liu BA, Knowles SR, **Shear NH.** Meta-analysis and adverse drug reactions [Letter]. Can Med Assoc J 1999; 160: 987 – 8.

216. Neuman MG, Shapiro LE, Phillips E, Malkiewicz I, **Shear NH.** A novel test to predict sulfonamide hypersensitive reaction in normal and immunocompromised subjects [Abstract]. J Hepatol 1999; 30 (Suppl 1): 276.

217. Neuman MG, Angulo P, **Shear NH**, Jorgensen, Malkiewicz I, Dickson ER, Lindor KD . Relationship between serum cytokine level, degree of liver damage and ursodeoxycholate in patients with primary biliary cirrhosis [Abstract, poster & oral presentation]. J Hepatol 1999; 30 (Suppl 1): 156.

218. Neuman MG, Benhamou JP, **Shear NH,** Martinor M, Malkiewicz I, Boyer N, Katz GG, Marcellin P. Interleukin 6 level normalization during interferon-ribavirin combination therapy in chronic hepatitis C [Abstract]. J Hepatol 1999; 30 (Suppl 1): 242.

219. Phillips EJ, Knowles SR, **Shear NH**, Weber EA. Cross-reactivity between ampicillin and cephalexin in patients with isolated delayed skin test responses to ampicillin. J Allergy Clin Immunol 1999;103(2):S64.

220. Knowles SR, Phillips EJ, Weber EA, **Shear NH**. Allergic reactions associated with HMG-CoA reductase inhibitors. J Allergy Clin Immunol 1999;103(2):S64-5.

221. Neuman MG, Benhamou JP, **Shear NH**, Martinot M, Malkiewicz I, Boyer N, Katz GG, Marcellin P. Serum tumor necrosis factor as predictor of sustained response to alpha interferon – ribavirin combination in chronic hepatitis C [Abstract]. J Hepatol 1999; 30 (Suppl 1): 257.

222. **Shear NH.** Oral isotretinoin: prescribers beware [Editorial]. Can Med Assoc J 1999; 160: 1723 – 4.

223. Neuman MG, Cameron R, Haber J, Katz G, Malkiewicz I, **Shear NH.** Silymarin protects against methotrexate-induced hepatotoxicity. Complimentary and alternative medicines in chronic liver disease. NIH Conference (NIDDKD Branch). [Poster, abstract] 1999; page 101.

224. Angulo P, Neuman MG, Jorgensen RA, **Shear NH,** Malkiewicz I, Dickson ER, Lindor KD. Serum cytokines in patients with primary biliary cirrhosis: Effect of treatment with ursodeoxycholic acid. [Abstract, **plenary** presentation] Gastroenterology 1999; 116; 116 (4-2): 1239.

225. Phillips EJ, Knowles SR, **Shear NH,** Weber EA. Cross-reactivity between ampicillin and cephalexin in patients with isolated delayed skin test responses to ampicillin [Abstract, poster]. J Am College Immunol 1999; 103: S64.

226. Neuman MG, **Shear NH**, Benhamou I, Malkiewicz I, Katz GG, Boyer N, Marcellin P. Predictive value of serum cytotoxicity in non-cirrhotic patients with chronic hepatitis C: Effect of the treatment with IFN versus combination IFN and ribavirin. [Poster and presentation] First International Congress on Cytokines / Chemokines in Infectious Diseases (NIH – NIAID; International Immunocompromised Host Society) 1999; Abstract 113.

227. Wong AH, Oh PI, Shear NH. Economic analysis of antimicrobial agents for hospital-acquired pneumonia. [Abstract] Value in Health 1999; 2(3): 187.

228. Neuman MG, **Shear NH**, Eshchar J, Ishay J. In a co-culture of normal human liver stellate cells and Hep G2 hornet venom induces apoptosis. [Abstract] Ther Drug Monit 1999; 21: 462.

229. Knowles SR, Phillips EJ, Weber EA, **Shear NH.** Allergic reactions associated with HMG-CoA reductase inhibitors [Abstract, poster]. J Am Coll Immunol 1999; S64.

230. Fish JS, Cartotto R, Gomez M, **Shear NH.** Something new in the treatment of toxic epidermal necrolysis? [abstract, presentation] Proc Am Burn Assoc 2000; 21: S174.

231. Katz GG, **Shear NH**, Valentino K, Malkiewicz I, Neuman MG. Ethanol signaling apoptosis in normal human hepatocytes, role of tumor necrosis alpha, fas ligand and caspase 3 inhibitor [abstract, **plenary** presentation]. The Toxicologist 2000; 54: 130.

232. Shapiro LE, **Shear NH.** Studying the statins [letter]. Can Med Assoc J 2000; 162: 1124.

233. Neuman MG, Valentino K, Cameron RG, **Shear NH**. Ethanol signaling apoptosis in normal human hepatocytes, role of caspase-3 inhibitor [abstract]. J of Hepatology, suppl 2,vol 32, abs C03/08, p. 162, 2000.

234. Neuman MG, Benhamou JP, **Shear NH**, Malkiewicz I, Boyer N, Marcellin P. Serum IL10 in chronic hepatitis C. J of Hepatology, suppl 2,vol 32, abs C05/15, p. 175, 2000.

235. Neuman MG, Shapiro LE, Malkiewicz IM, **Shear NH.** Immunomodulation in hypersensitivity reactions to sulfonamides and anticonvulsants. Gastroenterol 2000; 118 (4) suppl 2, part 2: A1473.

236. Neuman MG, Blendis LM, Sapir D, Halpern Z, **Shear NH,** Malkiewicz IM, Katz GG, Benhamou JP, Marcellin P, Konikoff F**.** Serum TNFa and TGFb levels in patients with chronic hepatitis C reflect the severity of the disease. Gastroenterol 2000; 118 (4) suppl 2, part 2: A1473.

237. Katz GG, Cameron RG, **Shear NH**, Neuman MG: Signaling for apoptosis and repair in vitro. Alcoholism Clin Exp Research, vol. 24, no 5, suppl., Abs WS10:6, p. 191A, 2000.

238. Malkiewicz IM, Valentino K, **Shear NH**, Neuman MG: Modeling in vitro ethanol-induced apoptosis with caspase-3 inhibitor in normal human hepatocytes. Alcoholism Clin Exp Research, vol. 24, no 5, suppl., Abs 744, p. 130A, 2000.

239. Katz GG, **Shear NH**, Malkiewicz I, Abbott F, Neuman MG: CYP2E1 inducers trigger valproic acid-induced apoptosis in vitro. Alcoholism Clin Exp Research, vol. 24, no 5, suppl., Abs 87, p. 21A, 2000.

240. Sullivan JR, Gow E, Freeman S, **Shear NH**, Commens C. Intravenous cyclosporin in toxic epidermal necrolysis and Stevens-Johnson Syndrome. J Cut Med Surg 2000; 4 (Meeting guide): 36.

241. Sullivan JR, Neuman M, Knowles S, Malkiewicz I, **Shear NH**. Evidence for reactive drug metabolites in lamotrigine-associated drug hypersensitivity syndrome. J Cut Med Surg 2000; 4 (Meeting guide): 38.

242. Trudeau M, Crump M, Latreille J, Pritchard KI, Palmer M, Tu D, Shepherd L, **Shear NH**, Shapiro LE, Oldfield, S, etc. Escalating doses of docetaxel and epirubicin as first line therapy for metastatic

breast cancer: A phase I/II study of the NCI-Canada. [Poster] 23rd Annual San Antonio Breast Cancer Symposium, December 9, 2000, San Antonio, Texas.

243. **Shear NH**. Cross-allergic reaction between penicillin and cephalosporins [Response to query]. Patient Care Canada 2000; 11: 28.

244. Trakas K, Leiter L, **Shear NH**. Does drug therapy of obesity have a future? [Editorial] Can J Clin Pharmacol 2000; 7: 133 – 4.

245. **Shear NH**, Sullivan JR, Knowles SR, Malkiewicz I, Neuman M. Evidence for reactive metabolites in lamotrigine-associated drug hypersensitivity syndrome [abstract]. J Cut Med Surg 2000; 4: 228.

246. Sullivan JR, Gow E, Freeman S, **Shear NH**, Commens C. Intravenous cyclosporine in toxic epidermal necrolysis and Stevens-Johnson Syndrome [abstract]. J Cut Med Surg 2000; 4: 227.

247. Gupta AK, Katz HI, **Shear NH.** Terbinafine and potential drug interactions [Reply to letter]. J Am Acad Dermatol 2000; 43: 883 – 4.

248. Trakas K, **Shear NH.** Serotonin syndrome risk with anti-obesity drug [Letter]. Can J Clin Pharmacol 2000; 216.

249. Trakas K, Oh PI, Leiter L, **Shear NH.** Assessing lifestyle drugs for drug benefit formularies: A cost-utility analysis of orlistat and sibutramine for the treatment of obesity in adults [abstract, oral presentation]. Value in Health 2001

250. Neuman MG, Benhamou JP, Asselah T, **Shear NH**, Malkiewicz IM, Boyer N, Marcellin PM. Serum tumor necrosis factor alfa levels in chronic hepatitis C reflects the severity of the disease and are modulated by therapy [abstract, poster presentation]. Hepatology 2000; 32 (4, pt 2): 263A.

251. Neuman MG, Shapiro LE, Malkiewicz IM, **Shear NH.** Gender differences in serum cytokines in patients with hypersensitivity reactions to sulfonamide antibiotics [abstract, poster presentation]. Hepatology 2000; 32 (4, pt 2): 501A.

252. Neuman MG, Blendis L, Sapir D, **Shear NH,** Malkiewicz IM, Halpern Z. Triple therapy with interferon, ribavirin and ursodeoxycholate in patients with genotype 1 chronic hepatitis C [abstract, poster presentation]. Hepatology 2000; 32 (4, pt 2): 571A.

253. Mittmann N, Fish J, Gomez M, Knowles SR, Cornish P, Cartotto R, **Shear NH.** Evaluation of the extent of under-reporting of toxic epidermal necrolysis in Canada. American Burn Association [presentation]. 2001

254. Knowles SR, Shapiro LE, Weber EA, **Shear NH**. A pilot study evaluating the potential cross-reactivity between celecoxib and sulfonamide antimicrobials [Presentation]. J Allergy Clin Immunol 2001; 107(2): S134.

255. Sullivan JR, Gilbert CJ, Langley M, Dvorsky P, **Shear NH.** A case-based reasoning system to aid assessment of adverse drug reactions [Abstract, poster]. Allergologie 2001; 24: 225 - 6

256. Sullivan JR, Phillips EA, **Shear NH.** Buffalo hump dermatitis: a hat trick of anti-retroviral side effects [Abstract, poster]. Allergologie 2001; 24: 226

257. **Shear NH**. Drug safety – A long way traveled and a long way to go [Plenary presentation]. J Cut Med Surg 2001; 5: 30 – 1.

258. Murray C, Neuman MG, **Shear NH.** Minocycline drug hypersensitivity syndrome: In vitro assessment by lymphocyte toxicity assay [Abstract, presentation]. J Cut Med Surg 2001; 5: 45 - 6.

259. Shapiro L, Knowles SR, Weber L, **Shear NH.** A pilot study evaluating the potential cross-reactivity between celecoxib and sulfonamide antimicrobials [Abstract, presentation]. J Cut Med Surg 2001; 5: 49 - 50.

260. **Shear NH**, Shapiro LE, Neuman MG. Studies of the drug hypersensitivity syndrome – In vitro identification [Abstract, presentation]. J Cut Med Surg 2001; 5: 50 - 1.

261. **Shear NH**, Neuman MG, Ong D, Phillips EJ, Malkiewicz IM, Rachlis AR, Yeung E. Lymphocyte toxicity assay: A tool to assess trimethoprim-sulfamethoxazole hypersensitivity syndrome reactions to human immunodeficiency virus-infected individuals [Abstract, presentation]. J Cut Med Surg 2001; 5: 51.

262. Scalera A, **Shear NH.** Use and citation of Beck Depression Inventory for assessing depression in HIV infection [letter]. Psychosomatics 2002;43(1):88.

263. Neuman MG, Malkiewicz I, Phillips EA, Rachlis A, Yeung E, Ong D, **Shear NH.** Lymphocyte toxicity assay: a tool to assess trimethoprim-sulfamethoxazole hypersensitivity syndrome reactions in human immunodeficiency virus-infected individuals [Abstract, presentation]. Annual meeting of the American Association for the Study of Liver Disease. 2001

264. Neuman MG, Benhamou JP, Bourliere B, Malkiewicz I, Ibrahim A , Martinot-Peignoux M, **Shear NH**, Lecomte L, Asselah T, Akremi R, Katz G, Marcellin P. Transforming growth factor levels in chronic hepatitis C reflect the degree of fibrosis: Role of therapy with pegylated interferon in reducing fibrosis [Abstract]. Annual meeting of the American Association for the Study of Liver Disease. 2001

265. Neuman MG, Benhamou JP, Malkiewicz I, Valla D, Katz G, Akremi R, Martinot-Peignoux M, Asselah T, Cazals D, Degott C, **Shear NH**, Marcellin P. Kinetics of serum tumor necrosis factor levels in chronic hepatitis C patients with minimal fibrosis are markers of progression. Hepatology 2001; 34: 228A.

266. Neuman MG, Malkiewicz IM, Shapiro LE, **Shear NH**. Studies of the drug hypersensitivity syndrome: In vitro identification. Hepatology 2001; 34: 282A.

267. Neuman MG, Benhamou JP, Bourliere M, Malkiewicz I, Ibrahim A, Martinot-Peignoux M, **Shear NH**, Lecomte L, Asselah T, Akremi R, Katz G, Marcelin P. Transforming growth factor levels in chronic hepatitis C reflect the degree of fibrosis: Role of therapy with pegylated interferon in reducing fibrosis. Hepatology 2001; 34: 426A.

268. Neuman M, Malkiewicz I, Phillips E, Rachlis A, Yeung E, Ong D, **Shear NH**. Lymphocyte toxicity assay: A tool to assess trimethoprim-sulfamethoxazole hypersensitivity syndrome reactions in human immunodeficiency virus-infected individuals. Hepatology 2001; 34: 454A.

269. Neuman MG, Haber JA, Malkiewicz IM, Katz GG, **Shear NH**. Inducers of cytochrome P450 2E1 enhance methotrexate-induced apoptosis. Hepatology 2001; 34: 513A.

270. Knowles SR, Neilson H, Weber EA, **Shear NH**. Demonstrating drug safety: clinical usefulness of N-of-1 randomized controlled trials. J Allergy Clin Immunol 2002; 109(1): S154.

271. Murray C, Neuman MG, **Shear NH.** Positive in vitro diagnosis of drug hypersensitivity to minocycline [Poster]. Annales de dermatologie et de venerolgie; 129: S394.

272. Sullivan JR, Gilbert CJ, Knowles SR, **Shear NH.** Serious idiosyncratic reactions associated with lamotrigine [Presentation]. Annales de dermatologie et de venerolgie; 129: S47.

273. **Shear NH**, Knowles S, Shapiro, L. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? The authors reply. Drug Safety 2002; 25: 299-300.

274. **Shear NH.** Principles of influence [Letter]. Can Med Assoc J 2002; 167: 628.

275. Neuman MG, Thompson S, Malkiewicz IM, Popat A, **Shear NH.** Response to letter (re: Toxicity of Callilepsis.) [Letter] Clin Biochem 2002; 35: 180.

276. Neuman MG, Valentino K, Malkiewicz IM, **Shear NH**, Katz GG Ethanol-signaling for apoptosis in human normal hepatocytes: role of tumor necrosis factor alpha, Fas ligand and caspase 3 inhibitors. [Recipient of Presidential Award] Hepatol 36, 4, 2,abs. 941, p.398 A, 2002.

277. Neuman MG, Angulo P, Jorgensen R, **Shear NH**, Katz G, Malkiewicz IM, Ben-Ari Z Schmilowitz-Weiss H,Klein T. Ursodeoxycholic therapy affects cytokine network and plays an immunomodulatory role in patients with primary sclerosing cholangitis and primary biliary cirrhosis. Hepatol 36, 4, 2,abs. 1346, p.499 A, 2002.

278. Neuman M, Shapiro L, Malkiewicz I, Taeri M, Cohen L, Gomez M, Fish J, **Shear NH**. In-vitro investigations of the immunopathogenesis of toxic epidermal necrolysis [Presentation, Canadian Special Interest Group] American Burn Association 2003

279. Nigen S, Torok MT, **Shear NH.** Late onset cutaneous post-transplant lymphoproliferative disorder. [Presentation] Can Dermatology Association Annual meeting, Ottawa 2003.

280. Mandelcorn-Monson R, **Shear NH.** Lupus-associated toxic epidermal necrolysis (LATEN): A novel manifestation of lupus? [Presentation] Can Dermatology Association Annual meeting, Ottawa 2003.

281. Mandelcorn-Monson R, **Shear NH**, Yau E, Barber B, Spaner D, DeBenedette MA. Cytotoxic T lymphocyte reactivitty to GP 100 Melana/Mart-1 and tyrosinase in HLA-A2 positive vitiligo patients. [Presentation] Can Dermatology Association Annual meeting, Ottawa 2003.

282. **Shear NH,** EJ Phillips, Knowles SR. Patch testing in the investigation and management of antiretroviral associated hypersensitivity syndromes. [Presentation] Can Dermatology Association Annual meeting, Ottawa 2003.

283. **Shear NH,** Smith K, Vender R, Tan J, Haroun M, Sapra S, Lynde C, Kunynetz R, Somer G, Bulger L, Wiegand UW. Unexpected activity of the isotretionoin metabolite oxo-isotretinoin in acne patients. [Presentation] Can Dermatology Association Annual meeting, Ottawa 2003.

284. Walsh S, **Shear NH.** Acrodermatitis continua of Hallopeau. [Presentation] Can Dermatology Association Annual meeting, Ottawa 2003.

285. Neuman MG, Malkiewicz IM, Shapiro LE, Gomez M, Fish J, **Shear NH**, Cohen L. Diagnosis and monitoring of toxic epidermal necrolysis. [abstract, oral presentation]. Ther Drug Monitoring, 2003; 25: 537.

286. Notman MJ, Knowles SR, Phillips EJ, Weber EA, **Shear NH.** Diagnostic potential of cutaneous testing in fluoroquinonlone-associated hypersensitivity [abstract, poster]. Can J Clin Pharmacol 2003; 10: 141 – 2.

287. **Shear NH,** Smith KC, Tan J, Lynde C, Haroun M, Vender R, Kunynetz R, Sapra S, Somer G, Bulger G, Wiegand U. Isotretinoin metabolites contribute to its sebosuppressive effect [abstract, poster]. Can J Clin Pharmacol 2003; 10: 156.

288. Gilbert M, **Shear NH.** Pharmacokinetics and pharmacodynamics of efalizumab in the treatment of plaque-type psoriasis [Abstract, poster]. JEADV 2003; 17 (Suppl 3): 377.

289. Phillips EJ, Knowles SR, **Shear NH.** Serum sickness-like reaction associated with clopidogrel [letter to editor]. Br J Clin Pharmacol 2003; 56: 583.

290. Wong GA, Nigen S, Walsh S, **Shear NH.** Acneform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839 [Abstract, poster]. J Am Acad Dermatol 2004; 50 (Suppl) P39.

291. **Shear NH**, Gottlieb AB, Wolff K, Cherill R. Efficacy and safety in relation to systemic exposures from orally administered pimecrolimus in patients with moderate to severe plaque-type psoriasis and atopic dermatitis [Abstract, poster]. J Am Acad Dermatol 2004; 50 (Suppl) P64.

292. **Shear NH,** Leonardi CL, Lynde CW, Ouellet JP, Toth DP, Rosoph L, Papp K. Sustained efalizumab efficacy in patients with moderate to severe chronic plaque psoriasis: updated phase III trial findings. [Abstract, presentation] JEADV 2004; 18 (Suppl 1); 32.

293. Carey W, Menter A, Gilbert M, Gratton D, Rosoph L, **Shear NH**, Langley R. The effects of 24 weeks of continuous efalizumab therapy on health-related quality of life in pateints with moderate to severe chronic plaque psoriasis. [Poster] JEADV 2004; 18 (Suppl 1); 49.

294. **Shear NH**, Redelmeier DR; Callen JP, and the Ad Hoc Task Force of the American Academy of Dermatology on the Reported Link Between Antibiotic Use and Breast Cancer. Use of Antibiotics and Risk of Cancer [Letter] JAMA. 2004;291: 2699.

295. Koren G, **Shear NH.** Patient-physician-regulator triad [Response to letter]. Can Med Assoc J 2005; 172: 15 – 18.

296. Nigen S, Shapiro LE, Knowles SR, Neuman MG, **Shear NH**. Utility of patch testing in patients with anticonvulsant-induced hypersensitivity syndrome [Poster]. Can Dermatol Assoc Annual Meeting [Awarded Best Poster by CDA Scientific Committee]. Quebec City, Quebec July 1, 2005.

297. Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meurer M, Murrell D, Orlow S, Pallre A, de Prost Y, Puig L, Ring J, Saurat J-H, Schwarz T, **Shear N**, Stingl G, Taieb A,

Threstrup-Pedersen K. Consensus statement on the safety profile of topical calcineurin inhibitors [Editorial]. Dermatology 2005; 211: 77 – 8.

VISITING PROFESSORSHIPS

McMaster University Hamilton, Ontario.	Hamilton Academy of Medicine January 23, 1985.
University of Manitoba Winnipeg, Manitoba	Division of Dermatology October 29 -30, 1986.
University of California - San Francisco San Francisco, California	Department of Dermatology November 1986.
Case Western Reserve Cleveland, Ohio	Department of Dermatology February 25, 1987.
Dalhousie University Halifax, Nova Scotia	Division of Dermatology April 18 - 20, 1990
National Institutes of Health Bethesda, Maryland	NCI-Dermatology Branch September 12, 1991
Wayne State University, Detroit, Michigan	Dept. Dermatology March 16, 1994
University at Buffalo, SUNY Buffalo, New York	Department of Dermatology April 2, 1996
Dalhousie University Halifax, Nova Scotia	Division of Dermatology September 26 - 27, 1996
Harvard University Boston, Massachusetts	Department of Dermatology September 30 - October 1, 1996
Scottish Dermatological Society Glasgow, Scotland	27th Annual Meeting May 23, 1997
Montreal General Hospital, McGill Univ. Montreal, Quebec	Department of Medicine November 18, 1997
University of Ottawa Ottawa, Ontario	Division of Dermatology April 17 & 18, 1998
University of Washington Seattle, Washington	Division of Dermatology October 16, 1998
University of Louisville Louisville, Kentucky	Division of Dermatology May 17 & 18, 1999
University of Alberta Edmonton, Alberta	Division of Dermatology July 24, 2000
Indiana University School of Medicine Indianapolis, Indiana	Department of Dermatology November 16, 2000
University of British Columbia Vancouver, British Columbia	Division of Dermatology November 28 – 30, 2002
University of Santo Tomas Manila, Philippines	Department of Dermatology March 10 – 12, 2003
Columbia University New York, New York	Department of Dermatology Sept 16 – 17, 2003

University of Cincinatti Cincinatti, Ohio	Department of Dermatology August 25 – 6, 2004
Ehime Medical School Matsuyama, Japan	Department of Dermatology February 12 – 3, 2006
Catholic University of Korea Seoul, Korea	Department of Dermatology May 26 – 7, 2006
Duke University Durham, North Carolina	Division of Dermatology June 8 – 9, 2006
Baylor University Houston, Texas	Department of Dermatology December 4 – 5, 2006
University of Pennsylvania Philadelphia, Pennsylvania	Department of Dermatology March 7 – 8, 2007

MAJOR PRESENTATIONS
(Continuing Education)

1.	Hepatoerythropoietic porphyria. Vancouver, B.C.	Canadian Dermatology Association. June 28, 1980.
2.	A new porphyria syndrome. New York, N.Y.	American Academy of Dermatology. December 9, 1980.
3.	Porokeratosis of Mantoux. Toronto, Ont.	Atlantic Dermatology Meeting. November 1982.
4.	Sulfonamide hypersensitivity: In vitro verification. Calgary, Alta.	Canadian Society for Clinical Investigation September 20, 1983.
5.	Diffuse cutaneous mastocytosis: Calgary, Alta.	Canadian Society for Clinical Investigation Treatment with ketotifen and cimetidine. September 20, 1983.
6.	Pharmacogenetics and the skin: Toronto, Ont.	Fifth Postgraduate Dermatology Seminar An insight into some drug reactions. October 30, 1983.
7.	Diagnosis of adverse drug reactions. London, Ont.	Annual Meeting - Dermatology Division April 1984.
8.	New treatment of cystic acne. Toronto, Ontario.	Canadian Pediatric Society. June 27, 1984.
9.	An in vitro lymphocytotoxic assay for studying adverse reactions to sulfonamides Sophia Antipolis, France.	CIRD Annual Meeting October, 1984.
10.	The pharmacologic investigation of . adverse drug reactions Toronto, Ontario	Toronto Dermatological Society November 13, 1984.
11.	What pharmacogenetics can do for your patients. Washington, D.C.	American Academy of Dermatology December 1984.
12.	Dermatological emergencies. Hamilton, Ontario	Annual Day in Dermatology May 28, 1986.
13.	Pharmacogenetic defects of cytoprotection and hepatotoxicity. Toronto, Ontario	4th Annual Liver Research Day June 4, 1986.
14.	Clinical features and in vitro confirmation of adverse reactions to anticonvulsants. Vancouver, B.C.	Can. Dermatology Association June 30, 1986.
15.	Pharmacogenetics of cutaneous adverse drug reactions Stockholm, Sweden	Skin Pharmacology Society July 31, 1986.

16.	Recent advances in skin pharmacology. Toronto, Ontario	Chair of symposium - Canadian Society of Clinical Investigation September 23, 1986.
17.	New insights into the pathogenesis of adverse drug reactions. Toronto, Ontario	Chair of symposium - Canadian Society of Clinical Investigation September 23, 1986.
18.	Camouflage cosmetics: A success story. Toronto, Ontario	Post-graduate dermatology seminar September 27, 1986.
19.	Oral antifungal therapy. Toronto, Ontario	Post-graduate dermatology seminar. September 27, 1986.
20.	How to choose, use and not abuse oral antifungal therapy. Hamilton, Ontario	Basic Science Seminars October 15, 1986.
21.	Drug reaction clinics: When to refer. Toronto, Ontario	Toronto Dermatologic Society October 28, 1986.
22.	Interactions between drugs and humans. Hamilton, Ontario	Grand Medical Rounds Hamilton Civic Hospitals November 21, 1986.
23.	Sorting out drug reactions Toronto, Ontario	Canadian Society of Hospital Pharmacists February 5, 1987.
24.	When is a rash allergic Brampton, Ontario	Annual Pharmacy Clinic Day April 22, 1987.
25.	Adverse drug reactions: A clue. Toronto, Ontario	Addiction Research Foundation May 12, 1987.
26.	Camouflage cosmetics. Montréal, Quebec	Canadian Dermatology Association June 20, 1987
27.	Biochemical basis of adverse drug reactions. Symposium: Adverse Drug Reactions Winnipeg, Manitoba	Royal College of Physicians & Surgeons. September 12, 1987
28.	Adverse reactions to drugs Division of Rheumatology/Immunology Toronto, Ontario	Hospital for Sick Children March 23, 1988
29.	Pharmacist-physician interactions. (Wyeth Lecturer) Toronto, Ontario	Current topics in pharmacy practice. April 9, 1988
30.	Adverse drug reactions Toronto, Ontario	Pharm. Manufacturer's Association of Canada April 13, 1988
31.	Metabolic basis for pathogenesis and diagnosis of adverse drug reactions Jerusalem, Israel	International Conference on Pharmaceutical Sciences and Clinical Pharmacology May 30, 1988
32.	Hypersensitivity drug reactions Banff, Alberta	Canadian Dermatology Association - Annual meeting June 24, 1988.

33.	An update on antihistamine therapy Toronto, Ontario	September 6, 1988
34.	Biochemical basis of adverse drug reactions Toronto, Ontario	Addiction Research Foundation (Grand Rounds) September 9, 1988
35.	Hypersensitivity reactions: A new paradigm. Toronto, Ontario	Toronto Dermatological Society November 22, 1988.
36.	Adverse drug reactions: what do I do? Toronto, Ontario	Metro Toronto Pharmacy Association November 28, 1988
37.	Hypersensitivity reactions to drugs: A new paradigm. Toronto, Ontario	Research Day - Sunnybrook Med Centre December 9, 1988
38.	Dermatology for plastic surgeons Toronto, Ontario	Hospital for Sick Children December 10, 1988
39.	Camouflage cosmetics: the Sunnybrook experience Toronto, Ontario	Symposium on Burns February 17, 1989
40.	Hypersensitivity drug reactions Toronto, Ontario	Princess Margaret Hospital (Grand Rounds) March 23, 1989
41.	Clinical perspectives on risk perception Ottawa, Ontario	Workshop on Risk Perception and Drug Safety Evaluation Drugs Directorate, Health Protection Branch March 29 - 30, 1989
42.	An approach to drug reactions. Toronto, Ontario	Atlantic Dermatological Conference May 5, 1989.
43.	Adverse drug reactions: A clinical pharmacology perspective. Toronto, Ontario	OMA Annual Meeting May 17, 1989.
44.	Drug therapy day - ADR and the skin, - Acne update, - Skin infections London, Ontario	University of Western Ontario CME May 31, 1989.
45.	Physician-pharmacist interactions Toronto, Ontario	Ontario Pharmacy Assoc. Ann. Meeting June 2, 1989.
46.	Camouflage cosmetics Halifax, Nova Scotia	Canadian Dermatology Association June 28, 1989
47.	The skin as a target organ for idiosyncratic reactions. Heidelberg, West Germany	Idiosyncratic ADR: Impact on drug development and clinical use after marketing July 29-30, 1989

48.	Research in post-graduate clinical pharmacology Edmonton, Alberta	Royal College of Physicians Workshop September 22, 1989
49.	Competitive strategies for the future Ontario Hospital Association Toronto, Ontario	Hospital Pharmacy Institute September 25 - 26, 1989
50.	Acute skin conditions in the emergency room National audience	Telemedicine Canada October 2, 1989
51.	Sorting out nonsense drug reactions Sunnybrook Medical Centre Toronto, Ontario	Grand Medical Rounds October 10, 1989
52.	Medical Makeup Toronto, Ontario	Annual Prof. Practice Conference Canadian Society of Hospital Pharmacists January 29, 1990
53.	Diagnosing drug reactions North York, Ontario	Dermatology Grand Rounds North York General Hospital February 2, 1990
54.	Multiple Drug Allergies Hamilton, Ontario	McMaster CME Day February 21, 1990
55.	What is new in drug eruptions Toronto, Ontario	The Wellesley Hospital Grand Medical Rounds April 4, 1990
56.	Therapeutic applications of cosmetics Toronto, Ontario	Cosmetics for the Dermatologist April 28, 1990
57.	Physicians / pharmaceutical industry: Conflict of interest? Toronto, Ontario	PMAC Medical R&D Section May 1, 1990
58.	Ketoconazole 2% shampoo in the treatment of seborrheic dermatitis of the scalp. Whitehorse, Yukon	Canadian Dermatology Association Annual meeting June 2, 1990
59.	Cutaneous drug reactions in children Adverse drug reactions in children Strbské Pleso, Czechoslovakia	Satellite Symposium XIth International Congress of Pharmacology June 27, 1990
60.	Camouflage therapy for skin defects 10th Cosmetic Dermatology Seminar New York, USA	Beth Israel Medical Centre September 6, 1990
61.	Drug-induced adverse reactions Toronto, Canada	Focus on CE Sunday Canadian Society for Hospital Pharmacists November 11, 1990
62.	Drug eruptions: Is there a test? Atlanta, USA	Pediatric Dermatology Symposium American Academy of Dermatology December 2, 1990

63.	Pathogenesis of adverse reactions Atlanta, USA	Drug Reactions Forum American Academy of Dermatology December 4, 1990

64.	Ethics and the pharmaceutical industry Toronto, Ontario	Ethics of Research at the Outset of Life International symposium Hospital for Sick Children January 15, 1991
65.	Role of Canadian Adverse Drug Reaction Advisory Panel (CADRAC) Health and Welfare Canada Toronto, Ontario	Invitational workshop on a proposed Post-marketing Pharmaceutical Surveillance Program February 27, 1991
66.	Antifungal drug therapy Mt. Tremblant, Québec	Stiefel Canada Inc. April 17, 1991
67.	Dealing with the doctor dilemma Toronto, Ontario	Pharmaceutical Marketing Club of Ontario April 23, 1991
68.	Relationship of ultraviolet radiation to skin cancer Toronto, Ontario	Sunsense Trainers Workshop Canadian Cancer Society April 26, 1991
69.	Dermatological emergencies Toronto, Ontario (& 8 other centres)	Telemedicine Canada CME June 3, 1991
70.	Toxic epidermal necrolysis Niagara on the Lake, Ontario	Canadian Dermatology Association June 29, 1991
71.	Menkes syndrome Niagara on the Lake, Ontario	Canadian Dermatology Association June 29, 1991
72.	Drug treatment for hair loss American College of Physicians London, Ontario	Therapeutics Update - 1991 CME Course A11 July 13, 1991
79.	Skin reactions to drugs: Diagnosis and management. Ottawa, Ontario	Can. Soc. for Hospital Pharmacists Ottawa Valley Chapter September 25, 1991
73.	Sun Safety: Why and how? Sarnia, Ontario	Canadian Cancer Society Lambton County Unit October 28, 1991
74.	Diversification in Question Format for Pharmacology-Survival Advantages Toronto, Ontario	Examination and Student Assessment Sub-committee, UMCC November 7, 1991
75.	Hypersensitivity reactions to drugs Dallas, USA	Drug Reactions Forum American Academy of Dermatology December 10, 1991
76.	- Adverse Drug Reactions - How to Hide What You Can't Treat - Diagnosis & Management of Hair Loss Vancouver, BC	Annual Spring Dermatology Review University of British Columbia CME course March 7 & 8, 1992

77.	When do I need a consultation for possible adverse drug reactions? Toronto, Ontario	Annual Update in Pediatrics Hospital for Sick Children April 8, 1992
78.	Idiopathic hypersensitivity reactions Mississauga, Ontario	Parke-Davis Research Institute May 26, 1992
79.	Estimation of Risk *Plenary Session* Montreal, Québec	Management of Risk, Benefit and Cost of Pharmaceuticals June 1, 1992
80.	- Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: - The clinical and laboratory management of severe drug reactions. Toronto, Ontario	International Congress of Pediatric Dermatology June 8, 1992
81.	Clinical and Experimental Dermatol. *Chair* New York, New York	16th World Congress of Dermatology June 15, 1992
82.	Update in Skin Pharmacology Victoria, British Columbia	Canadian Derm Assoc Annual Mtg. June 25, 1992
83.	Skin reactions to drugs Niagara-on-the-Lake, Ontario	Therapeutics Update 1992 (ACP #A21) July 11, 1992
84.	Innovations in therapy: Cyclosporine, Interferon, Retinoids Niagara-on-the-Lake, Ontario	Therapeutics Update 1992 (ACP #A21) July 11, 1992
85.	Corrective cosmetics Toronto, Ontario	First Toronto Facial Rejuvenation Conference September 18, 1992
86.	Diagnosis and management of drug reactions Smolinice, Czechoslovakia	Workshop in Pediatric Clinical Pharmacology September 24, 1992
87.	Advances in the treatment of dermatomycoses - *Chair* Vancouver, B.C.	Dermatology Update 1992 October 14, 1992
95.	Pharmacology and mode of action of terbinafine. Vancouver, B.C.	Dermatology Update 1992 October 14, 1992
88.	Drug safety Is our drug system unraveling: Narrowing the information gap Toronto, Ontario	Association of Jewish Seniors Annual meeting October 29, 1992
89.	Adverse drug reactions with oral antimicrobials Toronto, Ontario	Management of common infectious diseases November 27, 1992
90.	Diagnostic aids and management of eruptions from sulfonamides and anticonvulsants San Francisco, California	American Academy of Dermatology Annual meeting December 8, 1992

91.	Drug reactions (Director of teaching forum) San Francisco, California	American Academy of Dermatology Annual meeting December 9, 1992
92.	Drug allergies & adverse reactions Toronto, Ontario (& 12 Canadian sites)	Telemedicine Canada February 5, 1993
93.	Antifungal therapy Halifax, Nova Scotia	19th Annual Refresher - Dalhousie CME February 16, 1993
94.	Management of Baldness Halifax, Nova Scotia	19th Annual Refresher - Dalhousie CME February 16, 1993
95.	Diagnosis & Management of Reactions to Drugs Halifax, Nova Scotia	19th Annual Refresher - Dalhousie CME February 16, 1993
96.	Understanding Drug Reactions in the Skin Mount Sinai Hospital Toronto, Ontario	Emergency Medicine - Citywide Residents Teaching Rounds April 27, 1993
97.	Pharmacoeconomic analysis of oral treatments for fungal infections of skin and nails - North American perspective. Vienna , Austria	Dermatology 2000 May 18, 1993
98.	Antifungals Toronto, Ontario	Sunnybrook Family Practice Rounds June 9, 1993
99.	The Good News about Sunshine Toronto, Ontario	International Conference on Meteorology and Oceanographic Education July 17, 1993
100.	Relative cost-effectiveness of systemic anti-psoriasis therapy Vancouver, British Columbia	Dermatology Update September 8, 1993
101.	Analysis of cost-effectiveness of anti-fungal therapy Vancouver, British Columbia	Dermatology Update September 8, 1993
102.	Cost-effectiveness analysis: Implications for dermatology Vancouver, British Columbia	Dermatology Update September 10, 1993
103.	Modern approach to antifungal therapy Vancouver, British Columbia	Dermatology Update September 10, 1993
104.	New antifungals Toronto, Ontario	The 15th Post-Graduate Dermatology Seminar October 1, 1993
105.	Adverse reactions to antibiotics (Possible pediatric implications) Niagara-on-the-Lake, Ontario	The Children's After Hours Clinic (Annual CE meeting) October 10, 1993
106.	Post-marketing surveillance of non-prescription drugs Toronto, Ontario	NDMAC Development Conference November 18, 1993

107.	Physiologic factors in using patches for systemic drug delivery Toronto, Ontario	PharmaPatch Development Meeting November 23, 1993
107.	Drug reactions (Director of teaching forum) Washington, D.C.	American Academy of Dermatology Annual meeting December 7, 1993
108.	There is no such thing as a free lunch. Toronto, Ontario	Wellesley Hospital Clerks' Day February 10, 1994
109.	New meds for fungal infections Toronto, Ontario	Ontario Society of Chiropodists - Annual Meeting February 25, 1994
110.	***Program Chair and Director*** Toronto, Ontario	A Team Approach to Drug Safety Research Feb 28 - March 1, 1994
111.	Severe cutaneous reactions to drugs Toronto, Ontario	A Team Approach to Drug Safety Research Feb 28 - March 1, 1994
112.	***Co-chair*** Adverse drug reactions forum New Orleans, Louisiana	American Society for Clinical Pharmacology Annual Meeting March 31, 1994
113.	Pharmacoeconomics: Where does theory meet practice? Toronto, Ontario	The Canadian Pharmacoepidemiology Forum April 26, 1994
114.	***Chair and organizer*** Adverse drug reactions to oral antimicrobials in pediatrics Toronto, Ontario	Infectious Disease Symposium May 14, 1994
115.	Severe cutaneous adverse drug reactions Adverse drug reactions to oral antimicrobials in pediatrics Toronto, Ontario	Infectious Disease Symposium May 14, 1994
116.	***Chair*** Pharmacogenetics and drug development Washington, D.C.	Drug Information Association Annual Mtg. June 6, 1994
117.	***Chair*** Toronto, Ontario	Issues in the Modern Management of Onychomycosis June 9, 1994
118.	Developing more effective management strategies. Toronto, Ontario	Issues in the Modern Management of Onychomycosis June 9, 1994
119.	***Chair*** Royal College of Physicians & Surgeons Toronto, Ontario	Measurement of cost-benefit Annual Meeting September 17, 1994

120.	Patients, Plans and Profits Royal College of Physicians & Surgeons Toronto, Ontario	Measurement of cost-benefit Annual Meeting September 17, 1994
121.	Current status of risk information - *Plenary* Reston, Virginia	Communicating Risk to Patients USP Open Conference September 20, 1994
122.	Drug reactions - *Plenary* Jerusalem, Israel	From Patient to Pipette - and Back Again An International Symposium October 4, 1994
123.	Norman Wrong Lecture: Drug Eruptions: Past, Present & Future Toronto, Ontario	The 16th Postgraduate Dermatology Seminar Toronto Dermatological Society October 7, 1994
124.	Antifungal therapy Vancouver, British Columbia	Dermatology Update October 21, 1994
125.	***Chair and organizer*** Vancouver, British Columbia	Adverse drug reactions to oral antimicrobials in pediatrics October 22, 1994
126.	Severe cutaneous adverse drug reactions Vancouver, British Columbia	Adverse drug reactions to oral antimicrobials in pediatrics October 22, 1994
127.	Adverse drug reactions to anticonvulsants New Orleans, Louisiana	Lamotrigine study group American Epilepsy Meeting December 3, 1994
128.	***Chair and organizer*** Montreal, Quebec	Frontiers in Dermatology December 9 & 10, 1994
129.	Camouflage of rosacea Montreal, Quebec	Frontiers in Dermatology December 9 & 10, 1994
130.	Oral antifungal safety: North American/Canadian Experience Paris, France	Onychomycosis Advisory Council December 15, 1994
131.	Adverse reactions to drugs - what needs to be done? Ottawa, Ontario	Drugs Directorate Seminar Series Health Canada January 19, 1995
132.	The cost of a free drug lunch Women's College Hospital Toronto, Ontario	Medical Grand Rounds January 25, 1995
133.	Oral antifungal safety: North American Experience New Orleans, Louisiana	Onychomycosis Forum February 3, 1995
134.	Drug reactions (Director of teaching forum) New Orleans, Louisiana	American Academy of Dermatology Annual meeting February 7, 1995

135.	***Program Chair and Director*** Toronto, Ontario	New Directions in the Mgmnt of Drug Safety February 13 - 14, 1995
136.	Canadian Adverse Drug Reaction Advisory Committee (CADRAC) Toronto, Ontario	New Directions in the Management of Drug Safety February 13 - 14, 1995
137.	Learning about drugs: From drug reps?! Therapeutic Initiative Vancouver, B.C.	Drug Therapy: Decision Making University of British Columbia April 29, 1995
138.	Every drug rash is not Stevens-Johnson Therapeutic Initiative Vancouver, B.C.	Drug Therapy: Decision Making University of British Columbia April 29, 1995
139.	The fungus among us - good news for nails Therapeutic Initiative Vancouver, B.C.	Drug Therapy: Decision Making University of British Columbia April 29, 1995
140.	New trends in the treatment of onychomycosis. Yokohama, Japan	Japanese Dermatological Assoc. Annual Meeting May 19, 1995
141.	Optimal drug therapy [Organizing comm. & Chair] Toronto, Ontario	Project 2000 A multi-stakeholder conference May 24, 1995
142.	Allergy testing for anesthetic drugs Toronto, Ontario	Anesthesia Grand Rounds June 2, 1995
143.	The Old Customers in the New Environment Toronto, Ontario	Customer focussed marketing strategies for the pharmaceutical industry June 5, 1995
144.	Serious Skin Problems Niagara-on-the-Lake, Ontario	Canadian Therapeutics Update 1995 July 9, 1995
145.	Modern Management of Drug Reactions Chicago, Illinois	American Academy of Dermatology July 28, 1995
146.	Important Drug Interactions Chicago, Illinois	American Academy of Dermatology July 30, 1995
147.	Adverse Drug Reactions to Antifungal Therapy and their Management Montreal, Québec	Dermatology Update October 21, 1995
148.	Systemic reactions to Drugs Toronto, Ontario	Grand Medical Rounds Toronto Hospital November 8, 1995
149.	How you can still have a life although your are taking drugs. Drugs and sex. Toronto, Ontario	Seniors & Safe Medication Toronto Mayor's Committee on Aging November 9, 1995
150.	New Treatment Options in Fungal Disease Toronto, Ontario	Sunnybrook Clinical Day '95 The Changing Face of Infection November 15, 1995

151.	Cost effective treatments in dermatology Toronto, Ontario	Saturday at the University January 27, 1996
152.	Drug reps: Friend or foe? Toronto, Ontario	Saturday at the University January 27, 1996
153.	Hair loss Toronto, Ontario	Saturday at the University January 27, 1996
154.	Antifungals Toronto, Ontario	Saturday at the University January 27, 1996
155.	Drug reactions Toronto, Ontario	Saturday at the University January 27, 1996
156.	Drug reactions and the liver Toronto, Ontario	GI resident rounds February 7, 1996
157.	Cutaneous drug reaction syndromes Washington, D.C.	American Academy of Dermatology February 10, 1996
158.	Drug reactions (Director of teaching forum) Washington, D.C.	American Academy of Dermatology Annual meeting February 12, 1996
159.	CADRAC - Making decisions the Canadian way Toronto, Ontario	3rd Annual Meeting of the Drug Safety Research Group February 13, 1996
160.	Working in the New Drug Safety Environment Toronto, Ontario ***Program Chair***	3rd Annual Meeting of the Drug Safety Research Group February 12 & 13, 1996
161.	Doctors, drugs and detailing Toronto, Ontario	Evidence-based Medicine Rounds February 16, 1996
162.	Dermatology Toronto, Ontario	Bruce Tovee Lecture Series February 26, 1996
163.	Systemic drug reactions Toronto, Ontario	Grand Medical Rounds Mount Sinai Hospital February 28, 1996
164.	Managing drug reactions North York, Ontario	Grand Medical Rounds North York General Hospital March 20, 1996
165.	Drug causing death- A national perspective Toronto, Ontario	Grand Medical Rounds Sunnybrook Health Science Centre April 2, 1996
166.	Drug safety in drug development Toronto, Ontario	Clinical Trials Nurses Network Sunnybrook Health Science Centre April 3, 1996
167.	Genital Herpes Department of Family Medicine Toronto, Ontario	Needs Assessment Program University of Toronto April 17, 1996

168.	Cutaneous reactions to chemotherapeutic agents Toronto, Ontario	73rd Atlantic Dermatologic Conference May 3, 1996
169.	Diagnosis of drug eruptions Brisbane, Australia	Australasian College of Dermatologists Annual Meeting May 20, 1996
170.	Review of severe skin reactions caused by drugs Brisbane, Australia	Australasian College of Dermatologists Annual Meeting May 21, 1996
171.	The modern use of antifungal drugs in dermatology Brisbane, Australia	Australasian College of Dermatologists Annual Meeting May 22, 1996
172.	Advancements in the management of herpes zoster and zoster associated pain. North York, Ontario	Dermatology Grand Rounds July 30, 1996
173.	The role of cosmetic cover-up North York, Ontario	The 18th Post-graduate Dermatology Seminar September 21, 1996
174.	Introduction to short and intermittent therapy regimens in dermatology Lisbon, Portugal	Dermatomycosis Therapy European Academy of Dermatology October 15, 1996.
175.	The thyroid is a target for drug reactions Sunnybrook Health Science Centre	Endocrinology Rounds January 23, 1997
176.	Research and Regulatory Advances in Drug Safety Toronto, Canada ***Program Chairperson***	4th Annual Symposium of the University of Toronto Drug Safety Research Group & the Drug Information Association February 10-11, 1997
177.	Adverse reactions to new antifungal drugs San Francisco, California	American Academy of Dermatology March 21, 1997
178.	Etiology and management of acute drug reactions in children San Francisco, California	American Academy of Dermatology March 22, 1997
179.	Cutaneous drug reaction syndromes San Francisco, California	American Academy of Dermatology March 25, 1997
180.	Drug interactions Toronto, Ontario	American College of Physicians April 4, 1997
181.	Drug-induced rashes Toronto, Ontario	1997 Pediatric Update Hospital for Sick Children April 18, 1997
182.	Drug safety in women Toronto, Ontario	Women's HealthCare: The pharmacotherapy initiative April 28, 1997

183.	Holding up your end of a conversation with a drug rep Montreal, Québec	29th Annual Course in Drug Therapy Montreal General Hospital May 2, 1997
184.	New antifungal for skin and nail infections Montreal, Québec	29th Annual Course in Drug Therapy Montreal General Hospital May 2, 1997
185.	New antivirals for varicella-zoster Montreal, Québec	29th Annual Course in Drug Therapy Montreal General Hospital May 2, 1997
186.	The treatment decision in onychomycosis Sydney, Australia	World Congress in Dermatology June 17, 1997
187.	Multinational pharmacoeconomic analysis of treatments for onychomycosis Sydney, Australia	World Congress in Dermatology June 18, 1997
188.	Pathogenesis of hypersensitivity reactions Sydney, Australia	World Congress in Dermatology June 18, 1997
189.	***Co-chair*** Cutaneous drug reactions Sydney, Australia	World Congress in Dermatology June 18, 1997
190.	Treatment of varicella-zoster infections-What's best? American College of Physicians Niagara-on-the-Lake, Ontario	Can. Therapeutics Update - 1997 CME Course A21 July 13, 1997
191.	Rosacea is easy to treat now American College of Physicians Niagara-on-the-Lake, Ontario	Can. Therapeutics Update - 1997 CME Course A21 July 13, 1997
192.	Drug reactions - Mechanisms and management Falmouth, Massachusetts	Massachusetts Acad. of Derm Annual Meeting September 19, 1997
193.	Drug interactions-3A4 and you Falmouth, Massachusetts	Massachusetts Acad. of Derm Annual Meeting September 20, 1997
194.	Antifungals: Their success and safety Falmouth, Massachusetts	Massachusetts Acad. of Derm Annual Meeting September 21, 1997
195.	Drug-drug interactions with antifungal therapy. Barcelona, Spain	November 14, 1997
196.	Severe drug reactions: Pharmacologic investigations Montreal, Quebec	Montreal General Hospital Grand Medical Rounds November 18, 1997

197.	How to learn about new drugs: What drug reps are really about. Montreal, Quebec	Montreal General Hospital November 18, 1997
198.	Severe reactions to anticonvulsant drugs Toronto, Ontario	City-wide Epilepsy Grand Rounds November 21, 1997
199.	Anticonvulsant hypersensitivity drug reaction syndrome Boston, Massachusetts	American Epilepsy Society Annual Meeting December 6, 1997
200.	A Scientific Approach to Herbal & Medicinal Phytopharmaceuticals Toronto, Ontario	Metropolitan Toronto Pharmacists' Association January 11, 1998
201.	Research and Regulatory Advances in Drug Safety Toronto, Canada ***Program Chairperson***	5th Annual Symposium of the University of Toronto Drug Safety Research Group February 2-3, 1998
202.	Drug safety - Global issues from a Sunnybrook perspective Toronto, Ontario	ICES - Grand Rounds in Clinical Epidemiology February 4, 1998
203.	Update on antifungal drugs Halifax, Nova Scotia	Atlantic Provinces Derm As'n Annual Meeting February 6, 1998
204.	Evaluation of life-threatening cutaneous drug eruptions Orlando, Florida	American Academy of Dermatology 56th Annual Meeting March 1, 1998
205.	Severe drug eruptions Defining the hypersensitivity syndrome Orlando, Florida	American Academy of Dermatology March 3, 1998
206.	Understanding severe reactions to anticonvulsants Toronto, Ontario	Epilepsy Grand Rounds Hospital for Sick Children March 4, 1998
207.	Patterns of drug eruptions Ottawa, Ontario	33rd Clinical and Scientific Meeting April 17, 1998
208.	The cytochrome P450 3A4 story Ottawa, Ontario	33rd Clinical and Scientific Meeting April 17, 1998
209.	Operations of an adverse drug event reporting centre Toronto, Ontario	Annual Education Day - PMAC Medical Information Group - Fostering Relationships April 28, 1998
210.	How to manage the patient with local anesthetic allergy Toronto, Ontario	Canadian Dental Association Annual Meeting May 8, 1998
211.	Pharmacology and the dentist **Chair** Toronto, Ontario	Canadian Dental Association Annual Meeting May 8, 1998

212.	Human dermal replacement through tissue engineering Toronto, Ontario	Management of the Diabetic Foot May 30, 1998
213.	**Scientific Committee** **Organizing Committee** Toronto, Ontario	First International Symposium on the Molecular Pathology and Clinical Aspects of the Inflamed Liver June 8 - 9, 1998
213.	Hypersensitivity Drug Reactions Toronto, Ontario	First International Symposium on the Molecular Pathology and Clinical Aspects of the Inflamed Liver June 8, 1998
214.	Antifungal drug interactions Singapore	Fifth International Summit on Cutaneous Antifungal Therapy June 17, 1998
215.	Medication: When right can be wrong. Toronto, Ontario	Toronto Drug Awareness Coalition Safe Use of Medications June 23, 1998
216.	Antifungal Drug Update Toronto, Ontario	Canadian Dermatology Association Annual Scientific Meeting July 4, 1998
217.	The top 10 drug interactions of importance to the dermatologist. Toronto, Ontario	Norma MacLeod Lecture The 20th Post Graduate Dermatology Seminar September 19, 1998
218.	The modern science and management of drug reactions. Nice, France	European Academy of Dermatology & Venerol. Annual Meeting October 9, 1998.
219.	Science behind drug interactions ***Visiting professor*** Seattle, Washington	Division of Dermatology University of Washington October 16, 1998
220.	Drug reactions, dermatology and me Seattle, Washington	Division of Dermatology University of Washington October 16, 1998
221.	Dermatology review - CME Toronto, Ontario	Amer College Physicians, MKSAP XI October 31, 1998
222.	Minimizing the risk – Safety in Drug Prescribing Toronto, Ontario	Medical Grand Rounds King's Health Centre November 18, 1998
223.	Drug Hypersensitivity Syndromes Toronto/Palo Alto via Videoconference	Department of Dermatology Stanford University School of Medicine January 21, 1999
224.	Research and Regulatory Advances in Drug Safety Toronto, Ontario ***Program Chairperson***	6th Annual Symposium of the University of Toronto Drug Safety Research Group February 1-2, 1999

225.	Oral Antifungal Therapy Toronto, Ontario	Annual Meeting of Ontario Society of Chiropodists February 11, 1999
226.	Acne, anti-fungal updates Toronto, Ontario	Family Practice Rounds February 10 & 17, 1999
227.	Drug interactions with cytochrome P450 3A4 Burlington, Ontario	February 25, 1999
228.	How do I manage dilemmas? New Orleans, Louisiana	Annual Meeting Council for Nail Disorders March 18, 1999
229.	Drug interactions simplified New Orleans, Louisiana	Annual Meeting of the American Academy of Dermatology March 19, 1999
230.	Drug reactions & interactions ***Plenary*** presentation New Orleans, Louisiana	Annual Meeting of the American Academy of Dermatology March 22, 1999
231.	Severe hypersensitivity reactions New Orleans, Louisiana	Annual Meeting of the American Academy of Dermatology March 23, 1999
232.	First line therapies for 5 common skin diseases Kingston, Ontario	Queen's CME – 10th Annual Therapeutics April 7, 1999
233.	An acne primer Kingston, Ontario	Queen's CME – 10th Annual Therapeutics April 7, 1999
234.	Drug reactions in the skin Kingston, Ontario	Queen's CME – 10th Annual Therapeutics April 7, 1999
235.	Erythema multiforme and friends Toronto, Ontario	Sunnybrook Dentistry Grand Rounds April 12, 1999
236.	Hypersensitivity syndromes from drugs: What they are and what they mean. Washington, D.C.	Atlantic Dermatological Conference April 30, 1999
237.	Cases from the Drug Safety Clinic Toronto, Cochrane, Timmins, & Kirkland Lake, Ontario	NORTH Network Teleconference May 14, 1999
238.	Drug reactions, Drug interactions ***Visiting professor*** Louisville, Kentucky	University of Louisville May 17, 18, 1999
239.	Demystifying drug interactions: How they occur and how to avoid them. Unionville, Ontario	Scarborough Grace Hospital Department of Family Medicine June 2, 1999
240.	Allergy to sulfonamides Montreal, Quebec	Annual meeting of Canadian Allergy Association September 26, 1999

241.	Drug reaction syndromes; Drug interactions Cairo, Luxor and on the Nile, Egypt	Egyptian Women's Dermatologic Society Annual Meeting October 20, 21, 23, 1999
241.	Drug reactions and interactions Montreal, Quebec	Montreal Dermatologic Society November 11, 1999
242.	Modern management of drug reactions Mississaugua, Ontario	Trillium Health Centre January 26, 2000
243.	Post marketing surveillance Plenary session Toronto, Ontario	Annual Professional Practice Conference February 1, 2000
244.	Drug reactions and interactions Toronto, Ontario	Practical Strategies for Advocates IX The Advocates' Society February 5, 2000
245.	Drug development in Canada Toronto, Ontario	Anderson Study Group February 23, 2000
246,	Non-gastrointestinal adverse reactions to celecoxib. Lake Louise, Alberta	Canadian Rheumatologic Association February 26, 2000
247.	Controversies in Drug Safety ***Program Chairperson*** Toronto, Ontario	7th Annual Symposium of the University of Toronto Drug Safety Research Group February 28 & 29, 2000
248.	Drug safety and the media: a clinician's perspective Toronto, Ontario	Controversies in Drug Safety February 29, 2000
249.	An approach to drug-induced skin disease Toronto, Ontario	Issues in HIV Drug Safety & Adherence March 3, 2000
250.	Drug safety: Sulfonamides & beyond ***Visiting Professor*** Edmonton, Alberta	Grand Medical Rounds University of Alberta July 21, 2000
251.	Drug actions, interactions, and reactions ***Symposium Director*** Nashville, Tennessee	American Academy of Dermatology Summer Annual Meeting August 5, 2000
252.	Celecoxib & sulfonamides: Cross-reaction or not. Nashville, Tennessee	American Academy of Dermatology August 5, 2000
253.	In vitro assays for immunologic injury Bethesda, Maryland	New Directions in Drug-induced Liver Injury National Institutes of Health October 18, 2000
254.	Pathophysiology of multi-organ drug hypersensitivity syndrome. New York, New York	New Insights into Drug Reactions The Allergy, Asthma, and Immunology Society of Greater New York October 27, 2000

255.	Current management of drug eruptions Orlando, Florida	American Osteopathic College of Dermatology Annual Meeting October 31, 2000
256.	Drug reactions and interactions ***Visiting professor*** Indianapolis, Indiana	Department of Dermatology Indiana University School of Medicine November 16, 2000
257.	Mechanisms of serious drug reactions Indianapolis, Indiana	Introduction to Cutaneous Biology Course November 17, 2000
258.	What is sulfa allergy and why should we care? Toronto, Ontario	Medical Grand Rounds Sunnybrook & Women's College Health Sci. Ctr. January 9, 2001
259.	Health Technology Transfer – Drug Safety Ottawa, Ontario	Optimal Drug Therapy National Symposium January 11, 2001
260.	Understanding Acne & Rosacea Toronto, Ontario	CME session for family doctors January 16, 2001
261.	Rosacea – Public forum Toronto, Ontario	Women's Health Matters January 20, 2001
262.	*Coordinator* Saturday at the University Toronto, Ontario	Therapeutics in Primary Care: A Prescribers Guide January 27, 2001
263.	P450: The route to understanding drug interactions Toronto, Ontario	Saturday at the University January 27, 2001
264.	Sulfa allergy update: Is there such a thing as "Allergic to sulfonamides"? Toronto, Ontario	2001 Ontario Region Scientific Meeting ACP / ASIM February 23, 2001
265.	Controversies in Drug Safety ***Program Chairperson*** Toronto, Ontario	8th Annual Symposium of the University of Toronto Drug Safety Research Group February 26 & 27, 2001
248.	The challenges of health technology assessment: How bad are we and what must be done? Toronto, Ontario	Controversies in Drug Safety February 25, 2001
249.	Understanding Drug Rep Physician Interactions Toronto, Ontario	NORTH Network Telemedicine March 1, 2001
250.	Managing severe drug reactions – The first 48 hours Washington, DC	American Academy of Dermatology Annual Mtg. March 6, 2001
251.	Adverse drug reactions Toronto, Ontario	NORTH Network Telemedicine April 5, 2001

252.	Drug safety: A long way traveled and a long way to go. Halifax, Nova Scotia	Canadian Dermatology Foundation Lectureship Canadian Dermatology Association Annual Mtg. June 28, 2001
253.	Evidence-based medicine: Rosacea Toronto, Ontario	The 23rd Post-Graduate Dermatology Seminar November 2, 2001
254.	Mechanisms of drug interactions Indianapolis, Indiana	Introduction to Cutaneous Biology Course November 9, 2001
255.	A talk about drug reactions Toronto, Ontario	Grand Medical Rounds, Scarborough Hospitals November 20, 2001
256.	Cooperation among major stakeholders Toronto, Ontario	Managing Drug Safety for Commercial Success December 7, 2001
257.	What's new in atopic dermatitis Toronto, Ontario	Ontario Allergy Asthma & Immunology Assoc. January 16, 2002
258.	Drug reactions: The first 48 hours Toronto, Ontario	ACP Ontario Region Scientific Meeting February 1, 2002
259.	How to be a drug reaction genius. Toronto, Ontario	Dermatology Associates Education Rounds February 5, 2002
260.	Cutaneous drug reactions: The first 24 hours revisited New Orleans, Louisiana	American Academy of Dermatology Annual Mtg February 22, 2002
261.	Adverse drug reactions and skin manifestations. New Orleans, Louisiana	Dermatology Nursing Association Annual Mtg February 23, 2002
262.	Pharmacoimmunology of topical pimecrolimus. New Orleans, Louisiana	American Academy of Dermatology Annual Mtg Novartis Workshop February 24, 2002
263.	What you need to know about mycophenolate mofetil. New Orleans, Louisiana	American Academy of Dermatology Annual Mtg February 25, 2002
264.	Stevens-Johnson syndrome / Toxic epidermal necrolysis: The first 24 to 48 hours. ***Plenary session*** New Orleans, Louisiana	American Academy of Dermatology Annual Mtg February 27, 2002
265.	Drug eruptions New York, New York	Dermatology issues in the primary care setting April 13, 2002
266.	Communicating risk and safety issues ***Plenary session*** Toronto, Ontario	Canadian Assoc. for Population Therapeutics April 14, 2002
267.	Making rash decisions about drug eruptions. Toronto, Ontario	Grand Rounds & **Plenary** Talk Therapeutics Day Hospital for Sick Children April 24, 2002

268.	The role of drug metabolism in the drug hypersensitivity syndrome. Paris, France	20th World Congress of Dermatology July 1, 2002
269.	Minocycline-associated skin disease Paris, France	20th World Congress of Dermatology July 2, 2002
270.	Oxo-isotretinoin: How much does it contribute to the clinical effects of isotretinoin? Paris, France	20th World Congress of Dermatology July 4, 2002
271.	Isotretinoin metabolites: Do we fully appreciate their sebostatic activity? Geneva, Switzerland	European Society for Dermatology Research September 20, 2002
272.	Psychological & Social Impact of Acne Vancouver, British Columbia	Dermatology Update October 17, 2002
273.	Pharmacoimmunology of pimecrolimus Vancouver, British Columbia	Dermatology Update October 18, 2002
274.	New therapies for hyperpigmentation Vancouver, British Columbia	Dermatology Update October 18, 2002
275.	Soaps & cleansers Vancouver, British Columbia	Dermatology Update October 19, 2002
276.	Pathogenesis of drug hypersensitivity Indianapolis, Indiana	Introduction to Cutaneous Biology Course October 25, 2002
277.	Drug eruptions: Learning from the skin Vancouver, British Columbia	Department of Medicine Grand Rounds November 28, 2002
278.	Drug interactions of interest to dermatologists Vancouver, British Columbia	British Columbia Section of Dermatology November 30, 2002
279.	Common drug reactions Toronto, Ontario	Sunnybrook & Women's Medical Grand Rounds December 5, 2002
280.	Rashes with anti epileptic drugs Seattle, Washington	American Epilepsy Society Annual Meeting December 10, 2002
281.	Pharmacovigilance: A consultant's perspective Toronto, Ontario	Effective Post-marketing Drug Adverse Event Management: Pharmacovigilance December 12, 2002
282.	Severe drug reactions in children: Lessons in risk management Paris, France	La Soiete Francaise de Dermatologie January 9, 2003
283.	Atopic dermatitis: A therapeutic update Toronto, Ontario	Ontario Allergy-Immunology Association February 19, 2003
284.	Drugs cause rashes – Why? Manila, Philippines	284th Dr. Luis E. Geurroro Memorial Lecture University of Santo Tomas March 10, 2003

285.	Drug interactions for dermatologists Manila, Philippines	Dermatopharmacology Update March 10, 2003
286.	Immunomodulators in dermatology Manila, Philippines	Dermatopharmacology Update March 11, 2003
287.	Update on Stevens-Johnson / TEN Manila, Philippines	Dermatopharmacology Update March 11, 2003
288.	Drug hypersensitivity: Higher vs lower risk reactions San Francisco, California	Amer. Acad. of Derm. Annual Meeting March 21, 2003
289.	Drug interactions made reasonably simple San Francisco, California	Amer. Acad. of Derm. Annual Meeting March 21, 2003
290.	Recognizing & managing drug interactions San Francisco, California	Amer. Acad. of Derm. Annual Meeting March 21, 2003
291.	Managing drug interactions in the clinic San Francisco, California	Dermatology Nurses Assoc. Annual March 22, 2003
292.	Drugs cause rashes – Why? Quebec City, Quebec	Quebec Dermatology Society - Annual Assembly April 11, 2003
293.	Isotretinoin metabolites: Do we fully appreciate their sebostatic activity? Miami, Florida	International Investigative Dermatology Meeting May 1, 2003
294.	Skin: The heart of drug reactions. Toronto, Ontario	Atlantic Dermatology Conference May 2, 2003
295.	An evidence based-review of the calcineurin inhibitors in atopic dermatitis. Ottawa, Ontario	Canadian Dermatology Association July 1, 2003
296.	Starting to understand drug rashes New York, New York	Columbia University Dermatology Rounds September 17, 2003
297.	Skin manifestations of drug reactions Toronto, Ontario	TEGH Family Practice Clinic Day September 24, 2003
298.	Is isotretinoin only a precursor for its sebostatic activity. Barcelona, Spain	European Acad. of Dermatology & Venereology October 16, 2003
299.	Drug rashes: Challenges in knowledge acquisition and translation. Washington, DC	Immune-mediated Drug Hypersensitivity Reactions Workshop ILSI Health and Environmental Sciences Inst. November 17, 2003
300.	The best drug rash study ever Washington, DC	American Academy of Dermatology February 9, 2004
301.	Drug Actions **Symposium Director** Washington, DC	American Academy of Dermatology February 10, 2004
302.	What is a drug rash and what does it mean? Washington, DC	American Academy of Dermatology February 10, 2004

303.	Raptiva: CLEAR demonstration of effectiveness Budapest, Hungary	European Academy of Dermatology & Venerology April 30, 2004
304.	Sustained efalizumab efficacy in patients with moderate to severe chronic plaque psoriasis: updated phase III trial findings Budapest, Hungary	European Academy of Dermatology & Venerology April 30, 2004
305.	***Co-chair / organizer of meeting*** Berne, Switzerland	Drug Hypersensitivity Meeting May 5 – 8, 2004
306.	Phase I study of gemifloxacin-associated rash. Berne, Switzerland	Drug Hypersensitivity Meeting May 5 – 8, 2004
307.	***Scientific advisory board member*** Toronto, Ontario	10th International Psoriasis Symposium June 10 – 13, 2004
308.	Longterm efalizumab therapy safely maintains efficacy: Preliminary results from an open label trial. Toronto, Ontario	10th International Psoriasis Symposium June 10 – 13, 2004
309.	Hidradenitis suppurativa and biologicals Toronto, Ontario	10th International Psoriasis Symposium June 10 – 13, 2004
310.	Efalizumab: A new approach in meeting the challenge of managing psoriasis. ***Chair*** Victoria, BC	Canadian Dermatology Association Annual meeting July 3, 2004
311.	The challenge of managing psoriasis. the challenge of managing psoriasis. Victoria, BC	Canadian Dermatology Association July 3, 2004
312.	Impact of efalizumab on health-related quality of life outcomes in patients with moderate to severe chronic plaque psoriasis. Victoria, BC	Canadian Dermatology Association Annual meeting July 3, 2004
313.	Getting to the core of eczema: Prevention of flares, maintenance of control. Victoria, BC	Canadian Dermatology Association Annual meeting July 3, 2004
314.	Drugs cause rashes – Why? Cincinatti, Ohio	University of Cincinatti Dept of Derm. August 26, 2004
315.	Use of IVIG in pemphigus Vacouver, BC	Dermatology Update October , 2004
316.	Systemic drugs in dermatology Toronto, Ontario	Toronto Post Grad Dermatology Meeting November 12, 2004
317.	Bob Lester Postgrad Dermatology Meeting	***Meeting director***

	Toronto, Ontario	November 12, 2004
318.	A rash of drug eruptions Toronto, Ontario	Pediatric Dermatology Update, HSC November 26, 2004
319.	Traditional therapeutic strategies for atopic dermatitis New Orleans, Louisiana	American Academy of Dermatology Symposium at Annual Meeting February 18, 2005
320.	Drug actions: Symposium Director New Orleans, Louisiana	American Academy of Dermatology Symposium 320 at Annual Meeting February 19, 2005
321.	Drug reaction update New Orleans, Louisiana	American Academy of Dermatology Symposium 320 at Annual Meeting February 19, 2005
322.	Evaluating life-threatening cutaneous drug reactions New Orleans, Louisiana	American Academy of Dermatology Symposium at Annual Meeting February 18, 2005
323.	Utility and availability of available biomarkers in the evaluation of drug-induced skin diseases. Leiden, Netherlands	Expert Meeting on Drug Safety European Federation for Pharmaceutical Sciences March 21, 2005
324.	Drug-induced skin diseases Louisville, Kentucky	AAD Dermatology Review April 30, 2005
325.	Drug interactions Louisville, Kentucky	AAD Dermatology Review May 1, 2005
326.	Intravenous immuneglobulin use in dermatology Quebec, Quebec	Annual meeting of Quebec Derm Society May 6, 2005
327.	New paradigms in drug safety: Challenges for information management Toronto, Ontario	Special Libraries Association Annual Conference June 6, 2005
328.	Rashes that kill Toronto, Ontario	Sunnybrook & Women's Grand Medical Rounds July 21, 2005
329.	IVIG in dermatology Montreal, Quebec	Dermatology Update November 6, 2005
330.	Making sense of cutaneous drug reactions Indianapolis, Indiana	Introduction to Cutaneous Biology Course November 11, 2005
331.	Making sense of drug intereactions Indianapolis, Indiana	Introduction to Cutaneous Biology Course November 11, 2005
332.	Camouflage cosmetics in dermatology Manila, Philippines	Philippine Dermatological Society Ann. Mtg. November 17, 2005
333.	Drug reactions, erythroderma & drug interactions Manila, Philippines	Philippine Dermatological Society Ann. Mtg. November 18, 2005

334. Drug reactions
Kapalua, Hawaii
Winter Clinical Dermatology Conference
January 17, 2006

335.	Perspectives on drug hypersensitivity syndrome Yokohama, Japan	International Symposium of Adverse Drug Reactions February 10, 2006
336.	Severe drug-induced skin diseases Matsuyama, Japan	Ehime Medical School, *Visiting Professor* February 13, 2006
337.	Evaluating life-threatening cutaneous drug reactions. San Francisco, California	Annual meeting, American Academy of Dermatology March 6, 2006
338.	Drug reaction myths San Francisco, California	American Academy of Dermatology March 7, 2006
339.	*Symposium chair* – Drug Actions San Francisco, California	American Academy of Dermatology March 7, 2006
340.	Epidemiology of drug hypersensitivity Liverpool, UK	2nd International Drug Hypersensitivity Conference April 19, 2006
341.	Erythema multiforme and Stevens-Johnson Syndrome Toronto, Ontario	Annual Pediatric Update Hospital for Sick Children May 3, 2006
342.	Diagnosis and management of severe drug reactions Seoul, Korea	Visiting Professor Graduate School, Catholic University of Korea May 26, 2006
343.	Increasing diagnostic accuracy in drug reactions Seoul, Korea	25th Annual Meeting of the Korean Society for Contact Dermatitis and Skin Allergy May 27, 2006
344.	*Chair* - Issues and advances in the acne Winnipeg, Manitoba	Canadian Dermatology Association Annual Mtg June 30, 2006
345.	Applying the Global Consensus guidelines in practice: An interactive case-based approach Winnipeg, Manitoba	Canadian Dermatology Association Annual Mtg June 30, 2006
346.	The effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. Winnipeg, Manitoba	Canadian Dermatology Association Annual Mtg July 1, 2006
347.	Toronto Psoriasis Seminar (ToPS) ***Program Chair*** Toronto, Ontario	Second Annual Meeting October 13, 2006
348.	Making successful rash decisions Toronto, Ontario	Sunnybrook Family Practice Rounds October 18, 2006
349.	Lichen Planus: 2006 Update Toronto, Ontario	Annual PostGraduate Meeting November 3, 2006
350.	***Program Chair*** Toronto, Ontario	Annual PostGraduate Metting November 3, 2006

351.	Cutaneous lymphoma – Patient program ***Program Chair***, Speaker Toronto, Ontario	Cutaneous Lymphoma Foundation November 4, 2006
352.	Drug reactions: From the mild to severe Indianapolis, Indiana	Annual Basic Science Seminars for Dermatology Residents November 10, 2006
353.	Becoming a Master of Drug Reactions Houston, Texas	Houston Dermatology Society December 4, 2006
354.	Dermatology Update Toronto, Ontario	Walter Wright Ophthalmology Meeting Update in Medicine and Ophthalmology December 8, 2006
355.	Understanding Drug Rashes Toronto, Ontario	Sunnybrook Emergency Department January 12, 2007
356.	Update on antibiotic and antifungals. Toronto, Ontario	DRIVE examination preparation program March 3, 2007
357.	Evaluating life-threatening drug rashes University of Pennsylvania Philadelphia, Pennsylvania	Duhring Grand Rounds March 8, 2007
358.	Drug reactions Dermatology Foundation Clinical Symposia Amelia Island, Florida	Werner K. Stiefel Lectureship Advances in Dermatology March 15, 2007
359.	IVIG use in dermatology Dermatology Foundation Clinical Symposia Amelia Island, Florida	 Advances in Dermatology March 17, 2007
360.	An approach to drug rashes University of Ottawa Ottawa, Ontario	50th Clinical and Scientific Meeting April 20, 2007
361.	Drug reactions that kill University of Ottawa Ottawa, Ontario	50th Clinical and Scientific Meeting April 20, 2007
362.	Drug reactions *Keynote speaker* Toronto, Ontario	Primary Care Today Annual Meeting May 11, 2007